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PREFACE 
 
Over the last few decades, several clinical trials have been conducted to clarify the 
possible benefits of phytoestrogens on different aspects of clinical health. The major 
hampering points in those studies are the lack of very well-defined test products and 
undefined molecular working mechanisms, which may lead to inconclusive and mixed 
results. The latter is often caused by inter-individual differences in metabolism and 
bioavailability. Nevertheless, distinct conclusions on the use of phytoestrogens in a clinical 
environment might be drawn if their absorption, bioavailability and metabolism could be 
analyzed.  
Since the beginning of the investigations for phytoestrogens and their metabolites in a 
large variety of biological matrices, from crude plant materials over dietary supplements to 
biological fluids, several analytical techniques for their determination and quantification 
have been reported. These methods can be divided, based upon separation technology, into 
chromatographic and non-chromatographic methods. In the former group liquid (LC) and gas 
chromatography (GC) coupled to UV- and mass-detection ((tandem) MS) are the most 
reliable and commonly used ones. In the latter, immunoassays based on antibodies are the 
most popular and innovating ones. 
Some important key points have to be kept in mind while choosing a correct analytical 
method. First of all, due to the fact that phytoestrogens sometimes have similarities in their 
structure, and the human metabolism can generate a wide range of metabolites, the chosen 
method has to be very specific. Next, when they are detected in biological fluids like urine or 
serum, their concentrations can be extremely low, even in the nanomolar region. Therefore, 
great sensitivity is another requirement. And, last but not least, when a large number of 
samples are generated in clinical studies, it is quite practical that the sample preparation and 
the method are as simple as possible, both for time and cost reduction. 
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CHAPTER 1 
 
 
General introduction  
PHYTOESTROGENS FROM HOPS, SOY AND FLAX IN 
BIOLOGICAL MATRICES 
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1. PHYTOESTROGENS 
1.1 History and classes 
Plant-derived food products can form a source of phytoestrogens in the Western diet, 
but not all classes of phytoestrogens are consumed in the same amount or have the same 
potency, which has direct implications on their biological effects and their prevalence in 
biological fluids [1]. Therefore, it is important to draw attention to those phytoestrogens 
that are commonly consumed or are ingested through dietary supplements, e.g., for the 
relief of menopausal symptoms. Phytoestrogens are secondary metabolites, typically 
phenolic compounds, synthesized by a plant, which may act as potent antioxidants [2]. In the 
mid-1920s, plant substances were already reported to cause estrus in animals [3]. Due to 
their aromatic conjugated structure phytoestrogens can serve as a protection mechanism 
against external influences like UV-radiation, micro-organisms or predators (e.g., the 
outbreak of infertility among sheep grazing from red clover in Western Australia in the late 
1940s [4]). 
 
Phytoestrogens mimic the endogenous mammalian 17β-estradiol (E2), both structurally 
and functionally. Classically, they are defined to exert estrogenic effects on the central 
nervous system, induce estrus and stimulate the growth of the genital tract of female 
animals. Moreover, they can interfere with endogenous estrogen signaling and associated 
processes. The ability to act both estrogenically as estrogen agonists and antiestrogenically 
as antagonists leads often to their classification as selective estrogen modulators (SERMs) 
[5]. Consequently, the use of several plants in traditional medicine, may often be ascribed to 
those diverse biological properties. The first report by Loewe et al. [6] of the estrogenic 
properties of plant extracts appeared in 1927, and half a century later the list of plants 
exhibiting estrogenic activity reached already several hundred [7]. Equol, an isoflavan from 
soy (Glycine max (L.) Merr.), was the first detected phytoestrogen in human urine, by 
Axelson et al. [8] and became one of the most studied phytoestrogens. Through 
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epidemiological studies and dietary surveys, the ingestion of phytoestrogens was linked to 
health-beneficial effects on Western diseases like cardiovascular disorders and breast and 
prostate cancer [2, 9]. Since the announcement of the results of the Women’s Health 
Initiative (WHI) study [10] and Million Women Study [11], concerning the negative effects of 
hormone replacement therapy (HRT), phytoestrogens have been in the spotlights as an 
interesting alternative for the relief of menopausal symptoms. 
 
Based on their chemical structures, the most consumed phenolic phytoestrogens  can be 
classified into four main groups, the flavonoids, isoflavonoids, lignans and stilbenes (Figure 
1.1). The first two groups are both derived from the heterocyclic hydrocarbon chroman, with 
substitution on C2 or C3 with a phenyl-group, for the flavonoids and isoflavonoids 
respectively [1, 4]. Further modifications of the basic structure of flavonoids results in three 
subgroups, i.e. flavones, flavanones and chalcones. The isoflavones and coumestans are the 
main players in the group of the isoflavonoids. The lignans differ in structure from the others 
with their dibenzyl-butane backbone. The last small group of the stilbenes, has resveratrol 
from grapevines (Vitis vinifera L.) as the most known representative but will not be further 
discussed in this thesis. 
 
Figure 1.1: Classification of dietary phytoestrogens. 
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 The aromatic ring and a hydroxyl group are important features for the binding of any 
chemical with the estrogen receptors. Additionally, the steric and hydrophobic properties, 
size and branching of the alkyl group and its location on the phenolic ring, will play an 
important role in their binding capacity. The structural similarity of estrogenic flavonoids to 
E2 lies in their composition of a planar ring system that includes a p-hydroxy-substituted 
aromatic ring that is approximately 12 Å away from a second in-plane hydroxyl group [12] 
(Figure 1.2). Generally, phytoestrogens have a narrow structural-activity relationship, which 
is influenced by certain structural features or deviations and often metabolisation can play a 
crucial role.   
 
Figure 1.2: Structural relationship between the endogenic 17β-estradiol and the flavan equol 
(arrow indicates the similar distance between the two hydroxyl-groups of both structures). 
1.2 Occurrence and sources 
 The family of the Leguminosae represents almost exclusively the isoflavones, which are 
also the most studied group of phytoestrogens [4]. Isoflavones are found in legumes and 
beans and side-products, but soybeans (Glycine max (L.) Merr.) are the main dietary 
source (1.2-2.4 mg/g dry weight) [13]. Nevertheless, isoflavone content of soy products 
widely varies, first of all due to different varieties, crop years and location [14] and 
secondly through processing like filtration, rinsing and extraction with alcohol [15]. 
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Daidzein, genistein and glycitein are the major isoflavones and they occur in plants as β-
D-glycosides daidzin and genistin and their respectively 4’-methyl ether derivatives 
formononetin and biochanin A (Figure 1.3). Despite the high stability of the glycosides 
during processing, once ingested, they are enzymatically hydrolyzed by the microflora to 
their corresponding aglycones. This biotransformation can result in the formation of 
dihydrodaidzein, O-desmethylangolensin (O-DMA) and finally equol from daidzein and 
dihydrogenistein, which is metabolized into 6’-hydroxy-O-desmethylangolensin, and the 
latter into 1,3,5-trihydroxybenzoic acid and finally p-ethyl-phenol, all originating from 
genistein [13, 16] (Figure 1.3). The flavan equol, which is a more potent phytoestrogen 
than its precursor daidzein, can be formed by only 30% of the humans, which 
contributes to the important inter-individual variability that is observed in studies [17]. 
 
Figure 1.3: Bacterial (gut) metabolism of the isoflavones daidzein and genistein. 
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 The female inflorescences of the hop plant (Humulus lupulus L.), a perennial climbing 
vine in the Cannabaceae family, which are used in the brewing industry to add flavor 
and bitterness to the beer, are the dietary source of several prenylated flavonoids (with 
an average daily intake of 0.14 mg prenylflavonoids). More specific, the polyphenolic 
fraction of hops includes the flavanones 8-prenylnaringenin (8-PN), 6–prenylnaringenin 
(6-PN), isoxanthohumol (IX) and their prenylated chalcones desmethylxanthohumol and 
xanthohumol (XN) (Figure 1.4). The most abundant chalcone in hops (up to 1% w/w in 
dry cones) and concomitantly beer, is XN, which can be thermally isomerised into the 
proestrogen IX during the brewing process [18]. The latter is prone to metabolisation to 
the very potent phytoestrogen 8-PN, by liver enzymes [19] or intestinal gut bacteria. In 
parallel with equol, this last process is also depending on the right microbial community 
for the conversion [20] and can be of great influence on the biological effectiveness. 
Although the concentration of 8-PN in beer is quite low (less than 20 µg/L) [21], its 
occurrence has to be considered, given the fact that it is a very potent phytoestrogen 
and the possible metabolic conversion of the more abundant IX.  
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Figure 1.4: Prenylated flavonoids from hops (Humulus lupulus L.). Thermal isomerization can give 
rise to isoxanthohumol from xanthohumol and 8-prenylnaringenin and 6-prenylnaringenin from 
desmethylxanthohumol. 
 
 Lignans are abundant in the most fibre-rich food sources like cereals, fruits and 
vegetables, with rye and flax seed (Linum usitatissimum L.) among the most important 
ones. Typically, flaxseed contains around 0.8 mg secoisolariciresinol per g dry weight 
[13] and this content increases after crushing and defatting [22]. The so-called 
mammalian lignans enterodiol and enterolactone, are the active phytoestrogens and are 
formed by microflora in the proximal colon, out of respectively, secoisolariciresinol and 
matairesinol, which occur as glycosides in the plant [23] (Figure 1.5). Enterolactone can 
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also be formed out of enterodiol. Also pinoresinol and lariciresinol, both precursors of 
secoisolariciresinol, as well as syringaresinol, can be metabolized to enterolactone [24]. 
Thus, many plant lignans from whole grain products can be converted to 
phytoestrogens. 
 
Figure 1.5: Mammalian lignans and their precursors. 
 
 The coumestans coumestrol (Figure 1.6)  and 4’-O-methylcoumestrol have as most 
significant sources sprouts of clover (Trifolium pratense L.) and alfalfa (Medicago sativa 
L.), with a coumestrol content of 5.6 mg and 0.7 mg/g dry weight, respectively [25].  
 
Figure 1.6: Coumestrol. 
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1.3 Oral bioavailability and disposition 
The assessment of bioavailability of phytoestrogens must be based on data from 
absorption, distribution, metabolism and excretion (ADME) and  implies the extent and rate 
at which they become available in the general circulation.  Generally, the oral bioavailability 
of isoflavones and lignans has already been well characterized in humans. In fact, a rather 
efficient absorption is observed after a single dose of aglycone equivalents of the isoflavones 
genistein and daidzein, with peak plasma concentrations appearing after 5.2 h and 6.6 h, 
respectively [26]. The same for enterolignans which appear in the plasma 9-10 h after the 
ingestion of purified secoisolariciresinol diglucoside [27]. In contrast, there are very few data 
on the bioavailability of prenylflavonoids. The ingestion of an oral single dose of 8-PN results 
in a first serum peak 1.0-1.5 h and a second peak after 7-8 h [28, 29]. Unfortunately, the 
hop-derived XN was suspected to have a very poor systemic bioavailability according to 
results from experiments with Caco-2 monolayers [30], and, in fact this was later confirmed 
by Bolca et al. in a human in vivo trial [31].  
 
Flavonoids, isoflavonoids and lignans mostly occur as inactive compounds in the plants 
and food products, mainly as glycosidic conjugates, except for the prenylated hopflavonoids 
which are already in their aglycone form [1]. The bioavailability depends on complex 
enzymatic conversions in the gastrointestinal tract and starts with the formation of the 
active form of the compounds through hydrolysis by membrane-associated β-glucosidases in 
the small intestine or members of the colonic microflora [32-34]. This deglycosylation is 
considered crucial, as proven by studies with human intestinal epithelial cell monolayers, 
where the aglycones are transported and their glycosides not [35, 36]. Moreover, glucosides 
of isoflavones have not been identified in plasma either [36]. Absorption of the formed 
aglycones takes already place by the enterocytes of the small intestine or lower, in the large 
intestine. Nevertheless, before this absorption takes place, intestinal bacteria can already 
accomplish some metabolisation, e.g. formation of enterolignans enterodiol and 
enterolactone from the most important precursors (iso)lariciresinol, pinoresinol and 
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matairesinol. Moreover, this metabolism appears to be a requirement for absorption of the 
former compounds, as concentrations of the parent compounds in blood are negligible [23].  
 
Then, via the portal vein, the absorbed compounds get distributed throughout the body 
and get conjugated with glucuronic and sulfuric acid by phase II enzymes (UDP-
glucuronosyltransferases and sulfotransferases) in the liver, a process that can also occur in 
the intestinal epithelium. Phase II conjugation, the main metabolism for isoflavones and 
lignans results preferentially in conjugation at position 7 of the molecule and gives primarily 
monoglucuronides [37, 38]. Also for XN (in vitro) [39] and IX and 8-PN, not phase I 
metabolism, but preferentially extensive phase II conjugation is observed [29, 40, 41]. The 
conjugated aglycones are then excreted either through urine or through bile, which in the 
last case implies their enterohepatic circulation. This recirculation exposes the conjugated 
compounds again to deconjugating microbial enzymes and promotes the re-uptake or 
further metabolism and degradation in the lower intestine or even fecal excretion [13]. For 
example, equol peaks in plasma can be observed even 36 h post ingestion [34] and for 
enterolactone the peak plasma and urinary concentrations were measured at 24 h and 
between 25 h - 36 h respectively.  
 
The metabolic conversions that plant isoflavones, lignans and prenylflavonoids undergo, 
can result in hormone-like compounds with an altered biological activity (increased or 
decreased bioactivity). Furthermore, these transformations, which depend largely on the 
intestinal environmental conditions, show considerable individual variation due to, among 
others, different consumption patterns, gender, age, food matrix, early exposure, chemical 
composition and e.g. the administration of antibiotics, which may completely put a stop to 
any conversion [34]. Concerning the conversion of daidzein, secoisolariciresinol and IX, into, 
respectively, O-DMA and equol; enterodiol and enterolactone; and 8-PN, it is even possible 
to classify the individuals into, weak, moderate and strong phenotype producers [42]. This 
variability is highly reflected in the reports of urinary and plasma levels of phytoestrogens 
from most clinical studies with phytoestrogen-containing food or dietary supplements.  
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1.4 Biological activities 
Although some early work has been conducted on isoflavones, the last two decades, 
they received more widespread attention for their possible role in disease prevention. The 
lignans and prenylflavonoids have also been studied likewise, moreover because of the 
suggestion to use them in dietary supplements as a safer alternative for the classical though 
controversial hormone replacement therapy. Besides that, numerous studies were 
dedicated to the investigation of other physiological effects and to the elucidation of the 
mechanisms by which they might function. The prediction of the in vivo effects of 
phytoestrogens is a difficult task, as it depends on numerous factors like route of 
administration, bioavailability, half-life, dose and duration of intake, intrinsic estrogenic state 
and nonhormonal secondary mediated actions [43]. In fact, their wide and complex range of 
biological activities can roughly be divided into estrogenic and antiestrogenic effects and 
others, like various cancers and cardiovascular diseases [44].   
 
As aforementioned, phytoestrogens, because of their estrogenic and antiestrogenic 
actions in vitro and in vivo, are often considered as selective estrogen receptor modulators 
or SERMs. Like endogenous estrogens, phytoestrogens can regulate processes in a wide 
variety of tissues, mostly by interacting with nuclear estrogen receptors (ER). Up till now, 
two isoforms of ER have been identified, i.e. ERα and ERβ, which differ in the N-terminal 
ligand independent transactivation domain and ligand binding domain at the C-terminus, as 
well as in tissue distributions and relative binding affinities [45]. Both ERα and ERβ are 
expressed in utero-ovarian, breast and vascular tissue, ERβ mainly in brain, bone, lung tissue 
and prostate [46].  
 
Regarding to the estrogenic potency, which can be deduced from in vitro bioassays, 8-
PN, still takes first place of all phytoestrogens, relative to the naturally occurring 17β-
estradiol [47, 48]. 8-PN is considered to be a pure ERα-agonist, exhibiting an estrogenic 
activity profile comparable to estrone, and is 70 times less potent than 17β-estradiol [48]. 
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Furthermore, it exerts a bone tissue-specific estrogenic effect, with minimal trophic effects 
on uterus and endometrium [49]. Therefore, 8-PN is suggested as a potential compound for 
HRT in menopausal women. Nevertheless, more in vivo trials with target groups are 
required, although preliminary results from a randomized, placebo-controlled trial with a 
hop extract by Heyerick et al. [50] showed a promising outcome on the relief of menopausal 
discomforts. Next, with decreasing estrogenic potency and in following order come 
coumestrol, genistein, equol and daidzein which all are partially ERβ selective agonists [46, 
47]. Both enterolignans enterodiol and enterolactone have even less estrogenic activity, the 
latter 10-fold higher than the former [51]. Although XN and IX do not possess any estrogenic 
activity themselves, due to bio-activation they can be categorized as pro-estrogens [19, 52]. 
At high plasma levels, the antiestrogenic effects of phytoestrogens may be provoked by 
competition with endogenous estrogens for binding with the ER, which can result in 
prevention of estrogen-stimulated cancer growth [53]. At micromolar concentrations, 
genistein, daidzein, equol and enterolactone showed estrogenic effects in vitro [54], but 
genistein, on the other hand, at higher concentrations also inhibited cell growth of human 
cell lines [55]. This last effect appeared not to be solely ER-dependent, as it also occurred in 
the ER-negative cell line. XN has been described to have an antiestrogenic activity by 
Gerhauser et al. [56], which was later refuted by Overk et al. [57]; however, both studies 
were conducted using a different methodological approach. 
 
In the Western world, breast, prostate and colorectal cancer still belong to the most 
leading causes of mortality [58]. A large body of epidemiological studies showed that 
consumption of food rich in isoflavones and lignans may contribute to the lower incidence 
rates of former diseases in Asian countries [59, 60]. Their protective effects may be due to 
the lowering of circulating levels of unconjugated sex hormone, as soy isoflavonoids and 
lignans were shown to increase the levels of sex hormone binding globulin (SHBG) [61]. In 
women, newly diagnosed with breast cancer, a high excretion of both equol and 
enterolactone was associated with reduced breast cancer risk, when compared with 
matched controls [62]. It has been noted that early exposure to genistein, with its dual 
activity on cancer cells and more effective in inhibiting growth of non-neoplastic human 
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mammary cell lines than mammary cancer cells, may be important for breast cancer 
chemoprevention [63]. This narrow balance between risk or prevention, presumably 
depending on dietary intake levels, is also observed with coumestrol and enterolactone [64]. 
A significant decrease of the urinary excretion of the genotoxic metabolites of estradiol and 
estrone, i.e. 16α-hydroxyestrogens and 4-hydroxyestrogens, has been correlated with higher 
ingestion of soy and flax-derived phytoestrogens. The ratio 2-hydroxyestrogens, which are 
known to exert protective effects and are negatively correlated with the level of SHBG, to 
16α-hydroxyestrogens is considered to be an important biomarker. Although, the evidence 
for possible preventive effects of phytoestrogens is sometimes conflicting. Importantly, the 
effects seem to be depending on the hormonal status of the women (pre- or 
postmenopausal).  
 
Then, concerning the possible cancer-related activities of hop-derived prenylated 
flavonoids, major attention has been focused on XN. The latter seems to inhibit in vitro the 
initiation, promotion and progression stages of carcinogenesis and therefore, appears as 
broad-spectrum chemopreventive agent [65]. Xanthohumol works on different pathways 
that may be of concern in the development of cancer, first, already at low micromolar 
concentration, by the inhibition of metabolic activation of procarcinogens, a process 
catalyzed by cytochrome P450 enzymes [66, 67]. This mechanism was demonstrated by 
Miranda et al. [66] for XN, but also for IX and 8-PN, which are potent inhibitors of the 
metabolic activation of the heterocyclic amine, 2-amino-3-methylimidazol[4,5-f]quinoline 
(IQ). Secondly, several research groups proved that XN is capable of inducing the 
detoxification enzyme (phase II enzyme), quinone reductase (QR), which is a marker of 
chemoprevention [56, 68, 69]. Finally, XN may also prevent the growth of tumors at an early 
stage, for instance by the induction of apoptosis [70] or the inhibition of inflammatory 
signals by inhibition of cyclooxygenase (COX) enzymes [56] and may, indirectly influence, by 
the inhibition of NO (nitric oxide) production, the induction of angiogenesis [71]. On the 
other hand, little is known concerning the possible chemopreventive effects or even adverse 
effects of the full ERα agonist 8-prenylnaringenin, and its precursor isoxanthohumol. 8-PN 
showed similar growth-stimulatory effects as 17β-estradiol in the human MCF-7 breast 
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cancer cell line [72]. Nevertheless, recently, Brunelli and co-workers suggested for 8-PN 
inhibitory effects on epidermal growth factor (EGF)-triggered pathways [73] and dose-
dependent apoptosis in breast cancer cells [74]. Other mechanisms, such as inhibition of 
aromatase activity [75, 76] and anti-angiogenic effects [77] have also been proposed. Bolca 
et al. [78], in their bioavailability study with hop prenylflavonoids, noted negligible hop-
derived E2α- and E2β-equivalents in human breast tissue (compared to the E2 tissue 
exposure) after a 5-day oral treatment period with hop-derived prenylflavonoids, which are 
unlikely to provoke adverse effects. More studies with longer-term administration will be 
required to rigorously evaluate possible effects and draw concise conclusions about the 
safety of the use of hop-derived food supplements.  
 
Another important focus has been on the possible health effects of phytoestrogens in 
cardiovascular diseases (CVD), a major death cause for both sexes, but especially for 
postmenopausal women, who suffer from an increasing risk due to a deficiency of gonadal 
steroid production. Apart from the direct influence on the vascular system due to the loss of 
endogenous estrogens, in general, postmenopausal women also show alterations in their 
lipoprotein profile. In fact, they mostly suffer from a decrease of the plasma concentrations 
of high density lipoprotein (HDL) and increasing plasma concentrations of low density 
lipoprotein (LDL) cholesterol [13]. The cardioprotective effect of higher estrogen levels or 
premenopausal hormone replacement therapy after menopause is already well established, 
but epidemiological data support that also the consumption of phytoestrogens can make a 
contribution [9]. Already for many years soy protein has been recognized for its 
hypocholesterolemic effect and a meta-analysis of 38 controlled clinical trials by Anderson et 
al. [79] has reported the reduction of total, LDL cholesterol and triglycerides by soy 
consumption. Although it must be emphasized that generally the effect on 
normocholesterolemic individuals is less or even not detectable [80]. Moreover, several 
clinical trials using isolated isoflavones have not shown a beneficial effect on serum lipids 
and, therefore, it is generally accepted that the protein matrix is necessary for the 
effectiveness of isoflavones on blood lipids [81-83]. The hypocholesterolemic effects may be 
acquired by an increased bile acid secretion and removal of LDL by hepatocytes as well as an 
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enhanced thyroid function [84]. Other mechanisms for the isoflavones, have been 
suggested, especially for genistein, which could acts as an inhibitor of tyrosine-specific 
protein kinases in vitro, and in this way may influence the process of coagulation [85]. 
However, in a clinical trial these results could not be observed after intake of soy 
supplements [86]. The antioxidant activity of soy isoflavones, in vitro and in vivo, provoked 
by a direct or indirect enhanrecement of catalase, superoxide dismutase, glutathione 
peroxidase and glutathione reductase enzymes, was reviewed by Kurzer and Xu [13] and 
affects the resistance of LDL to oxidation. The association between lignan intake and CVD 
has been studied to a far lesser extent.  
 
A prospective large-scale study among Dutch women has reported on the relation 
between lignan intake and cardiovascular disease risk. The results did not support the overall 
protective effects of dietary intake at the habitually low level, with the exception of a small 
risk reduction for smokers with a higher lignan intake [87]. Moreover, no association 
between dietary intake of lignans and CVD could be found in another prospective study [88]. 
One study, albeit, reported lower risk of acute coronary events and CVD-related death in 
men [89]. In post-menopausal women a higher intake of lignan and isoflavonoid containing 
foods was associated with a more favorable waist to hip ratio, triglyceride levels, metabolic 
score and aortic stiffness [90, 91]. Generally, clear clinical endpoints concerning the possible 
risk reduction of CVD by lignans have not been established yet, according to Peterson et al. 
[92] mainly due to differences in dosages between intervention studies and habitual 
Western diet patterns.  
 
The possibilities of applying coumestrol and prenylated flavonoids in CVD prevention 
have been scarcely explored. Their antioxidant properties will certainly be of importance in 
this health-related topic. For instance, Miranda et al. [93] and Stevens et al. [94] 
demonstrated that prenylated chalcones, especially XN, can inhibit oxidation of human LDL, 
at low micromolar concentrations. Furthermore, the inhibitory activity of XN against 
diacylglycerol acyltransferase (DGAT) can reduce the triglyceride synthesis and indirectly 
influence vascular health [95].  
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2. ANALYSIS OF PHYTOESTROGENS IN BIOLOGICAL MATRICES 
2.1 Introduction 
The determination of phytoestrogens in biological samples, either qualitatively or 
quantitatively, requires an optimized procedure, mostly unique for the sample, the target 
compounds and the used analytical method. Nevertheless, the growing laboratory costs for 
both staff and materials, necessitate the development of simple, but efficient protocols, 
which is a very challenging task. This starts with a dedicated clean-up procedure of the 
sample, which depends on the origin of the sample, the target compound(s) and the used 
analytical method. In the very beginning, phytoestrogens were analyzed with the use of 
imprecise and insensitive techniques, such as thin layer and paper chromatography. Then, in 
the mid-1980s, the principal method for phytoestrogen analysis was gas chromatography 
coupled with mass spectrometry (GC-MS), a technique which is nowadays still being used, 
although it is very labor intensive [96]. More commonly applied, mainly because it requires 
less sample preparation and is a relatively rapid way to separate and quantify 
phytoestrogens, is high performance liquid chromatography (HPLC) with ultraviolet (UV) 
detection. When more sensitivity is required, to measure concentrations of less than parts 
per million, the ultimate solution is HPLC coupled with (tandem) MS. The latter requires a 
less destructive sample preparation than for GC-MS, where conjugating groups must be 
removed prior to analysis. Nevertheless, the measurement stays dependent on the 
availability of internal standards for each analyte and the ability to produce molecular ions. 
Ultimately, there is a general and great demand for more rapid forms of analysis, and the 
non-chromatographic immunoassay techniques may offer a reasonable solution for this 
problem.  
 
The second section of this general introduction will mainly discuss the analytical 
methods that were relevant for this study and were applied during the research, more 
specifically, liquid chromatography-mass spectrometry (LC-MS) and immunotechniques 
based on monoclonal antibodies (mAbs) such as an enzyme-linked immunosorbent assay 
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(ELISA), immunocytochemistry (ICC) and immunoprecipitation (IP) techniques. The present 
state of the art of the former techniques in the analysis of phytoestrogens will be outlined. 
2.2  Sample preparation 
Generally, sample preparation for the analysis of phytoestrogens in food supplements is 
relatively simple compared to the one for biological samples. Phytoestrogens and their 
metabolites are present in biological samples such as urine and serum in parts per billion to 
parts per million concentrations, therefore, enrichment of the sample is in most cases 
necessary, also depending on the type of analysis that is being used. Before analysis there is 
also a need to separate them from the major constituents of these matrices. This isolation or 
extraction is not always 100% efficient and the addition of an internal standard (IS) is highly 
recommended to correct for unknown losses. The most commonly used internal standards 
range from deuterated (2H) or carbon-13 (13C) labeled stable isotopes or compounds that 
possess identical structural and chemical properties as the analytes of interest. The internal 
standards are naturally not present in the sample and have to be added in known 
concentrations. Correction is then done using the ratio of the analyte to the internal 
standard, measured during analysis. Nevertheless, no correction is made for losses before 
addition of the IS, during the hydrolysis of glucuronidated or sulfated ester forms of the 
phytoestrogens. Importantly, in biological fluids predominantly those conjugated forms are 
present, besides 1-5% of the total phytoestrogens that may be in the unconjugated form. 
Therefore, glycosides, glucuronidated or sulfated ester forms of suitable analogous 
compounds have also been used to correct for losses during extraction or incomplete 
hydrolysis [96, 97].  
 
To convert conjugated forms of the phytoestrogens into their aglycones, an enzymatic 
method is commonly used, applying a mixed β-glucuronidase/sulfatase preparation from 
Helix pomatia. Because biological samples often contain organic substances like proteins and 
lipids or other suspended material, a filtration step at the beginning of the sample 
preparation or at time of collection can be required. Although, a centrifugation step can also 
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be used for that purpose. For the analysis of plasma samples, protein precipitation with acids 
or water-miscible organic solvents has been an attractive technique, due to several 
advantages such as its speed, simplicity of application and universality. Nevertheless, the 
sample can never get so clean as with liquid-liquid extraction (LLE) or solid phase extraction 
(SPE) and in the end may require longer run times due to LC or MS problems or cause matrix 
effects, which has made the use of this traditional technique less obvious. Furthermore, the 
availability of automated LLE or SPE extraction in 96-well plates has made them even more 
attractive. This automation is especially recommended for the routine analysis of large 
batches of clinical samples, when accurate, precise and rugged high-throughput sample 
preparation is needed. SPE is commonly performed with silica-based reversed phase C-18 
cartridges, although newer materials like copolymers of N-vinyl-pyrrolidone and 
divinylbenzene, generating hydrophilic-lipophilic balanced reversed phase sorbents (trade 
named as Oasis HLB) start to gain popularity. LLE is performed using either diethyl ether or 
ethyl acetate. Even a combination of both SPE and LLE techniques can be used [96, 98].  
2.3 Liquid chromatography – (tandem) mass spectrometry (LC-
(MS/)MS) 
In contrast to the very labor-intensive gas chromatography (GC), which has been 
commonly used for many years in the analysis of phytoestrogens, because of its potential of 
high resolution, selectivity and sensitivity, liquid chromatography (LC) obviates the need for 
derivatization. All phytoestrogens and their metabolites contain at least one aromatic 
structure, and therefore are able to absorb UV-light (with a maximum wavelength (λmax) 
ranging from 230 nm to 280 nm). Using a diode array detector (DAD), it is even possible to 
register the complete UV-spectrum of the molecule, eliminating the problems caused by 
differences in maximum UV absorption. Nevertheless, the concentrations of phytoestrogens 
and their metabolites in biological samples are generally too low to be measured with UV-
detection alone, and the non-specificity of this detection method, has led to the coupling of 
LC with (tandem) mass spectrometry ((MS/)MS). This combination gives an efficient 
separation and excellent identification of individual compounds. Generally, chromatographic 
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separation of phytoestrogens is carried out with a reversed-phase (RP) C-18 column with a 
mobile phase of methanol and/or acetonitrile and water, all of them containing a small 
amount of an acid as modifier. Those modifiers (e.g. formic acid or acetic acid or 
trifluoroacetic acid), enhance the dissociation of phytoestrogens and their metabolites in a 
solvent system, and thus other parameters such as the separation, resolution and peak 
shape. Concomitantly, the addition of volatile additives also favors the ionization efficiency 
in the interface of the MS detector [96, 99]. 
   
 In the late 1980s, primarily a thermospray (TSP) interface was used in LC-MS analyses 
and was also applied for the analysis of phytoestrogens by Setchell et al [100].  Due to some 
practical limitations of robustness and stability of this type of source, atmospheric pressure 
ionization methods like electrospray and atmospheric pressure chemical ionization are 
nowadays the state-of-the-art. Phytoestrogens are relatively polar to apolar compounds, 
and the aglycones have a low molecular weight (< 1000 amu) and can be ionized through 
APCI as well as ESI [101].  
 
ESI has been dominating the field of MS detection for the determination of 
phytoestrogens. Little fragmentation of the analyte occurs with this technique, as ions are 
already formed in the solution that enters the source. The application of an electrical field 
then generates nebulization of the eluens and after drying by heated nitrogen gas or infrared 
lights, the formed ions enter a capillary and are attracted by the mass analyzer. Different 
from ESI, in APCI the ionization takes place chemically in the gas phase. A corona discharge 
needle, which generates a flow of electrons initiates this process. Charge transfer occurs 
over the nitrogen to the solvent molecules, to the compounds of interest. APCI can be 
applied to molecules of diverse polarity, on the condition that they are volatile and thermally 
stable. Generally protonated [M + H]+ or deprotonated [M – H]- ions are formed , for positive 
or negative mode MS, respectively. Formation of simple adduct ions [M + Na]+ or [M + NH4]
+ 
and [M + H – H2O]
- occasionally occurs too [99].  
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Next, the mass analyzer, mostly a quadrupole MS analyzer, sorts the formed ions on the 
basis of their mass to charge ratio (m/z). The use of multiple MS instruments, like the very 
popular triple quadrupole (Figure 1.7), leads to very detailed structural information (MS/MS 
spectrum) and highly selective detection of phytoestrogens, both for identification and 
quantification. By performing mass spectrometry in multiple reaction ion monitoring or 
MRM, a highly sensitive and selective method can be developed for the analysis of target 
compounds. The advanced triple quadrupole detector allows the selective introduction of 
ions with a specific mass-to-charge value, which are induced to fragment in the second 
quadrupole (collision induced dissociation or CID) and the daughter fragment ions are then 
analyzed in the third analyzer. This approach is most frequently used in the analysis of 
phytoestrogens. 
 
 
Figure 1.7: A triple quadrupole detector for MS/MS analysis. 
 
   Although the use of LC-MS(/MS) in the analysis of phytoestrogens has many 
advantages, one major limitation has to be considered, that is the effect of co-eluting 
residual matrix components on the ionization in API interfaces, the so-called matrix effect 
[102]. Typically, this effect results either in signal suppression or enhancement and 
concomitantly affects method performance parameters like limit of detection and 
quantification, accuracy, precision and linearity. Ion suppression or enhancement depends 
mainly on the sample matrix, exogenous materials (sample tubes, anti-coagulants), 
chromatography, mobile phase additives and the ionization mode (ESI > APCI) [103]. 
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Unfortunately, the underlying mechanism of matrix effect is not yet fully resolved, and even 
the source design of the mass spectrometer can play a role [104]. This issue has already 
been highlighted and discussed by many authors and various suggestions have been 
presented to minimize it in LC-MS analysis: (i) a more selective and extensive sample 
preparation, which of course is time-consuming and increases the risk of losses during the 
several consecutive steps [105]; (ii) improvement of the HPLC separation efficiency [106]; (iii) 
dilution of extracts or decreasing the injected amount of sample [107]; (iv) decreasing the 
flow rate [108]. If aforementioned approaches do not eliminate the matrix effects, 
compensation by an appropriate calibration technique is mandatory [109]. This can be done 
by the following options: (i) internal standard calibration with structural analogues or 
labeled internal standards, although the latter also have been reported to suppress analyte 
ionization and are not always commercially available or are quite expensive; (ii) matrix 
matched standards, which is often not possible due to the lack of appropriate matrices and 
(ii) standard addition, which is though labour-intensive and time-consuming, but the 
ultimate solution if previous alternatives are not possible. Less common analytical solutions 
have also been suggested, e.g. echopeak injection of standards (injection of standard in 
close proximity of the analytes) and the use of a nano-splitting device or continuous post-
column infusion.  
 
For the evaluation of matrix effects during LC-MS(/MS) method development and 
validation Matuszewski et al. [103, 110] have published a valuable strategic approach. It 
involves the determination of peak areas for the analyte in two different sets of samples, 
one consisting of neat standards, resulting in reference peak area(s) and one prepared in 
blank matrix extract which is spiked after extraction. By comparing those sets of quantitative 
data, the matrix effect can be calculated and expressed.  
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2.4 Immunochemical techniques 
The basis of all immunochemical techniques is the reversible interaction of an antibody 
with its corresponding antigen, which is a highly specific and mostly of high affinity. In 
research, antibodies can serve as key molecules to study almost any interesting molecule, 
which leads to a large possible variation in assay specificity. Antibodies can be implied in 
screening analysis for both single and simultaneous measurement of multiple analytes, for 
the elucidation of the subcellular localization of an antigen, the isolation of the antigen from 
a mixture of molecules or to study other molecules that interact with the antigen. 
Immunochemistry opens up possibilities for the implementation of simple, rapid, robust, yet 
sensitive and easy applicable routine analyses in clinical laboratories [111].  
 Antibody structure 
Antibodies or immunoglobulins (Ig), function as a part of the immune system and are 
produced by B-lymphocytes in response to the presence of foreign molecules. They consist 
of a large family of host glycoproteins visualized as forming a typical Y-shape and perform 
two key functional roles: (i) they bind an antigen with their antigen binding sites, known as 
Fab fragments (or antigen binding fragments) and (ii) can serve as linkers between effectors 
of the immune system and specific antigens through their Fc fragment (or complement- 
binding fragment). Each antibody contains two identical copies of a light chain polypeptide 
(Mw of 25 kDa) and two identical copies of a polypeptide known as the heavy chain (Mw of 
50 kDa). Each light chain consists of one variable VL and one constant domain CL and each 
heavy chain of one variable VH and three constant domains, CH1, CH2 and CH3. The four 
chains are held together with disulfide bridges and non-covalent bonds like salt bridges and 
hydrogen bonds. A hinge segment between the Fab and Fc fragments allows lateral and 
rotational movement of the two antigen binding domains, and consequently a flexible 
interaction of the antigen binding domains with various antigen conformations [111, 112].  
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On the basis of the number of Y-like units and type of heavy chain (γ, µ, α, ε, δ) five 
classes of immunoglobulins can be distinguished: IgG, IgM, IgA, IgE and IgD. The IgG class, is 
divided into four subclasses (often referred to as isotypes; IgG1, IgG2a, IgG2b and IgG3) and 
forms the most abundant one in serum. IgD, IgE and IgG are each made up of a single 
structural unit. IgA, on the other hand may contain either one or two units and IgM 
antibodies consist of five disulfide-linked structural units. All known antibodies contain 
either kappa (κ) or lambda (λ) light chains and any antibody will have only one type of light 
chain and one type of heavy chain [111, 112] (Figure 1.8).    
 
Figure 1.8: Structure of an immunoglobulin [113]. 
 
Antibodies interact with epitopes or immunodeterminant regions of antigens. The 
molecules that evoke antibody production must harbor a degree of intrinsic structural 
complexity which is named as immunogenicity. Macromolecules such as proteins or 
carbohydrates or combinations of these, which have molecular weights greater than 1000 
Da or more, are natural immunogens that can evoke an immune response quite easily. 
Smaller structures like steroids, substituted aromatic groups and peptides, also called 
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haptens, have to be covalently linked to larger carriers before they can induce immune 
responses [114].  
The reversible antigen-antibody (Ag-Ab) binding can be characterized using the 
parameters affinity and avidity. The strength of the binding is expressed by affinity and in 
terms of concentration Ag-Ab complex at equilibrium (typically from micro- to picomolar). 
The overall stability of the Ag-Ab complex which is determined by the antibody’s affinity for 
the epitope, the number of binding sites per antibody and the geometric arrangement, is a 
measure for the avidity. Cross-reactivity of antibodies may influence the degree of 
specificity, but on the other hand it makes the immunochemical method applicable in 
situations where a class of structurally related molecules is targeted [111].      
 Polyclonal and monoclonal antibodies 
A polyclonal antiserum can be generated by the immunization of an animal (usually a 
rabbit, sheep or goat) and contains several immunoglobulins of different types, which can 
bind at various epitopes of the structurally complex immunogen. Apart from the capacity to 
form large insoluble immune complexes with the antigen and the ability to identify the 
antigen by the mixture of specificities, the use of polyclonal antibodies (pAbs) in 
immunoassays has certain limitations. These are mainly the non-uniform characteristics 
from batch to batch and between animals, and the heterogeneity at many levels: specificity, 
classes and isotypes of the antibody, affinity and reactivity [112].  
 
The limitations of polyclonal antibodies have led to the first attempt to produce 
monospecific monoclonal antibodies (mAbs), by Köhler and Milstein in 1975. They have 
identical physical, biochemical, and immunological properties and each monoclonal product 
is specific to a single antigen determinant of the immunogen (monospecific). Monoclonal 
antibodies are derived from single-antibody-producing cells immortalized by fusion to 
myeloma cells (a type of B-cell tumor) to form hybrid cells or hybridomas. After the selection 
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in a particular culture medium and screening, an in vitro cell line clone which produces a 
specific mAb is obtained. Monoclonal antibodies are powerful immunochemical tools with 
several advantages: (i) they constitute a well-defined reagent derived from one isolated 
clone, (ii) may be prepared from non-purified antigens, (iii) unlimited quantities of the same 
homogeneous reagent can be produced and (iv) their affinity and specificity are well-defined 
[112].    
 
Most commonly BALB/c mice are used for the immunization, as many of the first 
examples of myelomas (referred to as MOPC or mineral oil plasmacytoma) were isolated 
from these mice by intraperitoneal injection of mineral oil. Nowadays, derivatives of those 
cells, such as Sp2/0 and NS0 have become the most used partners for fusions. The antibody-
secreting cells are prepared from immunized animals which are injected with an antigen 
preparation and developed a good humoral response. Polyethylene glycol (PEG) is used as a 
fusing agent for the production of the hybridomas and fuses the plasma membranes of 
adjacent cells to form a single cell with two or more nuclei. Mitosis of this heterokaryon and 
consequent dissolving of the nuclear membranes, is then followed by the segregation of the 
individual chromosomes into daughter cells during further rounds of division. Hybridoma 
fusion process is not very efficient and a large number of unfused cells remain in the culture. 
Therefore, unfused myeloma cells are eliminated by drug selection. The addition of 
aminopterin (A) to the medium of the hybrids, blocks the de novo biosynthesis of purines 
and pyrimidines, essential for DNA synthesis. Cells will then be forced to use the salvage 
pathway utilizing hypoxanthine (H) and thymidine (T) and require a functional thymidine 
kinase (TK) and HPRT; therefore, this allows only fusions of myelomas with a non-functional 
hypoxanthine phosphoribosyltransferase (HPRT) and cells with a functional HPRT to grow. 
The fusion products are diluted in this selective HAT medium and plated out in multiwell 
tissue culture dishes. After testing of the hybridoma supernatant for the requested mAb 
production in dedicated enzyme-linked immunosorbent assays (ELISA), cells from positive 
wells are subjected to several rounds of limiting dilution in order to attain single-cell clones, 
which can then be screened and further expanded. The final and stable hybridomas are 
frozen for storage and in this way an unlimited supply of mAbs can be maintained. This 
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whole production can take less than 2 months but can also take more than a year, as every 
stage has its inherent problems which have to be dealt with [112, 114].   
 Immunoassays 
The most popular and powerful of all immunochemical techniques are the 
immunoassays, which can be divided into three classes, (i) the antibody capture or indirect 
competitive  immunoassays, (ii) the antigen capture or direct competitive immunoassays and 
(iii) the two-antibody or sandwich immunoassays. In a heterogeneous system, at least one 
separation step is involved to distinguish reacted from unreacted material, and those 
immunoassays that do not require separation are referred to as homogenous immunoassays 
[112].    
 
In the antibody capture assay (Figure 1.9), the antigen is attached to a solid support and 
the sample is added together with a constant and limited amount of labeled antibodies 
specific for the antigen. After washing, the quantitation is done by measuring retained 
antibody and the signal is inversely related to the concentration of antigen/standard in the 
sample. The detection can be performed in a one-step format with labeled antibody, but the 
two-step format, which makes use of a secondary labeled antibody specific for the bound 
antibody, provides several fold improved assay sensitivity.  
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Figure 1.9: Set-up of an antibody capture or indirect competitive immunoassay (competition < 
positive sample; no competition < negative sample in a one-step versus two-step format with color 
development). 
 
In the second and third type of assay a specific primary (or secondary IgG-specific 
antibody) is physically adsorbed or covalently attached to the solid support and unattached 
antibody is washed away.  
 
Then, in the direct competitive assay or antigen capture assay, in the presence of 
standard or sample antigen to be assayed, the quantitation is performed by measuring 
retained purified labeled antigen that was added (Figure 1.10).  
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Figure  1.10: Set-up of an antigen capture assay or direct competitive assay (competition < positive 
sample with color development; no competition < negative sample). 
 
In the popular sandwich immunoassay, which is primarily used to determine antigen 
concentrations, the binding of two antibodies occurs, either sequentially or simultaneously. 
For this purpose, multiple non-overlapping epitopes on the antigen are a requirement. A 
primary antibody recognizing an epitope of the molecule to be detected or an anti-Ig 
antibody can be immobilized to a solid phase. After incubation of the sample with the 
immobilized antibody and reaction with the first epitope, the solid phase is washed to 
remove unreacted components. The color reaction can be evoked, either directly by an 
enzyme-conjugated secondary antibody (Figure 1.11), or indirectly, by a third conjugated 
antibody against the Fc-portion of the second antibody [111]. The signal is proportional to 
the level of labeled detector antibody that is bound to the antibody-antigen complex.  
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Figure 1.11: Two types of sandwich assay format. 
Several possible formats of immunoassay can be performed with four variations in the 
assay, i.e. an assay in antibody excess, in antigen excess, as an antibody competition, or as 
an antigen competition [112].  
 
In immunoassays, the used proteins, which are antigens or antibodies, can be labeled 
with radioactive compounds, enzymes, biotin or fluorochromes. Radioimmunoassays (RIA) 
have been used in the beginning years of immunoassay application, but are now often 
replaced by the quicker and nonhazardous alternative using enzyme-conjugated labels, the 
enzyme immunoassay (EIA), such as the enzyme-linked immunosorbent assay (ELISA). The 
enzymes most widely used are horseradish peroxidase (HRP) and alkaline phosphatase (AP). 
A variety of aromatic phenols or amines, such as ABTS (2,2'-azinobis(3-ethylbenzothiazoline-
6-sulfonic acid) diammonium salt), TMB (3,3’,5,5’-tetramethylbenzidine) or OPD (O-
phenylethyldiamine) can be used as chromogenic substrates for HRP, and for AP the typical 
substrate used is p-nitrophenylphophate (pNPP). The labeling enzymes convert a colorless 
substrate to a colored end-product, which is being visualized in a spectrophotometer at a 
specific absorbance maximum and quantitated [111, 112, 115].  
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 Immunostaining (immunocytochemistry) 
Immunostaining, a technique first introduced by Coons et al. in 1941 [116], applies a 
labeled antibody to detect a specific protein or antigen in a sample (cells or tissues).  
Moreover, it will demonstrate both the presence and the subcellular localization of an 
antigen. Often cell staining is combined with conventional histological stains for the 
comparison of the localization of the antigen with other markers. Immunostaining 
techniques are conducted in four steps: (i) cell or tissue preparation, (ii) fixation, (iii) 
antibody binding and (iv) detection. The outcome of the immunostaining procedure or how 
easily the antigen is detected, depends on each of those steps, and consequently needs fine 
optimization. The local antigen concentration influences the signal strength and diffuse 
antigens are more difficult to detect than areas with concentrated antibody binding sites. 
The fixation is important for the preservation of cell morphology and tissue. Ideally, the 
fixation does not mask or alter the epitopes too much, and retains the authentic cellular and 
subcellular architecture. Hence, the type of antibody used to recognize the epitope(s) can 
also play an important role. For the antibody detection, mostly fluorescent markers are 
applied. They offer the advantage of a rapid visualization and improve assay sensitivity. 
Moreover, the use of new types of fluorophores diminishes the problem of photobleaching 
over time [111, 112]. Their advantage of speed and simplicity has made that the use of 
fluorescent labeling remains more popular than enzymatic labels. The availability of labeled 
antibodies with different emission spectra also offers the possibility to detect two or more 
antigens in the same experiment [117].  
 Immunoprecipitation 
Another useful application of specific antibodies is immunoprecipitation (IP), which is 
used to isolate and concentrate a certain antigen (usually a protein) out of a sample. A 
number of important characteristics of the antigen, like presence and quantity, relative 
molecular weight, rate of synthesis or degradation, presence of certain post-translational 
modifications, and interactions with other ligands, can be determined, especially when IP is 
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coupled to SDS-polyacrylamide gel electrophoresis. A protein mixture of the conditioned 
cells or tissue is made by lysis with detergent, to release the targeted antigens. Then, in the 
direct way, antibodies which are immobilized on (agarose) beads are added to the mixture 
and the antigens are captured onto the beads, via the antibodies. On the other hand, in the 
indirect procedure, antibodies are pre-incubated with the protein mixture to form Ab-Ag 
complexes. Then afterwards, protein A/G coated beads are added, to capture the antibodies 
with corresponding bound specific antigens. Finally, the immune complexes are purified 
from the bulk mixture and can then analyzed by gel electrophoresis, possibly followed by 
sequencing using MALDI mass spectrometry. Or, the gel can be transferred in Western Blot 
with other antibodies interacting with the antigen. IP combined with those other techniques 
can be used to gather a large amount of information about the antigen [112, 118].   
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CHAPTER 2 
 
 
Objectives  
AIMS AND OUTLINE OF THE THESIS 
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At each level of the research on phytoestrogens, from the original plant to the dietary 
supplement and finally the biological sample, an accurate, precise and reliable method for 
determination is mostly wanted. It is a necessary tool in the correlation of epidemiological 
and clinical intervention data with health outcome. Since the growing interest in the 
phytoestrogens and their application in the clinical environment, mainly as dietary 
supplement by peri- and postmenopausal women for the relief of vasomotor symptoms, 
the range of methods has broadly expanded.  
 
The determination of phytoestrogens in biological samples, either qualitatively or 
quantitatively, requires an optimized procedure, mostly unique for the sample, the target 
compounds and the used analytical method. Nevertheless, the growing laboratory costs for 
both staff and materials, necessitate the development of simple, but efficient protocols, 
which is a very challenging task. This starts with a dedicated clean-up procedure of the 
sample, which depends on the origin of the sample, the target compound(s) and the used 
analytical method. Initially, phytoestrogens were analyzed using imprecise and insensitive 
techniques, such as thin layer and paper chromatography. Then, in the mid-1980s, the 
principal method for phytoestrogen analysis was gas chromatography coupled with mass 
spectrometry (GC-MS), a technique which is nowadays still being used, although it is very 
labor intensive. More commonly applied, mainly because it requires less sample 
preparation and is a relatively rapid way to separate and quantify phytoestrogens, is high 
performance liquid chromatography (HPLC) with ultraviolet detection (UV). When more 
sensitivity is required, to measure concentrations of less than parts per million, the 
ultimate solution is HPLC coupled with (tandem) MS. The latter requires a less destructive 
sample preparation than for GC-MS, where conjugating groups must be removed prior to 
analysis. Nevertheless, the measurement stays dependent on the availability of internal 
standards for each analyte and the ability to produce molecular ions. Ultimately, there is a 
general and great demand for more rapid forms of analysis, and the non-chromatographic 
immunoassay techniques may offer a reasonable solution for this problem.  
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This PhD started as part of an integrated project on phytoestrogens present in the diet 
or in nutritional supplements (acron: FYTOES). The contracted research, which was 
supported by the Federal Public Services, department of Health, Safety of the Food Chain 
and Environment, aimed to study the biological availability, the physiological and 
toxicological impact of phytoestrogens with respect to human health. Moreover, the aim of 
the research was to get an estimation of the possible toxic effects, acute and chronic 
biological effects linked with the intake of phytoestrogens.  
 
At the beginning of this research project profound literature review (see Appendix; 
table A.1) demonstrated a clear demand for accurate and sensitive quantification methods 
for phytoestrogens in biological samples. Although both LC-MS and the more sensitive LC-
tandem MS methods were successfully applied for the simultaneous determination of 
isoflavones and lignans in urine and serum, none of them also included the hop-derived 
prenylflavonoids. Also, the majority of the reported methods for the quantitation of 
prenylflavonoids in biological samples focused on HPLC-UV instead of the more sensitive 
LC-MS. Therefore, the first objective and challenge was to develop and optimize a 
selective and sensitive analytical method based on high performance liquid 
chromatography–mass spectrometry (LC-MS) for the determination of thirteen 
phytoestrogens including their gut metabolites. Furthermore, this method had to be 
validated for its use in the quantification of the phytoestrogens in urine and serum. Next, 
the aim was to apply the method for high-throughput quantitative analysis of biological 
samples generated in an intervention dose-related study using phytoestrogen-containing 
products in test subjects. Moreover, this study included a co-supplementation phase 
(administration of isoaflavones, lignans and prenylflavonoids) and the developed method 
aimed to simultaneously measure all the phytoestrogens in one analytical run.  
 
 The second objective was to produce monoclonal antibodies against a selected group 
of phytoestrogens (genistein, daidzein, equol, coumestrol, enterodiol, enterolactone, 
xanthohumol, isoxanthohumol and 8-prenylnaringenin) and to apply them in a newly 
developed enzyme linked immunosorbent assay (ELISA). Furthermore, this ELISA test had 
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to be validated for its use in the analysis of urine and serum samples. Immunoassays 
applying polyclonal antibodies had already been successfully generated for both 
isoflavones, enterolignans and coumestrol (see Appendix: table A.2). To the best of our 
knowledge only monoclonal antibodies against daidzein, genistein and equol were 
available at the start of this PhD.    
 
A third objective of this thesis was to explore the possibility of using the developed 
antibodies in other immunochemical techniques, such as immunocytochemistry and 
immunoprecipitation. Those techniques were used for the determination of subcellular and 
molecular interactions of the hop-derived prenylchalcone xanthohumol. 
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CHAPTER 3 
 
 
Selective and sensitive detection 
of phytoestrogens with HPLC-MS 
METHOD DEVELOPMENT, OPTIMIZATION AND VALIDATION 
This chapter is partially based on:  
 
 
Development of a high-throughput LC/APCI-MS method for the determination of thirteen 
phytoestrogens including gut microbial metabolites in human urine and serum.  
Wyns, C., Bolca, S., De Keukeleire, D. and Heyerick, A.  
Journal of Chromatography B, 2010. 878(13-14): p. 949-956. 
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1. INTRODUCTION AND OBJECTIVES  
 
The investigation into the potential usefulness of phytoestrogens in the treatment of 
menopausal symptoms requires large-scale clinical trials that involve rapid, validated 
assays for the characterization and quantification of the phytoestrogenic precursors and 
their metabolites in biological matrices, as large inter-individual differences in metabolism 
and bioavailability have been reported. Since the beginning of research on phytoestrogens 
and their metabolites in a great diversity of matrices, from plants to human biological fluids 
and tissues, a wide range of analytical techniques for their determination and 
quantification have been reported. As reviewed by several authors [96, 99] the techniques 
used can be classified into chromatographic and non-chromatographic, with high-
performance liquid chromatography (HPLC) and gas chromatography (GC) as main tools in 
the former group and immunoassay techniques in the latter group. Generally, 
chromatographic separation is coupled to detection techniques like ultraviolet (UV) and 
mass spectrometry (MS). Most reported chromatographic methods cover detection and 
quantification of a limited number of phytoestrogens and/or their intestinal metabolites in 
biological fluids [119, 120]. Moreover, the greater part of the techniques require expensive 
equipment like a tandem mass spectrometer and analyses are often preceded by an 
intensive multi-step clean-up and complex sample preparation procedures such as 
derivatization to increase compound volatility for GC [121-123].  
 
This chapter describes how the development, optimization and validation of a new 
sensitive high-performance liquid chromatography-mass spectrometry method (HPLC-MS) 
for the quantitative and simultaneous determination of thirteen phytoestrogens including 
their most important gut microbial metabolites (genistein, daidzein, equol, 
dihydrodaidzein, O-desmethylangolensin, coumestrol, secoisolariciresinol, matairesinol, 
enterodiol, enterolactone, isoxanthohumol, xanthohumol and 8-prenylnaringenin) in 
human urine and serum was performed.  
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In the first part the development of a new and selective chromatographic method for 
the separation of 13 phytoestrogens is explained. A simple sample preparation procedure 
is used, consisting of enzymatic deconjugation using Helix pomatia β-
glucuronidase/sulfatase followed by organic liquid-liquid extraction (LLE) or solid-phase 
extraction (SPE) for urine or serum, respectively.  
 
In a second part the sensitivity of the mass detection of the phytoestrogens and their 
metabolites was optimized with an Agilent Multimode Source (MSD) SL (Superior Line) 
1200  single quadrupole mass spectrometer (Figure 3.1). This ion source is a MS-source, 
which can simultaneously generate APCI-ions and ESI-ions (mixed mode) and can operate 
both in the positive and negative mode. The SL-type also offers the possibility to set 4 MSD-
signals, which can solve problems of poor LC resolution for some compounds. For 
quantitative analyses preferably selective ion monitoring or SIM-mode is used. The latter 
influences detection sensitivity, but also the ionisation method and other settings of the 
ionisation source are important parameters. Using Flow Injection Analysis (FIA) (which 
introduces the sample directly in the mass detector), the optimal settings of the MSD were 
obtained.   
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Figure 3.1: Agilent multimode ion source [124]. 
 
The third part decribes the full validation of the bioanalytical method following the 
guidance for Industry – Bioanalytical Method Validation recommended by the Food and 
Drug Administration of the United States. Validation is conducted in order to confirm that 
the developed method is suitable for the quantification of a concentration of a certain 
analyte in a certain biological matrix. It has to be proved to allow an accurate and precise 
quantification of the targeted phytoestrogens and their metabolites covering the lower 
parts-per-billion range for the measurement of relevant urine and serum levels following 
ingestion of phytoestrogen-rich dietary supplements. This method was developed for the 
analysis of samples collected in a clinical trial conducted by the same laboratory in 
collaboration with the Ghent University Hospital, but can also serve as a guiding principle 
for other research groups in the domain of phytoestrogens.    
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2. EXPERIMENTAL  
2.1  Chemicals and reagents 
Isoxanthohumol (IX), xanthohumol (X(N)) and 8-prenylnaringenin (8-PN) were available 
in our laboratory [52]. Daidzein (DAID) en genistein (GEN) were purchased from Acros 
Organics (Morris Plains, NJ, USA), equol (EQ) from Extrasynthèse (Genay, France) and 
dihydrodaidzein (DHD) and O-desmethylangolensin (O-DMA) from Plantech UK (Reading, 
UK). Secoisolariciresinol (SECO), matairesinol (MAT), enterodiol (END), enterolactone (ENL), 
coumestrol (COUM), the internal standard 4-hydroxybenzophenone (4-HBPH) and β-
glucuronidase/sulfatase from Helix pomatia (Type H1) were obtained from Sigma-Aldrich 
(St. Louis, MO, USA). All reference standards had a minimum HPLC purity of 95%, except for 
matairesinol (85%). Sodium acetate was obtained from UCB (Leuven, Belgium). Methanol, 
diethyl ether and n-hexane used during sample preparation were from ChemLab 
(Zedelgem, Belgium). Formic acid was purchased from Acros Organics. Water, methanol 
and acetonitrile used for chromatography were of LC-MS grade (Biosolve, Valkenswaard, 
The Netherlands).  
2.2 Standards and samples 
Primary stock solutions of standards and internal standard were prepared in methanol 
at a concentration of 1.0 mg/mL and 0.2 mg/mL, respectively. From these, a working 
solution containing each of the thirteen standards was made at a concentration of 10 
µg/mL for IX, XN, 8-PN and COUM, and 100 g/mL for DAID, GEN, DHD, O-DMA, EQ, SECO, 
MAT, END and ENL. This mixture and further dilutions were used for spiking of urine 
samples, whereas a 2:5 dilution was used for serum samples. All the above mentioned 
solutions were kept at -20 °C.  
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For method development and validation, pooled human blank urine was collected 
from volunteers in the laboratory and pooled human blank serum was purchased from 
Innovative Research (Novi, MI, USA). Blank urine and serum from different individuals were 
obtained from the dietary intervention trial (FYTOES) for which the method was developed. 
All samples were stored at -20 °C until analysis. Prior to extraction, urine samples were 
centrifuged at 3000 rpm for 10 minutes to remove solids and the serum was defatted using 
n-hexane (1:1; v/v).       
2.3 Preparation of calibration standards and quality control samples 
Calibration standards (calibrators), except blanks, were prepared by spiking with the 
standard mixture to give concentrations for IX, XN, 8-PN and COUM ranging from 0.1 to 
400.0 ng/mL in urine, and 0.04 to 100.0 ng/mL in serum; for DAID, GEN, DHD, O-DMA, EQ, 
SECO, MAT, END and ENL, final concentrations in urine ranged from 1.0 to 4000 ng/mL and 
in serum from 0.4 to 1000 ng/mL. The added volume was less than 5% of the total volume 
of the samples in order to maintain the integrity of matrix. Quality control (QC) samples 
were freshly and independently prepared at three levels (low, medium and high). 
Moreover, DAID, GEN, DHD, O-DMA, EQ, SECO, MAT, END and ENL were spiked in urine at 
800 ng/mL for low QC level, at 2000 ng/mL for medium QC level, and at 3000 ng/mL for 
high QC level, and IX, XN, 8-PN and COUM were spiked at 80 ng/mL for low QC level, at 200 
ng/mL for medium QC level, and at 300 ng/mL for high QC level. In serum, a 1:5 dilution of 
the three QC level spike solutions was used. All these prepared solutions were aliquoted 
and stored at -20 °C until required.  
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2.4 Preparation of samples 
 Urine 
Urine sample preparation was based on a simple protocol previously published by 
Bolca et al. [125]. Prior to extraction, thawed urine samples (2.0 mL) were diluted with an 
equal volume of sodium acetate buffer (pH 5.0; 0.1 M), spiked with 100 µL internal 
standard (20 µg/mL) and 30 µL of deconjugation mixture (Helix pomatia 33 mg/mL; β-
glucuronidase activity: 300 U/mg and sulfatase activity: 15.3 U/mg) and then incubated for 
one hour at 37 °C. After incubation, a liquid-liquid extraction (LLE) was carried out (twice) 
using 5 mL diethyl ether and subsequent vortex mixing (30 s). The collected organic solvent 
layers (5 mL (2 x 2.5 mL) in total) were dried under a gentle nitrogen stream, dissolved in 
100 µL injection solvent and transferred into a vial for LC-MS analysis. The injection volume 
was set at 25 µL.  
 Serum 
For the extraction of the target compounds from the serum samples, a standard 
protocol that makes use of solid-phase extraction (SPE) was evaluated and optimized. The 
final method is summarized as follows: 800 µL of each sample was transferred to an 
eppendorf tube, diluted with an equal volume of sodium acetate buffer (pH 5.0; 0.1 M), 
and spiked with 50 µL internal standard and 800 µL deconjugation mixture and then 
incubated at 37 °C overnight. Bond Elut C18 SPE cartridges were preconditioned with 3 mL 
methanol and 3 mL sodium acetate buffer prior to use. The sample was applied and after 
washing with 3 mL aqueous methanol (5%) and 5 minutes drying of the sorbent under 
vacuum, the target compounds were eluted with 3 mL methanol. This was followed by 
drying of the eluents under a gentle stream of nitrogen and dissolving in the injection 
solvent. An injection volume of 25 µL or 50 µL was applied.    
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2.5 Instrumentation 
Method development, optimization and validation were conducted on an Agilent 
Technologies (AT, Santa Clara, CA, USA) 1200 series LC, equipped with a binary gradient 
pump, autosampler, thermostatted column oven and photodiode array UV detector. 
Chromatographic separation of all compounds in one single run was performed with a 
Waters XBridge C18 reversed phase (3.5 µm) column (3.0 mm id x 150 mm column) 
connected to a 3.0 mm id x 20 mm C18 guard column (3.5 µm) and maintained at a 
temperature of 55 °C. The mobile phase was degassed by the integrated AT 1200 series 
vacuum degasser. The mobile phase consisted of H2O (eluent A) and MeOH/MeCN (80:20, 
w/w) (eluent B), both acidified with 0.025% (v/v) formic acid. The gradient and flow rate 
were programmed as follows: 0-3.5 min: 35% to 45% B (flow: 0.6 mL/min), 3.5-5.5 min: 
isocratic 45% B (flow: 0.6 mL/min), 5.5-13 min: 45% to 100% B (flow: 0.6 mL/min), 13-16 
min: isocratic 100% B (flow: 0.8 mL/min), 16-16.10 min: 100% to 35% B (flow: 0.6 mL/min) 
and 3.9 min for re-equilibration of the column.  
 
MS analysis was performed using an AT multimode ionization source coupled to a 
single quadrupole detector (MSD), SL version. A standard APPI/APCI calibration mix was 
used for daily tuning of the MSD and processing of the data was carried out using the 
LC/MSD Chemstation software (Rev. B.02.01).  
2.6 Method development 
The development of a selective and sensitive analytical method for phytoestrogens 
was completed in two phases. In the first phase a selective chromatographic method for 
the separation of 13 phytoestrogens and their metabolites was optimized. Three important 
aspects that determine the selectivity of a chromatographic separation were considered: 
the mobile phase, the stationary phase and the pH. The mobile phase was composed of 
eluent A and eluent B, which were respectively H2O and a mixture of MeOH and MeCN. The 
addition of different concentrations of formic acid or trifluoroacetic acid and their 
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influence on retention and separation was regarded. Traditionally for the separation of 
phytoestrogens hydrophobic stationary phases are used, like a C18 column. The second 
phase of the development was optimization of the sensitivity of mass detection using the 
Agilent MSD. For quantitative analyses Selective Ion Monitoring or SIM-mode is preferably 
used. The latter will influence the sensitivity of the detection, but also the ionization 
method and the settings of the ion source are important. For each compound separately 
and the internal standard, using Flow Injection Analysis (FIA), a technique which directly 
introduces the sample on the mass detector, the optimal settings of the MSD-parameters 
were determined.  
2.7 Method validation 
The HPLC/APCI-MS method was fully validated following the guidance for industry of 
the US Food and Drug Administration (FDA) for the Validation of Bioanalytical Methods 
[126], with emphasis on the key elements described by Bansal et al. [127]. The following 
parameters were evaluated: selectivity, linearity, sensitivity, accuracy, inter- and intra-
assay precision and stability. Additionally, recovery for the analytes of interest was 
calculated and an assessment of matrix effects was made in correspondence with the 
strategy applied by Matuszewski et al. [110]. SPSS for Windows version 17.0 was used to 
carry out all statistical analyses.   
 Selectivity 
The selectivity, i.e. the ability of an analytical method to differentiate and quantify the 
analytes in the presence of other components in the sample, was assessed by analyzing five 
different batches of blank urine and serum. Samples (blank and zero) were processed by 
the appropriate extraction procedure and the resulting MS chromatograms were evaluated 
for the presence of interferences at the retention times of the analytes and the internal 
standard. 
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 Linearity and sensitivity 
Calibration curves were constructed over individually specified ranges using eight non-
zero standard points in six replicates. In addition, a blank (non-spiked sample) and a zero 
sample (only spiked with IS) were run to exclude the presence of interferences. Peak area 
ratios between the analytes and the internal standard were plotted against the nominal 
concentrations of the calibration standards. Unweighted linear regression analysis 
generated calibration curves with the standard equation: y= ax + b, where y is the peak 
area ratio, x the concentration, a the slope, and b the intercept of the regression line. The 
adequacy of the assumed model and the linearity of the calibration curves was evaluated 
by observing correlation coefficients (r²) and by visual inspection of the plots of the 
residuals (assumption of homoscedasticity). In addition, linearity was also assumed if the 
relative residuals did not exceed 15% and when at least 75% of the calibration standards 
met the stated acceptance criteria. Daily prepared calibration curves were constructed by 
injecting calibration standards at the beginning and at the end of each batch of samples. 
The limit of detection (LOD) and the limit of quantification (LOQ) of the method were 
defined as the lowest concentration with a signal-to-noise ratio of 3 and 10, respectively, in 
spiked samples, where the noise data were taken from the analysis of blank matrices.  
 Accuracy and precision  
The accuracy and the precision of the method were evaluated by analyzing QC samples 
at three levels (low, medium and high) (n=6) according to the procedure described above 
on four consecutive days. The accuracy (%RE) was calculated for each analyte in terms of 
correspondence of the measured mean value to the nominal concentration value. Analysis 
of variance (ANOVA) was used to calculate inter- and intra-assay precision for each QC 
level. To determine inter-assay variation (intermediate precision), the QC samples were 
analyzed at the three levels on four different days. The intra-assay variation (repeatability) 
was expressed for each QC level as the coefficients of variation (%CV) of measurements on 
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the same day. The accuracy and intra-assay precision values should be less than 15% and 
should not exceed 20% for the inter-assay variation.     
 Stability 
Two types of short-term stability experiments were performed at the low and high QC 
level. The autosampler stability was estimated on processed samples (n=3) at room 
temperature before and after an interval of approximately 15 h. The stability of the 
compounds was also examined during three freeze-thaw cycles at – 20 °C. Three replicates 
of spiked urine and serum samples were allowed to thaw at ambient temperature and 
were then refrozen for minimum 12 h. Aliquots of all samples were quantified at the end of 
the third freeze-thaw cycle. The concentration of each compound was compared to that of 
fresh samples and expressed in terms of degradation.  
 Recovery and matrix effect 
For the assessment of recoveries of the analytes and matrix effects caused by 
constituents in urine and serum, a strategy was applied which has previously been 
described by Matuszewski et al. [110]. The recovery was calculated as the ratio ((C/B)x100) 
between the responses of the QC samples in real blank matrix (low and high level, n=3) 
spiked after extraction (B) and before extraction (C) and is therefore not influenced by 
effects of the sample matrix. The absolute matrix effect (ME%) can be defined as the ratio 
of the responses between samples spiked after extraction (B) and pure standards in the 
mobile phase (A). When the value of this ratio ((B/A)x100) is < 100% there is signal 
suppression and signal enhancement is noted if the value is > 100%. Taking into account 
the heterogeneity of this effect between different sample batches, experiments were 
performed in six independent batches of blank urine and serum. 
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3. RESULTS AND DISCUSSION 
3.1 Chromatographic and mass spectrometric method development 
First, the reversed chromatographic separation of the thirteen analytes of interest and 
the internal standard was optimized. The Waters XBridge C18 column was preferred over 
the Omnispher (Varian) and Xterra (Waters) column because of its high separation 
efficiency. A gradient elution method for the separation of 13 phytoestrogens and their 
metabolites and an internal standard was optimized by varying the amount of methanol 
and acetonitrile in eluent B from 100% methanol to 100% acetonitrile with steps of 5%. 
Starting from a basic gradient (30% B to 100% B in 30 minutes) the final gradient was 
developed (as described in section 2.5). The mobile phases were acidified to 0.025% formic 
acid. The type of acid does not influence chromatography directly, but can influence the 
response of the mass detector. Formic acid is preferred over trifluoroacetic acid, because 
the latter with its high surface tension can negatively influence the ionisation efficiency and 
sensitivity. At last the column temperature was varied from 30 °C to 60 °C and finally set at 
55 °C, which resulted in the most efficient separation and a faster elution. Finally, our 
target compounds were eluted within 13 minutes with a resolution higher than 1.5, except 
for three components (Requol, genistein= 1.13 and Rgenistein,enterolactone= 1.06). After 20 minutes 
the column was washed and equilibrated for a next injection.  
 
Although complete resolution of EQ, GEN and ENL on UV-detection was not 
accomplished with the optimized LC method, subsequent mass selective detection allowed 
full separation of these compounds. The interface and MS parameters were optimized 
individually for each component and are listed in Table 3.1. Atmospheric pressure chemical 
ionization (APCI) in the positive mode was selected, except for END and for ENL which gave 
the highest sensitivity with APCI in the negative mode. Pseudomolecular ions were 
predominant, with [M+H]+ for the positive and [M-H]- for the negative mode. However, for 
SECO, the fragment ion [M+H-2H2O]
+ was found to constitute the base peak (i.e., 100% 
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relative intensity of the ion), in agreement with the observations by Bambagiotti-Alberti et 
al. [128] and Schmidt et al. [129]. Formation of this fragment ion is probably due to 
protonation of the γ-hydroxyl groups of SECO and subsequent loss of water from the 
unstable oxonium ions. In Figure 3.2, a typical mass spectrum of 8-prenylnaringenin is 
depicted (m/z= 340). Finally, using single-ion monitoring (SIM) and operating the MS in the 
chosen ionization method, the fragmentor voltage, a component-dependent parameter in 
MS sensitivity and possible initiator of collision-induced dissociation (CID), was varied from 
50 V to 400 V. A typical FIA-analysis on fragmentor voltage for 8-prenylnaringenin in SIM-
mode (pseudomolecular ion m/z= 341) and ionization through APCI+ is shown in Figure 3.3.  
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Figure 3.2: Scan of 8-PN in APCI positive mode (m/z 100-1000; fragmentor voltage 150 V; 
standard solution 8-PN (1 mg/mL; 0,1 µL injection). 
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Figure 3.3: FIA on fragmentor voltage through SIM on pseudomolecular ion of standard solution 
8-PN (1 mg/mL; 0,1 µL injection). 
 
Gain values and MS cycle times were individually defined per MS signal to obtain 
maximum sensitivity. Moreover, two time groups were assigned to the first of four MSD 
signals, in order to benefit the detection (i.e. 100% cycle time) of the hop-derived 
compounds XN, IX and 8-PN, which elute at the end of the solvent gradient. The HPLC 
effluent entered the ionization chamber only in the time window between 3.5 and 14.0 
min (Table 3.1). 
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Table 3.1: MSD signal groups with target ion values (m/z), gain values, fragmentor voltages and 
cycle times. 
MSD 
signals 
Time windows 
& Analytes 
Ions 
(m/z) 
Gain 
value 
Fragmentor 
voltage (V) 
Cycle 
Time (%) 
MSD 1 
(APCI +) 
 
 
 
 
 
 
 
MSD 2  
(APCI +) 
 
 
 
MSD 3 
(APCI +) 
 
 
MSD 4 
(APCI -) 
3.5-10.4 min 
IS 
DHD 
DAID 
GEN 
 
10.41-14.0 min 
8-PN 
IX, XN 
3.5-10.4 min 
EQ 
O-DMA 
COUM 
 
3.5-10.4 min 
SECO 
MAT 
 
3.5-10.4 min 
ENL 
END 
 
199 
257 
255 
271 
 
 
341 
355 
 
243 
259 
269 
 
 
327 
359 
 
 
297 
301 
1.0 
 
 
 
 
 
2.0 
 
 
3.0 
 
 
 
 
3.0 
 
 
 
3.0 
 
125 
175 
125 
200 
 
 
150 
200 
 
100 
125 
175 
 
 
120 
125 
 
 
125 
175 
10.0 
 
 
 
 
 
100.0 
 
 
30.0 
 
 
 
 
30.0 
 
 
 
30.0 
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In Figure 3.4, merged, normalized MS chromatograms of the standard mixture in 
solvent are illustrated at medium level of the calibration range. 
 
 
Figure 3.4: Normalized and merged MS chromatograms of the four MSD signals (pure standard 
mixture at medium range of calibration). Note: the appearance of some peaks in multiple signals 
are due to overlay of the window of m/z values and/or small impurities in the standards; peak 
tailing is due to the solvent strength of the injection solvent (100% MeOH). 
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3.2 Method validation results 
 Selectivity 
Only a few small peaks were observed in the mass chromatograms of the different 
blank and zero urine and serum samples (resolution between target and interfering peak 
always between 0.5 and 1.0). Since the present method also makes use of extracted ions 
for quantification, the background is further reduced and the sensitivity as well as 
specificity are increased. Moreover, simultaneous recording of characteristic retention 
times and UV spectra favoured accurate identification and quantitation of the target 
compounds. During validation, appropriate blanks were included to correct for any possible 
interference problems.   
 Assessment of linearity and sensitivity 
The linearity was tested in urine for the range of concentrations 0.1-400.0 ng/mL for 
IX, XN and COUM and 1.0 to 4000.0 µg/mL for DAID, GEN, DHD, O-DMA, EQ, SECO, MAT, 
END and ENL. In serum, the concentrations ranged from 0.04 to 100.0 ng/mL for IX, XN and 
COUM, and 0.4 to 1000.0 ng/mL for the other compounds. Calibration curves showed 
linear responses for all analytes over the dynamic ranges and the corresponding regression 
correlation coefficients (r²) were all > 0.995. Weighting was not considered since the 
linearity of all thirteen compounds in both urine and serum was satisfactory. Indeed, visual 
inspection of residual plots confirmed the hypothesis of homogeneity of variance 
(randomly scattered). In addition, the residuals were in accordance with the stated 
acceptance criteria, as the %RRE (% relative residual error, i.e. percent relative difference 
of the residual from the nominal value at a certain calibration point) was for all standards ≤ 
15% at each calibration point. The limits of detection (S/N=3) for all compounds, both in 
urine and serum, are listed in Table 3.2. In urine, the LODs ranged from 0.2 to 7.7 ng/mL, 
and in serum, from 1.4 to 20.4 ng/mL, except for SECO which gave LODs in urine and serum 
of 65.1 ng/mL and 132.6 ng/mL, respectively. If necessary, the target compounds, at the 
  
54 
 
levels which are assumed to be below the corresponding LOD in real samples, can be 
reanalysed with only one MSD signal active to further improve the sensitivity of detection. 
The limits of quantification were set as the lowest point of the calibration curves with a 
signal-to-noise ratio of at least 10.  
Table 3. 2: Limits of detection (LOD) in urine and serum. 
Limit of detection (LOD) 
                                 (ng/mL) (nmol/L) 
Compound Urine Serum  Urine Serum 
Dihydrodaidzein 
Daidzein 
Genistein 
Isoxanthohumol 
8-Prenylnaringenin 
Xanthohumol 
Enterodiol 
Enterolactone 
Equol 
Coumestrol 
O-DMA 
Secoisolariciresinol 
Matairesinol 
2.4 
1.0 
0.8 
0.2 
0.4 
0.6 
2.7 
2.5 
5.8 
0.4 
7.7 
65.1 
7.5 
7.9 
1.9 
2.2 
1.5 
1.5 
1.4 
3.1 
2.4 
13.8 
6.2 
20.4 
132.6 
17.8 
9.4 
3.9 
3.0 
0.5 
1.2 
1.7 
8.9 
8.4 
24.0 
1.5 
29.8 
179.8 
20.9 
31.1 
7.4 
8.1 
4.2 
4.4 
4.0 
10.3 
8.1 
57.0 
23.1 
79.1 
366.3 
49.7 
 Accuracy and precision 
The accuracy and precision of the method were determined by spiking blank urine and 
serum samples at low, medium and high quality control levels, with six replicates on four 
consecutive days. The accuracy, expressed as the percentage relative error (%RE), was 
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within the acceptable ranges of 20% for all compounds at all concentrations. In urine, the 
accuracy ranged from 0.2% to 14.6% and, in serum, from 0.01% to 18.7% (Table 3.3).  
The precision of the method is reflected in the variance of quality control samples over 
time. Inter- and intra-assay variations in urine and serum were thoroughly investigated for 
the three QC-levels and were expressed as %CV (Table 3.4). The %CV for the inter-assay 
precision in urine and serum did not exceed the acceptable 20% and ranged from 4.3% to 
18.8% and 4.4% and 15.7% in urine and serum, respectively. The intra-assay precision in 
urine was overall better than 10% (%CV < 15% as required by the acceptance criteria), 
except for END, for which, at medium level was 14.0%. In serum, the intra-assay precision 
results were also conform with the stated criteria and with the exception of DAID and END, 
at respectively high and low QC-level, were also below 10%.   
Table 3.3: Accuracy (%) in urine and serum for three different QC levels (n=6). 
 
Urine 
Low QC Medium QC High QC 
 
Serum 
Low QC Medium QC High QC     
 
DHD 
DAID 
GEN 
IX 
8-PN 
XN 
END 
ENL 
EQ 
COUM 
O-DMA 
SECO 
MAT 
4.7 
1.6 
1.8 
7.1 
10.5 
12.0 
6.9 
11.0 
2.7 
0.9 
5.2 
10.4 
4.7 
0.5 
10.3 
13.1 
2.6 
11.1 
4.5 
5.2 
5.6 
1.1 
0.7 
9.2 
6.2 
0.2 
0.7 
11.4 
13.4 
0.2 
8.6 
14.6 
8.5 
7.3 
1.4 
1.5 
3.2 
0.2 
6.9 
 
3.8 
4.0 
3.1 
11.8 
6.6 
6.4 
15.0 
17.3 
1.7 
14.4 
8.2 
14.8 
12.9 
6.3 
0.7 
0.08 
14.0 
6.4 
9.0 
8.3 
4.6 
6.7 
3.0 
12.7 
4.9 
12.8 
0.4 
4.9 
7.5 
6.0 
9.2 
0.01 
16.7 
14.4 
6.5 
18.7 
8.4 
4.5 
14.5 
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Table 3.4: Inter- and intra-assay precision (%CV) for three different QC levels (n=6) in urine and 
serum. 
 
Inter-assay (urine/serum)  
Low QC Medium QC High QC 
 
Intra-assay (urine/serum)  
    Low QC   Medium QC High QC 
 
DHD 
DAID 
GEN 
IX 
8-PN 
XN 
END 
ENL 
EQ 
COUM 
O-DMA 
SECO 
MAT 
14.3 / 13.4 
17.8 / 12.8 
11.7 / 13.7 
18.7 / 11.1 
15.6 / 11.2 
16.0 / 10.5 
10.7 / 11.2 
14.0 / 10.5 
14.3 / 11.0 
13.3 / 13.1 
18.8 / 10.0 
14.8 / 15.7 
12.3 / 13.4 
10.8 / 7.6 
10.5 / 6.1 
8.4 / 5.3 
9.2 / 15.0 
12.6 / 7.5 
15.3 / 7.8 
15.8 / 5.2 
14.4 / 7.8 
15.2 / 7.5 
16.8 / 4.4 
17.8 / 6.4 
13.4 / 11.9 
14.7 / 7.1 
14.6 / 11.5 
14.4 / 11.3 
13.0 / 13.2 
4.3 / 11.2 
15.0 / 10.4 
17.6 / 11.9 
10.9 / 6.5 
10.4 / 15.4 
12.1 / 13.4 
15.1 / 14.1 
6.6 / 12.5 
16.5 / 15.5 
17.6 / 9.5 
 
6.9 / 2.9 
6.9 / 9.1 
7.4 / 3.0 
7.2 / 3.3 
8.7 / 3.1 
9.3 / 3.4 
8.1 / 10.7 
9.4 / 3.2 
5.6 / 3.3 
7.3 / 9.3 
6.0 / 3.0 
7.4 / 2.8 
7.1 / 2.9 
6.6 / 6.8 
5.0 / 5.1 
5.0 / 3.7 
5.4 / 5.7 
6.1 / 1.2 
8.1 / 3.7 
14.0 / 7.8 
5.6 / 3.2 
6.5 / 1.4 
5.1 / 1.3 
10.0 / 5.2 
3.8 / 5.1 
4.1 / 6.2 
5.6 / 5.9 
6.4 / 10.8 
4.1 / 5.6 
3.1 / 7.9 
3.3 / 7.4 
3.8 / 8.4 
5.4 / 6.4 
4.5 / 3.5 
8.2 / 6.8 
3.3 / 10.0 
5.7 / 5.8 
6.9 / 8.4 
7.0 / 7.5 
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 Stability 
The chemical stability of the analytes was assessed in the target matrix under specific 
conditions of time and temperature. In particular, the short-term stability was investigated 
in urine and serum. In urine, all components were stable in the processed samples after a 
period of 15 h in the autosampler (room temperature), except for END and ENL. At both 
low and high levels a significant (P < 0.05) and consistent increase in concentration was 
found for END and ENL (i.e. 54.5% increase at low and 37.8% increase at high level for END 
and 54.0% at low and 31.5% at high level for ENL). With the exception of a significant (P < 
0.05) average decrease of 26.1% in concentration of COUM at low QC level, the stability of 
processed serum samples after 15 h in the autosampler was confirmed. Furthermore, in 
urine, following three repeated cycles of freezing and thawing, only IX and 8-PN showed 
degradation in the low QC samples (i.e. > 20% difference in concentration between 
reference and stability samples). At both low and high levels, an acceptable but slight 
degradation was noticed for END and ENL (> 15% and < 20% difference). Finally, an 
instability of MAT, estimated as an average of 42.0% (± 4.8%) loss in concentration of MAT 
at low and high levels was observed after three freeze and thaw cycles.  
 Recovery and matrix effect 
The recoveries (IS-normalized) in urine for all analytes were greater than 67%, both for 
low and high concentrations. In serum samples, the average recoveries were found to be 
higher than 83% for most analytes, except for IX, XN and COUM. The lower recoveries in 
serum for IX and XN (i.e. 40.6% and 46.8% for IX and 69.1% and 58.8% for XN at low and 
high level, respectively) and especially for COUM, which had an average recovery of 24.1% 
(± 5.0%), can be explained by strong retention on the SPE sorbent due to their relatively 
non-polar character and the low solubility of COUM in the elution solvent (MeOH). All 
recoveries at high level are listed in Table 3.5.  
 
 
  
58 
 
Table 3.5: Absolute recovery (%) in urine and serum at high QC level (n= 6) (%RSD). 
    Urine 
 
Serum 
 
DHD  
DAID 
GEN 
IX 
8-PN 
XN 
END 
ENL 
EQ 
COUM 
O-DMA 
SECO 
MAT 
97.3 (14.4) 
119.0 (11.4) 
99.6 (10.6) 
91.9 (16.9) 
78.7 (14.9) 
74.1 (16.1) 
99.8 (9.7) 
115.5 (10.1) 
91.1 (11.9) 
89.7 (16.4) 
91.7 (15.2) 
67.5 (15.9) 
87.8 (14.6) 
89.2 (7.8) 
95.2 (6.2) 
90.6 (8.5) 
46.8 (9.4) 
88.3 (12.2) 
58.8 (16.1) 
95.6 (9.4) 
95.0 (7.1) 
95.5 (6.2) 
19.7 (14.0) 
83.2 (9.3) 
95.8 (7.8) 
98.0 (7.2) 
 
In this study, matrix effects (ME%) in urine and serum were evaluated by analyzing low 
and high QC samples (only the matrix effects of the high QC samples in urine and serum are 
shown here in Table 3.6). In urine, an overall ion enhancement was observed, especially for 
GEN and COUM, with an average of 43% and 49% increase of the signal due to matrix 
effects, respectively. Serum matrix components resulted for SECO in more than a twofold 
increase of the observed signal. The high matrix effect observed with SECO may be 
attributed to co-elution in the beginning of the gradient with retained matrix components 
that lead to a strong enhancement of the ionization of SECO and subsequent 
overestimation of measured concentrations. 
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Table 3.6: Matrix effects (ME% (RSD%)) in urine at high QC level in 6 different matrix blanks (n=3). 
 
  Urine    
 A B C D E F 
DHD  
DAID 
GEN 
IX 
8-PN 
XN 
END 
ENL 
EQ 
COUM 
O-DMA 
SECO 
MAT 
95.2(7)  
104.9(8) 
131.0(13) 
109.7(3) 
112.4(7) 
107.5(12) 
98.1(11) 
86.6(11) 
86.6(10) 
149.2(13) 
108.1(6) 
95.6(6) 
99.1(5) 
111.9(4) 
115.5(13) 
136.0(6) 
116.6(5) 
115.8(5) 
108.8(10) 
123.6(4) 
106.7(4) 
122.5(9) 
145.4(9) 
102.2(7) 
128.4(12) 
121.2(8) 
111.3(6) 
111.3(7) 
146.9(9) 
125.1(4) 
109.0(2) 
91.2(3) 
127.2(3) 
110.3(7) 
93.6(5) 
165.1(9) 
99.9(6) 
138.6(11) 
113.3(5) 
113.8(7) 
117.7(10) 
159.8(14) 
148.6(3) 
120.3(15) 
102.2(6) 
124.9(5) 
117.9(5) 
111.0(3) 
127.4(12) 
102.8(8) 
116.8(7) 
127.9(9) 
104.0(7) 
134.0(3) 
150.7(7) 
107.8(7) 
102.7(6) 
85.6(8) 
101.1(7) 
101.3(6) 
94.3(12) 
161.6(10) 
98.8(7) 
105.3(13) 
101.8(6) 
106.6(3) 
132.4(1) 
133.4(3) 
120.5(6) 
105.2(2) 
82.5(6) 
85.5(6) 
66.6(8) 
93.3(7) 
147.1(1) 
103.4(9) 
109.1(5) 
108.2(2) 
 
A relative overall ion enhancement was noticed in serum (Table 3.7), although more 
stabilized matrix effects for SECO and the other components were observed in one of the 
six batches of serum (serum F). In that particular case, the serum was obtained from a 
totally different source (see section 2.2, purchased pooled human blank serum) and did not 
represent the average type of serum sample that is generally obtained during the clinical 
trials this method was developed for.  
 
  
60 
 
Table 3.7: Matrix effects (ME% (RSD%)) in serum at high QC level in 6 different matrix blanks 
(n=3). 
   
Serum 
   
 A B C D E F 
DHD  
DAID 
GEN 
IX 
8-PN 
XN 
END 
ENL 
EQ 
COUM 
O-DMA 
SECO 
MAT 
107.3(4) 
113.0(4) 
131.3(5) 
119.6(6) 
104.5(8) 
135.8(3) 
106.8(6) 
98.1(4) 
114.2(8) 
131.4(4) 
126.6(2) 
253.4(10) 
130.9(9) 
116.9(4) 
116.3(3) 
135.6(3) 
126.4(1) 
111.8(7) 
136.4(1) 
131.6(5) 
112.5(1) 
113.5(2) 
132.3(5) 
123.9(7) 
235.3(9) 
127.4(5) 
112.0(5) 
118.4(4) 
136.2(2) 
117.4(2) 
91.1(11) 
181.0(8) 
150.7(3) 
141.3(4) 
108.2(7) 
127.8(3) 
130.0(3) 
261.9(7) 
119.3(4) 
113.0(6) 
120.3(5) 
137.2(5) 
123.6(4) 
103.4(6) 
162.8(3) 
158.8(3) 
144.5(2) 
110.5(7) 
129.3(3) 
123.5(4) 
281.6(4) 
121.7(8) 
101.1(7) 
124.2(3) 
131.7(8) 
121.9(7) 
99.8(1) 
139.5(14) 
133.4(5) 
124.3(6) 
109.4(15) 
125.3(3) 
113.4(11) 
214.8(3) 
128.7(3) 
83.9(6) 
93.3(2) 
93.2(1) 
91.2(2) 
70.9(11) 
96.8(3) 
101.7(2) 
101.6(2) 
88.6(6) 
99.4(4) 
85.6(4) 
150.2(5) 
92.7(5) 
Moreover, the variation of the overall matrix effect in urine and serum samples was 
typically less than 15% (urine (A - F): 3.5 to 14.8% and serum (A - E): 2.0 to 15.7%) and 
considered relatively stable. This observation concerning matrix effects again highlights the 
need for multiple source relative matrix effect evaluation instead of assessments based on 
single source biological fluid measurements. As a conclusion, these findings of the matrix 
effects caused by urine and serum factors have clearly shown the relevance of a profound 
and extensive investigation during LC/MS method development and validation but were 
not the initial intention of this project.  
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4. CONCLUSION 
 
This HPLC/APCI-MS methodology represents a new quantitative assay for the 
simultaneous determination of thirteen phytoestrogens, including their most important 
precursors and gut microbial metabolites, in human urine and serum. The method applies a 
relatively short and low-cost sample preparation procedure. Validation parameters 
revealed that accuracy, inter- and intra-assay precision are within the general ranges for 
acceptance and furthermore the sensitivity is in the lower ppb-range. Moreover, the 
detection system can be easily integrated in a standard small-scale analytical laboratory. 
This validated method was successfully applied for the analyses of various urine and serum 
samples collected in a dietary intervention trial with food supplements combining different 
classes of phytoestrogens, as reported in detail in Chapter 4 [130]. The strength of our 
method, as mentioned above, is the ability to measure a wide panel of analytes in complex 
biological matrices, even after supplementation of mixtures of phytoestrogen-rich 
supplements. It can be concluded that the present method, covering the detection of a 
wide and representative range of dietary phytoestrogens should provide a framework for 
extensive analysis in a (pre)clinical environment, whenever efficiency studies are impeded 
by inter-individual differences in exposure levels. 
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CHAPTER 4 
 
 
Application of a LC-MS method to 
a dietary intervention study with 
mixed phytoestrogens  
     
This chapter was published as:  
 
Cosupplementation of isoflavones, prenylflavonoids, and lignans alters human exposure to 
phytoestrogen-derived 17β-estradiol equivalents. 
Bolca,  S.,  Wyns, C., Possemiers, S., Depypere, H., De Keukeleire, D., Bracke, M., Verstraete, 
W. and Heyerick, A.  
Journal of Nutrition, 2009. 139(12): p 2293-300. 
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1. INTRODUCTION 
 
Whether mixtures of phytoestrogens at relevant nutritional doses can add to, 
synergize or antagonize with the endogenous estrogens is currently debated [131-133]. 
Yet, an important aspect that tends to be overlooked in these multi-exposure experiments 
is the crucial role of the gut microbiota with regard to the bioavailability and bioactivity of 
phytoestrogens [134, 135]. In the colon, several microbial transformations generating more 
bioactive metabolites, can occur. The conversion of daidzein to equol [136], 
isoxanthohumol (IX) to 8-prenylnaringenin (8-PN) [137], and secoisolariciresinol (SECO) to 
enterolactone (ENL) [138] results in an approximately 15- [139], 100- [140], and 75- [141] 
fold increase in estrogenic potency, respectively. Since, unlike most other animals and 
especially rodents, not all humans are hosting phytoestrogen-metabolizing intestinal micro-
organisms [142], the extent of these microbial bioactivations varies considerably among 
individuals and, consequently, weak, moderate, and strong producer phenotypes can be 
differentiated [143].  
 
In view of the increasing number of food supplements combining several classes of 
phytoestrogens, we investigated the microbial potential to activate various proestrogens 
within an individual, and evaluated the final exposure to microbial metabolites of 
isoflavones, prenylflavonoids, and lignans upon coadministration in 3 randomized dietary 
crossovers (Figure 4.1). To the best of our knowledge, this is the first controlled human 
study addressing these issues. 
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R 1     2      3     4     5     6     7     8     9
RUN-IN TREATMENT
enzymatic deconjugation
extraction
HPLC-UV/MS
GC-FID
Fecal sample
in vitro-production
Equol/8-PN/ENL
Blood & urineBreath methane
FFQ, BMI, age, 
antibiotic use...
≥ 45%
SCREENING
Incubation with 
D, IX and/or SECO
3-6d @ 37°C
ether extraction 
HPLC-UV
SOY FLAXHOP MIX
Dose (mg aglycon equivalents/d)
12.5  0.4 4.0  0.1 6.2  0.1
 
Figure 4.1: Study design of a dietary intervention trial, focusing on the screening and the first 
intervention arm of a crossover. Treatment allocation was based on participants’ eligibility (i.e., 
>45% in vitro-bioactivation of ≥2 separate proestrogens by fecal cultures; n= 40/100). After a run-
in of ≥4 d, participants were given soy, hop, and/or flax-based food supplements, dosed either 
separately (SOY, HOP or FLAX; reference intervention) or simultaneously (MIX; test intervention), 
3 times/d during 5 d, followed by a wash-out (≥7 d) and the second intervention. 
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2. EXPERIMENTAL 
2.1  Phytoestrogens 
 Standards and extracts 
Genistein, daidzein, secoisolariciresinol (SECO), matairesinol, enterodiol (END), and 
ENL were purchased from Sigma-Aldrich (Bornem, Belgium), equol from Extrasynthèse 
(Genay, France), and dihydrodaidzein (DHD) and O-desmethylangolensin (O-DMA) from 
Plantech UK (Reading, UK). Xantho-Flav™, a xanthohumol (XN)-rich extract, was kindly 
provided by Hopsteiner (Mainburg, Germany) and used for the isomerization of XN into 
isoxanthohumol (IX) and preparation of 8-prenylnaringenin (8-PN) [144]. SoyLife® EXTRA 
and LinumLife™ EXTRA, provided by Frutarom Netherlands (Veenendaal, The Netherlands), 
were used as a source of daidzein and SECO, respectively, in the incubation experiments. 
 Food supplements 
Commercially available food supplements, kindly provided by their manufacturers, 
were used in this study with following contents: soy-based tablets (Bio-Flavon, Metagenics 
Europe, Ostend, Belgium): 6.09±0.10 mg genistein and 2.83±0.05 mg daidzein aglycone 
equivalents per tablet; hop-based capsules (MenoHop®, Metagenics Europe, Ostend, 
Belgium): 2.04±0.06 mg XN, 1.20±0.04 mg IX, 0.10±0.01 mg 8-PN per capsule; flax-based 
tablets (Linidol, NutriPhyt, Oostkamp, Belgium): 2.08±0.02 mg SECO aglycone equivalents 
per tablet. 
 Participants 
Since so far, no studies revealed gender effects as major determinants of 
phytoestrogen metabolism and kinetics [34, 145], both men (n= 30) and women (n= 70) 
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were recruited. A total of 100 generally healthy individuals, living and/or working in the 
area of Ghent, Belgium, participated in this study. Their age and BMI, based on self-
reported weight and height measurements, ranged between 18-78 y and 17-32 kg/m², 
respectively. The exclusion criteria were the use of antibiotics within the previous month 
and soy or flax allergy. Ethical approval was granted by the Ethics Committee of the Ghent 
University Hospital (EC UZG 2007/199; Belgian registration number: B67020072203). The 
volunteers were fully informed on the aims of the study and gave their written consent.  
2.2 Study design 
 Screening 
Participants were asked to deliver a fresh fecal sample to assess their equol, 8-PN, and 
ENL producer phenotypes. Within 6 h after collection, fecal suspensions were prepared and 
incubated (10/90, v/v) anaerobically at 37 °C in Brain Heart Infusion broth (37 g/L, Oxoid, 
Erembodegem-Aalst, Belgium) supplemented with L-cystein.HCl (0.5 g/L), resazurin (2 
mg/L), and a source of either daidzein (529.8±5.3 µmol/L daidzein aglycone equivalents as 
SoyLife® EXTRA, Frutarom Netherlands, Veenendaal, The Netherlands; ‘SOY’) or IX 
(61.2±0.2 µmol/L IX, ‘HOP’) or SECO (645.8±20.1 µmol/L SECO aglycone equivalents as 
LinumLife™ EXTRA, Frutarom Netherlands, Veenendaal, The Netherlands; ‘FLAX’), as 
described by Possemiers et al. [143]. After 3 and 6 d, samples were taken to analyze the 
daidzein and IX metabolism, and the SECO metabolism, respectively. This phenotyping 
based on the phytoestrogen metabolism by fecal cultures, proved to be valid for equol 
[144] and 8-PN [31].  
 
At the same time, the microbial cultures were additionally incubated with a mixture of 
daidzein glycoside, IX, and SECO-diglucoside (529.8±5.3 µmol/L daidzein aglycone 
equivalents + 61.2±0.2 µmol/L IX + 645.8±20.1 µmol/L SECO aglycone equivalents, ‘MIX’) to 
investigate the ability to metabolize simultaneously isoflavones, prenylflavonoids, and 
lignans in vitro. 
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 Run-in and wash-out phases 
Only ‘multi-producers’, defined as individuals hosting intestinal microbiota 
bioactivating >45% of 2 or more separately supplemented precursors in vitro (n= 40/100), 
were included in the dietary intervention trials. These consisted of a run-in phase of at 
least 4 d, a first intervention with phytoestrogens (test or reference) during 5 d, a wash-out 
phase of at least 7 d, and a second intervention with phytoestrogens (test or reference) 
during 5 d. The participants were counseled not to change their habitual, Western-type 
dietary patterns, but were asked to abstain from soy, hop, and flax-derived products in 
order to minimize interferences from other dietary sources of isoflavones, prenylflavonoids 
or lignans. A detailed list of phytoestrogen-containing foods and dietary supplements was 
distributed in order to guide the volunteers in this respect. Additionally, participants were 
instructed to report in a diary every case of doubt or fortuitous consumption, and to 
provide detailed information on that eating occasion, including type and portion size. 
 Dietary interventions 
The dietary intervention trials were randomized crossovers. As reference treatment, a 
food supplement containing either isoflavones (‘SOY’) or prenylflavonoids (‘HOP’) or 
lignans (‘FLAX’) was dosed, whereas the test treatment consisted of coadministration of 
these 3 supplements as one dosage (‘MIX’). During each intervention phase (5 d), food 
supplements were taken daily with meals at breakfast, lunch, and dinner (3 dosages/d). 
Following the eligibility assessment, 40 volunteers were invited to the dietary intervention 
trials, but 3 withdrew. Thirty-seven were allocated to the SOY+MIX (n= 22), HOP+MIX (n= 
21) or FLAX+MIX (n= 21) interventions according to their in vitro-producer phenotypes, 
e.g., an equol+8-PN producer was randomly assigned to either SOY+MIX or HOP+MIX or 
both. In total, 35 individuals (10 men, 16 premenopausal and 9 postmenopausal women) 
completed the study: 22 equol producers, 19 8-PN producers, and 21 ENL producers 
participated in the SOY+MIX, HOP+MIX, and FLAX+MIX trials, respectively. Compliance was 
evaluated by participant inquiry, remaining supplement counts, and urinary phytoestrogen 
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excretion. The volunteers were also asked to record when they took the food supplements 
or, in case, forgot them.  
 Sample collection 
After the run-in and wash-out phases, and on the last day of each intervention, spot 
urine and blood samples were collected together with the diaries. Timing of the 
venipunctures and urine collections was standardized for each individual and ranged 
between 0.5-5.0 h after the first supplement intake of that day (breakfast). Although 
steady-state levels are reached after 5 d of regular intake throughout the day [147, 148], 
diurnal fluctuations are expected, especially for the plant precursors, because of the 
discontinued dosing during night, as shown for daidzein and genistein [149]. At the study 
onset, however, no information was available on an optimal time of sampling for 
isoflavones, prenylflavonoids, lignans, and their microbial metabolites. Therefore, the 
sampling interval was chosen based on feasibility aspects, such as participant burden. 
Serum was obtained by centrifugation (10 min, 600 g, room temperature (RT)) after 
coagulation. Aliquots of both urine and serum samples were stored at -20 °C until analysis.  
In addition, a general questionnaire was used to get information on the 
participants’ history of antibiotic treatments, hormonal therapies, use of any other 
medication, dietary habits and food supplement intakes, anthropometric measures, and 
physical activities.  
2.3 Analytical methods 
 Enzymatic hydrolysis (urine and serum) 
Total, i.e., free and conjugated, phytoestrogens in the urine and serum samples were 
extracted upon enzymatic hydrolysis with a Type H-1 Helix pomatia extract (Sigma Aldrich, 
Bornem, Belgium) in sodium acetate buffer (0.1 mol/L, pH= 5), using a protocol validated in 
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Chapter 3 [150]. The urine samples (2 mL) were incubated with 30 U β-glucuronidase and 
1.53 U sulfatase for 1 h at 37 °C, whereas the serum samples (800 µL) were spiked with 15 
µL internal standard (0.4 mmol/L 4-hydroxybenzophenone in methanol) and defatted with 
hexane (50/50, v/v) prior to incubation with 7380 U β-glucuronidase and 376 U sulfatase 
for 24 h at 37 °C. 
 Liquid-liquid extraction (fecal incubation broths and urine) 
The protocols described by Bolca et al. [146] were adapted to extract isoflavones, 
prenylflavonoids, and lignans simultaneously. Each sample (fecal incubations: 1 mL; urine: 
2 mL) was mixed (50/50, v/v) with sodium acetate buffer (0.1 mol/L, pH= 5), spiked (fecal 
incubations: 50 µL, urine: 25 µL) with internal standard (0.4 mmol/L 4-
hydroxybenzophenone in ethyl acetate) and extracted twice with 5 mL diethyl ether. The 
combined extracts were evaporated to dryness at RT under a gentle stream of N2, 
reconstituted in the mobile phase (fecal incubations: 200 µL, urine: 100 µL), and stored at -
20 °C prior to HPLC-UV (fecal incubations) or HPLC-UV/MS (urine) analysis.  
 Solid-phase extraction (serum) 
Serum phytoestrogens were measured after enzymatic hydrolysis and solid-phase 
extraction (SPE), as validated in Chapter 3 [150]. The SPE-cartridges (Bond Elut® C18, 3 mL, 
200 mg, Varian, Sint-Katelijne-Waver, Belgium) were activated with 3 mL methanol and 
conditioned with 3 mL sodium acetate buffer (0.1 mol/L, pH= 5), consecutively. After 
sample application, the cartridges were rinsed with 3 mL methanol/water (5/95, v/v) and 
the compounds of interest were eluted with 3 mL methanol using a VacMaster 20 sample 
processing unit (IST, Hengoed, Mid Glamorgan, UK). The solvent was evaporated to dryness 
at RT under a gentle stream of N2, reconstituted in 80 µL of the mobile phase, and stored at 
-20 °C prior to HPLC-UV/MS analysis. 
 C
h
a
p
te
r 
4
: 
A
p
p
lic
a
ti
o
n
 o
f 
a
 L
C
-M
S 
m
et
h
o
d
 t
o
 a
 d
ie
ta
ry
 in
te
rv
en
ti
o
n
 s
tu
d
y 
w
it
h
 m
ix
ed
 p
h
yt
o
es
tr
o
g
en
s 
71 
 
 Creatinine measurement (urine) 
To allow standardization of diuresis, the urinary excretion of creatinine was measured 
based on a modified protocol of Hall et al. [151]: upon incubation of 100 µL urine with 1.5 
mL alkaline picrate reagent (i.e., a 57 mmol/L-picric acid solution (Sigma Aldrich, Bornem, 
Belgium) mixed with 8.8 g/L NaOH, 19.0 g/L Na2HPO4, and 19.0 g/L Na2B4O7.10 H2O in 
deionized water, 1:1 (v:v), pH 12.6) during 30 min at 37 °C, 100 µL acetic acid (5.2 mol/L) 
was added and incubated again for 5 min at 37 °C. The absorbance at 540 nm was 
measured (Tecan Sunrise™, Tecan Benelux, Mechelen, Belgium) before and after 
acidification and used to calculate the creatinine concentrations. Daily urinary 
phytoestrogen excretions were calculated according to the conventional kinetic Jaffé 
method [152] based on creatinine clearance rates of 0.187 mmol/(d.kg) for men and 0.163 
mmol/(d.kg) for women [153]. 
 HPLC-UV analysis (fecal incubation broths) 
Quantitative analyses of phytoestrogens and their microbial metabolites (isoflavones: 
genistein, daidzein, DHD, O-DMA, and equol; prenylflavonoids: IX and 8-PN; and lignans: 
SECO, END, and ENL) were performed by HPLC-UV using a Waters 2695 Alliance 
separations module and 996 PDA (Waters, Milford, MA, USA), combined with an XBridge™ 
C18 reversed-phase column (5 µm, 4.6x250 mm; Waters, Milford, MA, USA) and using a 
gradient of solvent A (i.e., 6.6 mmol/L aqueous formic acid) and solvent B (i.e., 6.6 mmol/L 
formic acid in acetonitrile/methanol, 20/80 (v/v)) with the following profile: 0-4 min, 40% B 
in A; 4-6 min, from 40% to 45% B in A; 6-21 min, 45% B in A; 21-25 min, from 45% to 87% B 
in A; 25-27 min, from 87% to 99% B in A, 27-30 min, from 99% to 40% B in A; 30-35 min, 
40% B in A; and a flow rate of 1 mL/min. The injection volume was 20 µL and the column 
temperature was set at 40 °C. UV detection was done simultaneously at 280 nm for the 
isoflavones and lignans, and at 295 nm for the prenylflavonoids and the internal standard.  
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 HPLC-UV/MS analysis (urine and serum) 
The developed and validated HPLC-UV/MS method as described in Chapter 3 was used 
for the analysis of urine and serum samples.  
 Statistical analyses 
All extractions were performed in triplicate. SPSS for Windows version 15.0 (SPSS, 
Chicago, IL, USA) was used to carry out all statistical analyses. Results were considered 
statistically significant at an α two-tailed level of 0.05. Tests for normality and equality of 
the variances were performed using the Kolmogorov-Smirnov and Levene’s test, 
respectively. Means and SEM of metabolite formation, and serum and urine 
concentrations, and differences (Δ) between mean values obtained after separate (‘SOY’, 
‘HOP’, ‘FLAX’, reference method) and simultaneous (‘MIX’, test method) supplementation 
were calculated. The paired Student’s t-test or the Wilcoxon’s matched-pairs signed-rank 
test was used to determine significant differences between means. Associations (r) were 
described using Pearson’s correlation coefficients or non-parametric Spearman’s 
correlations. Bland & Altman-plots visualized the agreement between the test and 
reference methods for each compound under investigation at an individual level [154]. 
Participants were separated according to the bioactivation potential of their fecal cultures 
(i.e., equol/(daidzein+DHD+equol+O-DMA) [144], 8-PN/(IX+8-PN) [31], and 
ENL/(SECO+END+ENL)) into significantly different groups using the TwoStep cluster 
protocol. Cross-classification analyses and κ-statistics were applied to evaluate the level of 
agreement between the producer phenotypes based on the in vitro-microbial metabolism 
of separate vs. mixed phytoestrogens. 
Power calculations [153] based on an α level of 0.05 and β of 0.05, showed that, with a 
sample size of 18 participants, differences between the separate and mixed 
supplementations exceeding 1.25 times the intra-individual variations, would be detectable 
without generating statistically significant, but scientifically meaningless differences. 
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3. RESULTS  
3.1 Phytoestrogen metabolism 
As expected, the in vitro-microbial metabolism of isoflavones, prenylflavonoids, and 
lignans varied from 0% up to 100% conversion of daidzein into equol (‘SOY’ incubations), IX 
into 8-PN (‘HOP’ incubations), and SECO into ENL (‘FLAX’ incubations). Consequently, 
participants were phenotyped as poor (n= 65, 68, and 34), moderate (n= 7, 14, and 21), and 
strong (n= 28, 18, and 45) in vitro-equol, 8-PN, and ENL producers, respectively. Since the 
average bioactivation of the moderate producers (mean±SEM: 60±1.5% equol, 64±1.3% 8-
PN, and 52±2.1% ENL) exceeded the threshold value of 45%, we merged the moderate and 
strong producer phenotypes for further analyses. In this way, fecal cultures bioactivating 
none (n= 19), only one (n= 41: 12 equol, 7 8-PN, and 22 ENL producers), two (n= 33: 0 
equol+8-PN producers, 16 equol+ENL producers, and 17 8-PN+ENL producers) or all three 
(n= 7 equol+8-PN+ENL producers) classes of phytoestrogens were characterized (Figure 4.2 
A).  
 
 However, these bioactivation profiles changed substantially upon incubation with a 
mixture of isoflavones, prenylflavonoids, and lignans (‘MIX’ incubations): 64%, 28%, 7%, 
and 1% of the fecal cultures converted none, only one (n= 23 equol, 4 8-PN, and 1 ENL 
producers), two (n= 2 equol+8-PN producers, 2 equol+ENL producers, and 3 8-PN+ENL 
producers) or all three precursors (Figure 4.2 B). In general, compared to the reference, i.e., 
separate incubations, the mixed ones yielded lower equol (mean±SEM Δ= 4.4±2.0%, P= 
0.164), 8-PN (mean±SEM Δ= 20.5±3.9%, P< 0.001), and ENL (mean±SEM Δ= 44.3±4.3%, P< 
0.001) formations. Despite this underestimation, statistically significant correlations were 
found between the separate and mixed incubations for equol (r= 0.925, P< 0.001) and 8-PN 
(r= 0.309, P= 0.002) formations, but not for ENL (r= 0.116, P= 0.259). In line with these 
findings, the homogenous scattering in Figure 4.3 A showed that good estimations were 
obtained for the equol formation, although some outliners widened the limits of 
agreement, whereas the Bland & Altman-plots of 8-PN and ENL (Figure 4.3 B and C) 
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diverged strongly and indicated a high degree of underestimation and considerable 
variation. Cross-classification revealed a misclassification of 7% (κ= 0.84, P< 0.001), 31% (κ= 
0.11, P= 0.171), and 60% (κ= 0.02, P= 0.594), respectively, for the equol, 8-PN, and ENL 
producer phenotyping based on the mixed incubations. The eligibility assessment of the 
participants was therefore based on the reference incubations. 
 
To evaluate the biological relevance of these in vitro results, the percentages equol, 8-
PN, and ENL in urine and serum after administration of a specific type of food supplement 
(‘SOY’, ‘HOP’, ‘FLAX’ interventions) were compared to those obtained after 
coadministration (‘MIX’ interventions). Analyses of the urinary data revealed similar 
results: a robust equol (mean±SEM Δ= -1.3±1.4%, P= 0.149; r= 0.651, P= 0.001; Figure 4.3 
D), a more variable 8-PN (mean±SEM Δ= 1.3±0.5%, P= 0.101; r= 0.229, P= 0.346; Figure 4.3 
E), and a highly affected ENL (mean±SEM Δ= 64.2±3.2%, P< 0.001; r= -0.694, P< 0.001; 
Figure 4.3 F) formation. Additionally, the serum-derived daidzein and IX bioactivation 
profiles were in line with the in vitro-findings (equol: mean±SEM Δ= 5.3±1.2%, P= 0.040; r= 
0.455, P= 0.033; Figure 4.3 G; 8-PN: mean±SEM Δ= 1.5±2.5%, P= 0.634; r= 0.431, P= 0.074; 
Figure 4.3 H). In contrast, the percentages ENL circulating in serum after the FLAX and MIX 
interventions were similar (mean±SEM Δ= -3.3±0.7%, P= 0.030; r= 0.694, P< 0.001; Figure 
4.3 I). 
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Figure 4.2: Prevalence of different in vitro-phenotypes based on the equol, 8-PN, and ENL 
formation by fecal cultures after incubation with a source of daidzein, IX, and SECO (A) separately 
and (B) simultaneously (n= 100). 
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Figure 4.3: Bland & Altman-plots visualizing the differences between the percentages of (A, D, G) 
equol, (B, E, H) 8-PN, and (C, F, I) ENL (A-C) produced by fecal cultures, (D-F) excreted in urine, and 
(G-I) circulating in serum after supplementation of a source of daidzein, IX, and SECO separately 
and simultaneously. The dotted lines represent the mean differences, n is indicated on each 
panel. 
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3.2 Phytoestrogen exposure 
Analogously, absolute exposures to isoflavones, prenylflavonoids, lignans, and their 
microbial metabolites were assessed as the sum of unconjugated forms and deconjugated 
(sulfo)glucuronides and sulfates excreted in urine (Table 4.1) or circulating in serum (Table 
4.2), and compared between the treatments (‘SOY’, ‘HOP’ or ‘FLAX’ intervention vs. ‘MIX’ 
intervention). The estimated daily urinary phytoestrogen excretions varied considerably 
between individuals and were in the low µmol/d-range after intake of isoflavones (‘SOY’ 
interventions: 2.21-18.2 µmol daidzein/d, 0.35-10.3 µmol DHD/d, 0.59-30.8 µmol equol/d, 
<LOD-19.3 µmol O-DMA/d, and 1.35-13.6 µmol genistein/d) and lignans (‘FLAX’ 
interventions: <LOD-2.53 µmol SECO/d, 0.06-3.80 µmol END/d, and 1.75-13.9 µmol ENL/d), 
whereas clearance rates of 96.7-2065 nmol IX/d and 14.8-266 nmol 8-PN/d were estimated 
after the ‘HOP’ interventions. The serum concentrations were in the nmol/L-range for 
isoflavones (42.8-488 nmol daidzein/L, 18.7-143 nmol DHD/L, 41.5-540.3 nmol equol/L, 
<LOD-399 nmol O-DMA/L, and 62.6-1051 nmol genistein/L), lignans (3.80-109 nmol 
SECO/L, 18.6-275 nmol END/L, and 126-469 nmol ENL/L), as well as prenylflavonoids (24.0-
186 nmol IX/L and 26.8-162 nmol 8-PN/L) after intake of soy, flax, and hop-derived food 
supplements, respectively. 
 
No significant differences were observed between the bioavailabilities of isoflavones, 
prenylflavonoids, and lignans, proxied by the sum of precursor aglycone equivalents 
quantified in urine and serum, upon separate and simultaneous administration (total 
daidzein aglycone equivalents in urine: P= 0.391, in serum: P= 0.074; total IX equivalents in 
urine: P= 0.503, in serum: P= 0.104; SECO aglycone equivalents in urine: P= 0.928, in serum: 
P= 0.067). However, participants were exposed to generally lower levels of bioactivated 
molecules (i.e., equol: Δ= 28.3%, P= 0.009; 8-PN: Δ= 35.4%, P= 0.107; ENL: Δ= 35.9%, P= 
0.003) after simultaneous administration of isoflavones, prenylflavonoids, and lignans.  
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Table 4.1: Urinary excretion of isoflavones, prenylflavonoids, lignans, and their microbial 
metabolites (mean ± SEM) upon intake of soy-, hop-, and flax-based food supplements separately 
or simultaneously, difference, and correlation between these excretion profiles. 
    Excretion                  
(nmol/mmol creatinine)
 
Δ  Correlation# 
  SOY/HOP/FLAX MIX
 
% P
§ 
r P 
Is
o
fl
a
v
o
n
e
s
 (
n
=
2
2
) 
Daidzein 729.4 ± 94.4 741.7 ± 87.3 -2.9 0.918 0.163 0.531 
DHD 312.5 ± 55.2 224.4 ± 35.9 26.0 0.177 0.483 0.050 
Equol 488.8 ± 105.8 633.9 ± 151.0 1.9 0.174 0.738 0.001 
O-DMA 264.0 ± 855.5 368.2 ± 91.0 -30.0 0.215 0.451 0.069 
Genistein 355.4 ± 58.7 313.7 ± 44.8 7.8 0.488 0.381 0.131 
P
re
n
y
lf
la
v
o
n
o
id
s
 
(n
=
1
9
) 
IX 57.7 ± 8.3 52.6 ± 9.5 8.7 0.624 0.361 0.155 
8-PN 4.1 ± 0.5 3.4 ± 0.7 29.3 0.113 0.397 0.115 
L
ig
n
a
n
s
 (
n
=
2
1
) 
SECO 46.5 ± 9.3 52.0 ± 11.1 -18.7 0.705 0.012 0.962 
END 110.1 ± 28.7 163.9 ± 76.1 25.5 0.748 0.588 0.008 
ENL 526.2 ± 55.0 567.8 ± 78.7 0.7 0.665 0.034 0.891 
#Pearson’s correlation coefficient for all phytoestrogens under investigation, except DHD, O-DMA, 
8-PN, and END (Spearman’s correlation coefficients); §Paired Student’s t-test for all phytoestrogens 
under investigation, except DHD, O-DMA, 8-PN, and END (Wilcoxon’s matched-pairs signed-rank 
test). 
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Table 4.2: Serum concentrations of isoflavones, prenylflavonoids, lignans, and their microbial 
metabolites (mean ± SEM) upon intake of soy-, hop-, and flax-based food supplements separately 
or simultaneously, difference, and correlation between those concentrations. 
    Concentration (nmol/L) Δ  Correlation# 
  SOY/HOP/FLAX  MIX
 % P§ r P 
Is
o
fl
a
v
o
n
e
s
 (
n
=
2
2
) 
Daidzein 189.3 ± 26.6 157.5 ± 18.6 11.8 0.181 0.530 0.013 
DHD 60.9 ± 8.6 72.1 ± 9.7 -18.7 0.156 0.664 0.001 
Equol 189.5 ± 17.4 137.4 ± 12.4 28.3 0.009 0.311 0.169 
O-DMA 115.7 ± 25.8 109.3 ± 16.4 -14.4 0.795 0.410 0.072 
Genistein 298.4 ± 48.0 155.3 ± 18.8 54.0 0.003 0.457 0.037 
P
re
n
y
lf
la
v
o
n
o
id
s
 
(n
=
1
9
) 
IX 52.0 ± 10.2 38.1 ± 9.6 52.6 0.233 0.546 0.035 
8-PN 73.4 ± 6.9 59.6 ± 10.4 35.4 0.107 0.636 0.011 
L
ig
n
a
n
s
 (
n
=
2
1
) 
SECO 26.5 ± 5.8 50.1 ±7.9 -70.9 0.009 0.104 0.663 
END 77.1 ± 14.0 75.3 ± 10.2 -0.8 0.868 0.645 0.002 
ENL 226.4 ± 18.4 149.6 ± 7.4 35.9 0.003 -0.429 0.059 
#Pearson’s correlation coefficient for all phytoestrogens under investigation, except IX, and SECO 
(Spearman’s correlation coefficients); §Paired Student’s t-test for all phytoestrogens under 
investigation, except IX and SECO (Wilcoxon’s matched-pairs signed-rank test). 
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4. DISCUSSION 
 
To the best of our knowledge, human exposure to microbial metabolites of 
isoflavones, prenylflavonoids, and lignans administered simultaneously, has not been 
reported previously, although human nutrition [156] and an increasing number of food 
supplements contain mixtures of various phytoestrogens. The in vitro-incubation 
experiments with fecal cultures showed that the interplay of phytoestrogens alters the 
microbial bioactivation profiles yielding generally lower formations of equol, 8-PN, and 
ENL. Equol formation proved to be the most robust process, whereas conversion of SECO 
to ENL was severely disturbed by coadministration with soy and hop-derived 
phytoestrogens. Moreover, similar shifts in bioactivation profiles were observed upon 
coadministration in vivo, yet without affecting the exposure to total isoflavones, 
prenylflavonoids, and lignans significantly.  
 
 The microbial metabolism of daidzein, IX, and SECO as separate compounds was in 
line with earlier findings [31, 146, 157]. Here, we elaborated on the producer phenotyping 
concept and found that the interclass-bioactivation potential of gut microbiota varies from 
non-equol+non-8-PN+non-ENL producers to strong equol+8-PN+ENL producers. The 
prevalence of these phenotypes approximated the distribution of mutually independent 
events (i.e., 15% non-producers, 8% equol, 7% 8-PN, 29% ENL, 4% equol+8-PN, 16% 
equol+ENL, 14% 8-PN+ENL, and 7% equol+8-PN+ENL producers). With some exceptions of 
enhanced metabolism, the formations of equol, 8-PN, and especially ENL were however 
generally lowered or even completely inhibited when their precursors were administered 
simultaneously.  
 
Although these microbial metabolites are formed through different pathways, similar 
chemical conversions and rather closely related micro-organisms (demethylation [144, 158, 
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159] and reduction [159-162] are involved. Therefore, one of the explanations for the 
observed interferences upon cosupplementation may relate to competition for a common 
substrate, electron donor or cofactor. Hydrogen gas is formed in the colon by a variety of 
hydrolytic and saccharolytic bacteria to dispose reducing equivalents during fermentation 
[163], and has an important role in daidzein metabolism [160]. Competition for 
fermentative H2 is well described [164] and equol-producing microbiota have been 
suggested to interact with the interspecies H2 transfer [143]. Daidzein acts as an electron 
acceptor during equol formation and might divert H2 away from ENL formation. On the 
other hand, a specific precursor or metabolite can directly or indirectly cause a selective 
stress or stimulus to specific phytoestrogen-metabolizing organisms. Similarly, the 
increased total phytochemical load potentially exceeds a minimal inhibitory concentration 
(MIC-value) or triggers an inducible pathway. Finally, a preferential metabolism (e.g., 
demethylation of IX over SECO) may prevail, but more detailed experiments are required to 
unravel the underlying mechanisms. 
 
Before testing whether overall health effects result from a combination of 
phytochemicals with multiple and perhaps additive or interfering activities, the first 
attention should go to the bioavailability and especially the microbial metabolism of 
isoflavones, prenylflavonoids, and lignans as part of a mixture, warranting the importance 
of this prospective study. Due to the study design, i.e., the selective inclusion of multi-
producers and multiple dosing of specific food supplements, literature reports of similar 
intervention trials are limited for the reference administrations, and lacking for the 
coadministrations. The urinary excretion of isoflavones and prenylflavonoids agreed with 
the results of similar dietary interventions with soy- and hop-derived food supplements 
administered separately to postmenopausal women classified as strong equol and 8-PN 
producers, respectively [146, 165]. Without differentiating between weak and strong ENL 
producers, the (entero)lignan concentrations measured in the urine samples were also in 
line with previous reports [166]. The impact of the timing of venipunctures, dosing 
regimen, and formulation on circulating phytoestrogen concentrations often hampers 
sound comparisons between dietary intervention trials. Nevertheless, we discuss the ‘HOP’ 
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interventions, since this and the study by Rad et al. [167] are the only reports on human 
serum prenylflavonoid concentrations. The latter found peak serum concentrations of 
approximately 400, 1800, and 5500 nmol/L of total 8-PN in healthy postmenopausal 
women after oral single doses of 50, 250, and 750 mg of 8-PN, respectively. Therefore, our 
results suggest cumulative effects caused by the multiple dosing protocol as described for 
isoflavones [149], and the administration of IX as a slow-release formation for 8-PN. The 
striking difference in relative 8-PN formation derived from the urine and serum samples 
(Figure 4.4 D vs. H) corresponds with the observations of Possemiers et al. [135] in human 
microbiota-associated rats, and likely reflects differences in pharmacokinetic behavior 
analogous to the consistently higher urinary and lower serum or plasma daidzein 
concentrations compared to genistein (Tables 4.1 and 4.2).  
 
We translated the exposure to isoflavones, prenylflavonoids, lignans, and their 
microbial metabolites to an overall exposure to phytoestrogen-derived 17β-estradiol-
equivalents towards estrogen receptor (ER) α (E2α) and ERβ (E2β), based on the generally 
accepted dose-addition concept [166] and thereby assuming i) relative estrogenic 
potencies towards ERα of 1/5000, 1/100, 1/200, 1/10, and 1/10000, and towards ERβ of 
1/100, 1/2, 1/35, 1/100, and 1/5000 for daidzein, genistein, equol, 8-PN, and ENL, 
respectively, [137-139], ii) binding to serum proteins of 81%, 55%, 50%, 50%, and 50% for 
daidzein, genistein, equol, 8-PN, and ENL, respectively, [169], and iii) an overall 98% 
attenuation due to glucuronidation and sulfatation [134, 167] (Table 4.3). Upon 
coadministration of soy, hop, and flax-based food supplements men (n= 10) were exposed 
to calculated 0.024-0.115 nmol/L E2α and 0.180-1.336 nmol/L E2β, whereas premenopausal 
women (n= 16) to 0.020-0.121 nmol/L E2α and 0.261-1.603 nmol/L E2β, and 
postmenopausal women (n= 9) to 0.042-0.137 nmol/L E2α and 0.175-3.054 nmol/L E2β. As 
a reference, the circulating 17β-estradiol (E2) concentrations in men, pre-, and 
postmenopausal women are approximately 0.1 nmol/L, 0.15-1.00 nmol/L, and 0.015-0.050 
nmol/L, respectively. The contribution of the isoflavones’ estrogenicity towards ERβ 
(99.4%) was by far the most important one, whereas 8-PN was the most potent E2α 
contributor (67.8%). Moreover, the exposure to E2β after intake of food supplements 
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containing only isoflavones exceeded significantly (Δ= 57.1%, P= 0.002) the superimposed 
activities of isoflavones, prenylflavonoids, and lignans in the mixture (Table 4.3). This 
observation and the lower bioactivation upon coadministration question the added value 
of food supplements combining various classes of phytoestrogens.  
Table 4.3: Calculated serum concentration of isoflavone-, prenylflavonoid-, and lignan-derived 
E2α and E2β-equivalents (mean±SEM) upon intake of soy-, hop-, and flax-based food supplements 
separately or simultaneously, and difference between these concentrations. 
 Concentration, pmol/L Δ 
SOY/HOP/FLAX MIX % P# 
E2α     
Isoflavones (n= 22) 34.2 ± 13.5 21.0 ± 1.9 47.0 0.001 
Prenylflavonoids (n= 19) 60.4 ± 0.12 60.0 ± 10.4 63.9 0.107 
Lignans (n= 21) 0.162 ± 0.014 0.150 ± 0.007 35.9 0.003 
E2β     
Isoflavones (n= 22) 1399 ± 560 744 ± 85.5 52.6 0.003 
Prenylflavonoids (n= 19) 6.04 ± 0.01 5.96 ± 1.04 63.9 0.107 
Lignans (n= 21)
 
0.325 ± 0.028 0.299 ± 0.015 35.9 0.003 
#Paired Student’s t-test for all phytoestrogens under investigation. 
In conclusion, this was the first intervention trial with a specific mixture of soy, hop, 
and flax-based food supplements, in which the microbial bioactivation of daidzein, IX, and 
SECO was taken into account to strengthen the estimates of maximal exposure to dietary 
phytoestrogen-derived E2-equivalents. Further studies are needed to evaluate the impact 
of microbial bioactivation on the final health effects of mixtures of phytoestrogens and to 
extrapolate these results to the general population or to other phytoestrogenic mixtures 
e.g., as would occur through dietary exposure. Nevertheless, this study revealed that the 
bioavailability of mixed phytoestrogens is strongly determined by the microbiome of each 
individual and personalized screenings prior the use of these combinations in supplements, 
are therefore highly recommended. 
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CHAPTER 5 
 
 
Monoclonal antibodies against 
phytoestrogens  
DEVELOPMENT AND PRODUCTION - VALIDATION OF ELISA 
      
This chapter is partially based on:  
 
Production of monoclonal antibodies against hop-derived (Humulus lupulus L.) 
prenylflavonoids and the development of immunoassays.  
Wyns, C., Derycke, L., Soenen, B., Bolca, S., Deforce, D., Bracke, M. and Heyerick, A.  
Talanta, 2011. 85(1): p. 197-205. 
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1. INTRODUCTION AND OBJECTIVES 
 
Generally the reported quantitative methods for the determination of phytoestrogens 
are based on reversed-phase liquid chromatography (RP-HPLC) combined with UV-detection 
or mass spectrometric detection (MS or tandem MS) [18, 101, 122, 170-172]. Those methods 
are rather expensive, and require experienced personnel and can be quite labor-intensive. 
Therefore, the access to immunoassays may offer a low-cost, high-throughput alternative to 
labs that do not have access or skills to do LC-MS(/MS). The first report of antibodies against 
phytoestrogens dates from 1969, when Bauminger et al. [173] reported the application of 
antibodies against genistein as a way of passive immunization and protection against 
interruptions of the reproductive system. This was soon followed by the development of 
several radioimmunoassays (RIAs) for phytoestrogens which are very sensitive, though, they 
mostly lack stability and cause waste and safety issues. Therefore, the conventional enzyme-
linked immunoassays (EIAs) were introduced, as well as the immunoassays using fluorescent 
labeled antigen (FIA) and their sensitive variant, time-resolved immunoassays (TR-FIA). 
Schaefer et al. [40] have reported on the generation of polyclonal antibodies against 8-PN 
and the subsequent development of a radioimmunoassay for the quantitative determination 
of 8-PN in beer and urine. Lapcik et al. [174] also reported on a very specific immunoassay 
for coumestrol. Additionally, over the last few years, various papers have reported on 
immunoassays based on polyclonal antibodies for soy- or flax-derived phytoestrogens 
(daidzein, genistein and enterolactone) for the quantitation in biological samples [175-179]. 
Next to the application of monoclonal antibodies in quantitation methods, a wide range of 
other immunological techniques can be explored to elucidate metabolisation- and 
distribution profiles of phytoestrogens in biological matrices.  
 
We preferred the technology of monoclonal antibodies, because they are known to 
show a highly specific binding to their haptens, to exert negligible cross-reactivities 
compared to polyclonal antisera and ensure the continuous production of a well-
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characterized product. Literature search showed that monoclonal antibodies were 
developed only against daidzein, genistein by Kohen et al. [180, 181] and for the same 
compounds and equol by Talbot et al. [182]. In this study we aimed to develop monoclonal 
antibodies against a range of biologically relevant phytoestrogens: genistein, daidzein, equol, 
coumestrol, enterodiol, enterolactone, xanthohumol, isoxanthohumol and 8-
prenylnaringenin. Although xanthohumol and isoxanthohumol are not estrogenic, the 
availability of monoclonal antibodies can be of great value during assays for the detection 
and distribution of phytoestrogens in several biological matrices. The generated monoclonal 
antibodies will be used to establish a competitive enzyme-linked immunosorbent assay 
(ELISA) using immunogen-coated microtitration plates and a peroxidase-labeled anti-mouse 
IgG1 secondary antibody to measure concentrations in human biological fluids. Finally, the 
established ELISA will be validated for its use to measure concentrations of phytoestrogens 
in urine and serum samples.  
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2. EXPERIMENTAL 
2.1 Chemicals and reagents 
Xanthohumol (XN), isoxanthohumol (IX), 8-prenylnaringenin (8-PN), 
desmethylxanthohumol (DMX), and 6-prenylnaringenin (6-PN) were available in our 
laboratory [52]. Equol (EQ) was purchased from Extrasynthèse (Genay, France). Daidzein 
(DAID), genistein (GEN) and naringenin were obtained from Acros Organics (Morris Plains, 
NJ, USA). Coumestrol (COUM), enterodiol (END), enterolactone (ENL) and β-estradiol (E2) 
were purchased from Sigma-Aldrich (St. Louis, MO, USA). Bovine serum albumin (BSA), 
polyethylene glycol (PEG 1500), Tween-20, alkaline phosphatase-labeled anti-mouse IgG 
antibody, a Mouse Monoclonal Antibody Isotyping kit and SIGMA FAST para-nitrophenyl 
phosphate (pNPP) tablets were purchased from Sigma-Aldrich. All other chemicals and 
solvents for the synthetic work and supplements for the biological work were obtained from 
Acros Organics and were all of analytical reagent grade. The solvents for the 
chromatography were all of LC-MS quality and purchased from Biosolve (Valkenswaard, The 
Netherlands). Phosphate-buffered saline (PBS) solution was prepared as 0.137 M NaCl and 
2.7 mM KCl in 0.01 M phosphate buffer, pH 7.4. Complete serum-free Dulbecco’s modified 
eagle medium (DMEM) (Invitrogen, Carlsbad, CA, USA) was supplemented with L-glutamine 
(0.05%), penicillin (100 units/mL), and streptomycin (100 µg/mL). The murine NS0 cell line, a 
non-secreting plasmacytoma cell line (myeloma) from Balb/c mice was kindly provided by 
the Laboratory for Cellular Immunology (P. De Baetselier, Vrije Universiteit Brussel, Belgium). 
For the cultivation of the NS0 cell line complete DMEM was supplemented with heat-
inactivated FBS (10%, Invitrogen) and thioguanine (10 µM). HAT medium was used to select 
and culture hybridomas and consisted of complete DMEM with heat-inactivated FBS (20%), 
hypoxanthine (120 µM), thymidine (19 µM) and aminopterin (0.6 µM). Dialysis of the antigen 
conjugates and cell media was performed with Slide-A-Lyzer cassettes (0.5-3.0 mL; MWCO 
7000 Da and 12.0-30.0 mL; MWCO 10 kDa) from Pierce (Rockford, IL, USA). For the 
production of monoclonal antibodies large scale Integra Biosciences CELLine bioreactors 
(type CL350) were used and were purchased from Integra Biosciences (Chur, Switzerland). 
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For the purification of the monoclonal antibodies, HiTrap protein G columns from GE 
Healthcare (Piscataway, NJ, USA) were used. The ultracentrifugation was performed with 
Amicon Ultra-15 centrifugal filter units (Millipore, Billerica, MA, USA). For the protein gel 
electrophoresis TEMED, sodium dodecyl sulfate-polyacrylamide (SDS) and β-mercapto-
ethanol were purchased from Bio-Rad Laboratories (Richmond, CA, USA) and all other used 
products were from Acros. The acetate buffer (0.1 M; pH 5.0) was made from sodium 
acetate hydrate obtained from UCB (Leuven, Belgium). The enzymatic deconjugation 
solution (33 mg/mL) was prepared in acetate buffer with sulfatase from Helix pomatia (type 
H-1 with sulfatase activity: 15.3 units/mg and β-glucuronidase activity: 300 units/mg) from 
Sigma-Aldrich. Peroxidase-labeled anti-mouse IgG1 antibody, unlabeled mouse IgG antibody 
and ABTS stop solution were obtained from SouthernBiotech (Birmingham, Alabama, USA). 
ABTS (2,2'-azinobis(3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt) tablets and 
peroxidase substrate buffer were purchased from Pierce. The ELISA technique was carried 
out on microtiter plates (Nunc Maxisorp, Nunc, Roskilde, Denmark) with 96 wells. 
2.2 Instrumentation 
Semi-preparative chromatography was performed with a Varian Omnisphere C18 column 
(250 mm x 21,4 mm, 10 µm) from Varian (Palo Alto, CA, USA) using a Gilson 322 pump 
(Gilson, Middleton, WI, USA) with a Gilson UV-VIS 156 detector and a Gilson 206 fraction 
collector. The identity of the haptens was confirmed by interpretation of proton magnetic 
resonance spectra (1H NMR, 300 MHz) and carbon magnetic resonance spectra (13C NMR, 75 
MHz) data obtained with a Varian Mercury-VX 300 MHz spectrometer. Thin-layer 
chromatography (TLC) was performed using silica-coated aluminium plates with fluorescent 
indicator (Alugram SIL G/UV 254 plates, 0.2 mm; Macherey-Nagel & Co., Düren,  Germany) 
and TLC separations were examined under UV light at 254 nm and 350 nm and revealed by a 
sulfuric acid-anisaldehyde spray. The hapten/carrier protein ratio of the antigen conjugates 
was estimated by UV-spectrometry at characteristic wavelengths using a Shimadzu UV-
1600PC spectrophotometer (Shimadzu, Kyoto, Japan) in scan mode in a 1 cm quartz cuvette 
and using UV Probe 2.20 software. Purification of the produced monoclonal antibodies was 
performed on an AKTA-FPLC apparatus (GE Healthcare). Microtiter plates from the primary 
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screening assays were read with a Molecular Devices (Wokingham, Berkshire, UK) microplate 
reader and the absorbances of the competitive immunoassays were determined with a 
Beckman Coulter Paradigm Detection Platform (Fullertan, CA, USA). The HPLC-MS system 
was an Agilent 1200 (Agilent Technologies, Waldbronn, Germany) equipped with vacuum 
degasser (G1379B), binary pump (GG1312A), autosampler (G1329A), column thermostat 
(GG1316A) and diode array detector (G1315B). The system was coupled online to the mass 
selective MSD detector (G1956B), SL version, controlled by Chemstation software (Rev. B 
02.01) and the MSD was tuned with Agilent APPI/APCI tuning mix. Statistical analyses during 
validation were performed using SPSS version 17.0 for Windows (SPSS Inc., Chicago, IL, USA). 
2.3 Synthesis of phytoestrogen derivatives and immunogen synthesis 
The molecular weight of phytoestrogens is too low (< 1000 Da) to evoke immune 
responses, and consequently immunization had to be conducted with conjugates, i.e. 
haptens (phytoestrogen + linker) covalently linked to an immunogen protein, BSA. The 
resulting conjugate is immunogenic and antibodies will be produced against the low-
molecular non-protein part. The linker is a short spacer with a carboxylic acid group, and is 
held as small as possible to restrict flexibility and to result in an immune response as high as 
possible. The carboxylic acid group serves for the chemical coupling to an ε-amino group of a 
lysine-residu of BSA. To ensure the specificity of the antibodies, the linker was positioned in 
favor of a minimal structural loss of the antigen molecule. Therefore the haptenisation was 
conducted at the biological least important position, which is the 4’-OH group (except for 
coumestrol, which was linked to BSA with the 3-OH group).  
 
The first step in the synthesis was the formation of ethoxycarbonylmethylderivatives of 
the targeted phytoestrogens. The O-carboxymethylderivatives 4’-O-carboxymethyl-
genistein,  -daidzein and -xanthohumol were prepared by selective alkylation of the phenolic 
4’-hydroxy group using dry potassium-tert-butoxide and ethyl bromoacetate in dry DMF 
(HMPA for XN) according to Al-Maharik et al. with minor modifications [183]. For 
coumestrol, 3-O-carboxymethylcoumestrol was prepared using ethyl chloroacetate in 
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potassium carbonate. After alkylation the ethylester was hydrolyzed under acidic conditions 
to the desired acid in good yield. The 4’-O-carboxymethyl-derivative of isoxanthohumol was 
obtained by cyclization of the xanthohumol-derivative under alkaline conditions. For the 
preparation of the 4’-O-carboxymethyl-derivative of 8-prenylnaringenin synthesis was 
started from naringenin. After protection of the 7-OH-group and subsequent linking with the 
spacer, naringenin was prenylated at the 5-OH-group [184]. Through a Claisen 
rearrangement the 8-prenylnaringenin-derivative was obtained.  
 
Secondly, after the coupling of the phytoestrogen to the spacer, the resulting product 
had to be conjugated to BSA. For activation of the haptens the dicyclohexylcarbodiimide 
(DCC)/N-hydroxysuccinimide (NHS) coupling method of Hosoda et al. [185] was adapated. 
Briefly, a solution of the haptens was put for 2 to 5 hours at room temperature with DCC and 
NHS in dry DMF. The mixtures were then centrifuged to deposit the crystals of 
dicyclohexylurea. The supernatants containing the respective NHS-esters were conjugated 
with BSA in a reversed micellar system [186] at a molar ratio (between the activated 
compound and BSA) of approximately 70:1 which is sufficient for a high degree of 
haptenisation, since approximately 60 amino groups can be used for modification. As there 
is a positive correlation between the number of haptens incorporated and the buffer/octane 
ratio, a large amount of buffer was used (6/1 buffer/octane). Upon clearance of the mixture, 
the activated haptens in DMF solution were added immediately under vigorous shaking. 
After a slight transient turbidity was observed the reaction mixture was allowed to react 24 
to 36 h at room temperature. Total disappearance of the activated hapten was checked by 
TLC (4/1 trichloromethane/methanol). Hapten-BSA conjugates (Figure 5.1 depicts the 
conjugates for XN, IX and 8-PN) were isolated from the mixture by precipitation with three 
volumes cold acetone at 0 °C followed by centrifugation. The supernatant was removed, the 
sediment was washed against PBSD- and dialyzed overnight at 4 °C under continuous stirring 
against PBSD- using Slide-a-Lyzer cassettes. The remaining solution was filtered through a 0.2 
µm filter and lyophilized. The hapten/carrier protein ratio of the conjugates was determined 
by spectrophotometric analysis. Aliquots of the conjugates were stored at -20 °C until use. 
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Figure 5.1:  Structures of three immunogens: (A) 4’-O-carboxymethyl-xanthohumol-BSA  and          
(B) 4’-O-carboxymethylisoxanthohumol-BSA  (R1= Me); 4’-O-carboxymethyl-8-prenylnaringenin-
BSA (R1= H). 
2.4 Immunization  
Three to four BALB/c female mice (12 to 16 weeks old) (Charles River Laboratories, 
Wilmington, DE, USA) were immunized subcutaneously (100 µL) with the respective hapten-
BSA conjugate (100 µg). Two and four weeks after the initial injection, booster injections 
were given intraperitoneally with an equal amount of immunogen. Three days after the last 
booster injection the mice were sacrificed for lymphocyte/myeloma cell fusion. Afterwards 
their spleens were isolated and transferred to 10 mL DMEM.  
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2.5 Cell fusion 
The procedure described by Brown and Ling [187] was used as basis for the cell fusion. 
Murine NS0 myeloma cells were cultured in complete DMEM supplemented with 10% FBS. 
Mice spleens were perfused with 20 mL serum-free DMEM, and the resulting lymphocyte 
suspension was mixed with the myeloma cells at a ratio of 10:1 and centrifuged. A few drops 
of alkaline DMEM were added to the cell pellet and after rolling of the tube 700 µL of a 50% 
PEG solution (w/v, in 1 mM NaOH) at 37 °C was added. Next, the procedure was completed 
with alternating of rolling steps and the addition of (in total) 15 mL serum-free DMEM. 
Finally, after completion of the fusion procedure, the cells were spun down and suspended 
in 20 mL of HAT selection medium. The resulting cell suspension was distributed (100 µL 
well-1) in 96-well tissue culture plates and incubated in a 10% CO2 incubator at 37 °C. The 
next day one drop of HAT medium was added to the wells and every two days culture 
medium was replaced.  
2.6 Hybridoma selection and cloning 
Two weeks after the cell fusion, culture supernatants from all fusion wells were 
screened for the presence of anti-hapten antibodies. Initial screening and selection was 
performed using two replicate non-competitive enzyme-linked immunosorbent assays 
(ELISA) with the conjugates of the phytoestrogens as the coating antigens. Next, antibodies 
from the selected hybridomas were tested in a competitive indirect ELISA to determine 
whether they recognize pure XN/IX/8-PN and the coating antigen on a competitive basis. The 
monoclonality of the produced antibodies was ensured via limiting dilution (two rounds of 
subcloning) of the selected hybridomas [187]. Several aliquots of the first hybridomas and 
their clones were cryopreserved in liquid nitrogen (in 10% FBS in DMSO) at several stages 
during the development.  
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2.7 Production and characterization 
The clones of interest were cultured for a period of 3 up to 5 months in vitro in Integra 
CELLine bio-reactors. After dialysis against PBS using Pierce Slide-A-Lyzer cassettes, 
monoclonal antibodies (mAbs) were purified from the collected culture media with fast 
protein liquid chromatography (FPLC) by their affinity for HiTrap Protein G columns and, 
subsequently, ultrafiltered against PBS. The protein concentration of the final antibody 
solutions was determined using a Bio-Rad protein concentration determination assay. Then, 
using the Sigma mouse monoclonal antibody isotyping kit, the isotype class was determined. 
Finally, the purity of the antibody solutions was confirmed by 12% SDS gel electrophoresis, 
followed by Coomassie blue staining [188]. The mAb stocks were stored at a 1 mg/mL 
concentration in PBS at -20 °C until further use. 
2.8 Indirect non-competitive screening ELISA 
The selection of the hybridoma’s was carried out using an antigen-coated ELISA, with 
supernatants from the hybridoma cultures. Briefly, microtiterplates  were coated overnight 
at 4 °C with 100 µL of a 10 µg/mL solution of phytoestrogen conjugates. After washing four 
times with PBS containing 0.05% (v/v) Tween-20 (PBS-Tw), the wells were blocked for 1 h at 
37 °C with 1% BSA in PBS. Next, after washing, 100 µL of supernatant was added and 
incubated during 2 h at 37 °C. After washing, 100 µL of the alkaline phosphatase-labeled 
rabbit anti-mouse IgG antibody at a 1:3000 dilution was added and incubated for 1 h at 37 
°C. Finally, after a final washing step, 100 µL of the pNPP substrate solution was added at 
room temperature and after 30 minutes the absorbance was measured at 405 nm. 
2.9 Indirect competitive ELISA 
After two screenings with the non-competitive ELISA, the affinity of the antibodies from 
the selected hybridomas for XN, IX or 8-PN was tested in an indirect, but competitive ELISA. 
Briefly, the same procedure as in section 2.8 was applied, except for the extra addition of 
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pure XN, IX or 8-PN (10 µL of a 1 mg/mL solution in methanol) together with the culture 
supernatants to the wells. Whenever the binding of the antibodies to the coating antigen 
was inhibited by their affinity for XN, IX or 8-PN, thereby decreasing the absorbance, the 
respective hybridomas were included for further experiments. Next, the different steps and 
parameters of this competitive ELISA were thoroughly optimized, using the purified 
monoclonal antibodies. In summary, checkerboard titrations were completed to establish 
the optimal working dilutions of the coating antigen, blocking buffer, primary and secondary 
antibody, and the type of secondary antibody and enzymatic substrate, incubation 
temperatures and time periods were optimized. Furthermore, the influence of organic 
solvent (i.e., methanol) for dissolvation of the prenylated flavonoid standards, on assay 
performance was examined. 
 
The optimized procedure for the competitive ELISA was as follows: wells were coated 
overnight (at least 12 h) at 4 °C with 200 µL of a 0.5 µg/mL solution of the respective antigen 
and after washing with PBS-Tw blocked with 250 µL of 3% BSA in PBS during 1 h at 37 °C. 
Then, per well 100 µL of serial dilutions of the competitor, i.e. XN in 50% methanol in PBS or 
IX or 8-PN (in 10% methanol in PBS) and an equal volume of the specific antibodies (5 ng/mL 
in PBS with 0.1 % BSA) were added and incubated during 2 h at 37 °C under slow agitation. In 
negative control (NC) wells, the primary antibody was replaced by an antibody of irrelevant 
specificity (unlabeled mouse IgG; 1:5000 dilution in 0.1% BSA in PBS). The plate was washed 
with PBS-Tw and 200 µL of peroxidase-labeled anti-mouse IgG1 antibody was added to each 
well. The plate was left at 37 °C for one hour. After washing the plate four times with PBS-
Tw, 200 µL ABTS substrate solution in peroxide substrate buffer was added and reaction 
took place in the dark at room temperature and was then stopped after 30 min by the 
addition of stop solution. Absorbance was measured at 405 nm and calibration curves were 
constructed by plotting [(Bi-NC)/(B0-NC)] (Bi= absorbance of wells with standard/biological 
sample; B0= absorbance from maximum binding of the antibody to the antigen without 
competition) against log(competitor concentration) and fitted to a four-parameter logistic 
equation using Sigmaplot version 11.0 (Systat software, Chicago, IL, USA). For each point of 
the calibration curve a minimum of five replicates was used and absorbances were the mean 
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value of duplicate readings. From the equation of the calibration curves, IC50 values 
(concentration at which the binding of the antibody to the coating antigen is inhibited with 
50%) were determined and subsequently used to express the sensitivity and the detection 
range of the ELISA. 
2.10 Determination of cross-reactivity 
A panel of phytoestrogens (daidzein, genistein, enterodiol, enterolactone, equol, 
coumestrol), 17 β-estradiol and structurally related compounds (desmethylxanthohumol, 6-
prenylnaringenin) were tested for cross-reactivity by determining their respective IC50 values 
in the competitive assay as described above. Cross-reactivity values were calculated as the 
ratio of the IC50 of the XN, IX or 8-PN standard to the IC50 of the test compounds and 
expressed as a percentage.  
2.11 Preparation of samples for validation and extraction of urine and 
serum 
For the validation of the competitive ELISA, spiked urine and serum samples, as well as 
some urine samples from the dietary intervention study described in Chapter 4 [130], were 
prepared. Briefly, for the hydrolysis of glucuronide and sulfate conjugates, one volume of 
(spiked) urine or serum was mixed with one volume of sodium acetate buffer and incubated 
with a β-glucuronidase/sulfatase solution overnight at 37 °C. Next, the samples were 
extracted using five volumes of diethyl ether under vigorous vortex mixing during 30 
seconds. This extraction was repeated three times to ensure complete recovery of the 
compounds. Finally, the collected solvent layers were evaporated to dryness under nitrogen 
and the residue was dissolved in assay buffer (50% methanol in PBS for XN and 10% 
methanol in PBS for IX/8-PN).  
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3. RESULTS AND DISCUSSION 
3.1 Monoclonal antibody production 
Conjugates with BSA were generated for daidzein, genistein, coumestrol, 
xanthohumol, isoxanthohumol and 8-prenylnaringenin. The hybridomas for the 
respective phytoestrogens were constructed. After the initial screening phase only the 
hybridomas against coumestrol, xanthohumol, isoxanthohumol and 8-prenylnaringenin 
were retained. Talbot et al. [182] described in 2008 the development and application of 
monoclonal antibodies against daidzein and genistein, and therefore, we did not give 
priority to this issue. The antibodies generated from the remained hybridomas were 
tested according to the competitive ELISA as described in section 2.9 of this chapter. For 
XN, IX and 8-PN the affinity of the antibodies for the pure phytoestrogen could be 
guaranteed. The development of antibodies against coumestrol was stopped, due to 
lack of conjugate stock. Figure 5.2 depicts a colony from 1 cell of the XN-hybridoma, at 
the 2nd cycle of cloning. Monoclonality of the antibodies generated from the three 
retained hybridoma cell lines (XN, IX and 8-PN) was tested by the procedure written in 
section 2.6 of this chapter. 
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Figure 5.2: Hybridoma colony (in a well of a 96-well plate) (5x magnification). 
Large quantities of anti-XN, anti-IX and anti-8-PN were produced and then purified, 
and consequently 59 mg, 195 mg and 52 mg of total protein was generated, 
respectively. Figure 5.3 depicts the result of the protein gel electrophoresis of the 
monoclonal antibodies, which are all of the IgG1 isotype, and shows their purity and lack 
of contamination with BSA (= 65 kDa).  
 
Figure 5.3:  Gel demonstrating purity of developed monoclonal antibodies (anti-XN, -IX and -8-PN). 
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3.2 Immunoassay optimization 
The concentrations of XN, IX and 8-PN in biological samples, upon ingestion of a hop-
based dietary supplement, most often only reach to lower ppb-levels. Therefore, the 
analytical sensitivity of the competitive ELISA, which is represented by its IC50 value, has to 
be as low as possible. Consequently, the amount of primary antibody and conjugate, as well 
as the concentration and type of blocking buffer (1% to 3% BSA in PBS or 0.5% milk powder 
in PBS), the amount of secondary antibody (1:2000 to 1:8000), type of substrate (ABTS, TMB 
or OPD) and the duration (0.5 to 2 h) and incubation temperature (room temperature or 37 
°C) of each step were optimized in order to enhance the analytical sensitivity. The standard 
curve characteristics were optimal at conjugate and antibody concentrations of 0.5 µg/mL 
and 5 ng/mL, respectively, for XN, IX and 8-PN and the other parameters were defined as 
described in section 2.9 of this chapter.  
 
Furthermore, the effects of different concentrations of methanol on the performance of 
the ELISA were studied. Given the relatively apolar nature of XN, IX and 8-PN, a certain 
amount of organic solvent is necessary to ensure full solubilization in PBS. Although DMSO is 
often used for this purpose, we opted for methanol, as it is generally the best tolerated 
solvent in ELISA. Methanol dissolves XN, IX and 8-PN very well and we did not notice any 
difference in solubility with the former. Consequently, a compromise had to be found 
between solubility and influence of methanol on assay performance. For that, the maximum 
signal or the maximum binding of the antibody was observed with increasing amounts of 
methanol added to the assay buffer (Table 5.1; amount of methanol expressed as 
percentage of the well). For the anti-IX and anti-8-PN antibodies the binding was attenuated 
starting from 12.5% methanol in assay buffer. The binding of anti-XN, on the other hand, 
benefits from increasing amounts of methanol, and only starts to decrease with 50% 
methanol in the well. The solubility of XN, IX and 8-PN in PBS with added amounts of 
methanol in the assay buffer, respectively 50% for XN and 10% for IX and 8-PN, was 
examined by triplicate analysis with HPLC-UV (quantification at 370 nm for XN and 295 nm 
for IX and 8-PN) [189]. The signal intensity of XN, IX and 8-PN (1.25 µg/mL) in increasing 
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methanol concentrations versus the same concentration in 100% methanol (or 100% 
dissolvation) was investigated. Analysis results showed that the solubility of XN increased 
from 76.10% in 1% methanol in PBS to 98.70% in 50% methanol in PBS. For IX and 8-PN 
(both at a concentration of 1.25 µg/mL), the solubility increased from 84.40% and 83.30% in 
1% methanol in PBS to 97.03% and 97.97% in 10% methanol, respectively. Additionally, 
calibration standards were prepared just before the beginning of each assay, to secure full 
solubilization and to minimize degradation of the analytes in PBS.  
 
Table 5.1: Influence of methanol (expressed as percentage in the well) on the binding capacity of 
the primary antibodies (0% methanol as reference)(n=6). 
Relative binding capacity (%) 
MeOH (%) anti-XN anti-IX anti-8-PN 
0 
0.25 
0.5 
2.5 
5 
12.5 
25 
50 
100 
111 
106 
123 
139 
155 
155 
75 
100 
92 
93 
92 
97 
90 
85 
81 
100 
98 
107 
106 
106 
94 
81 
77 
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Figure 5.4 depicts the color development in a standard 96-well plate in a completed 
competitive ELISA for XN.  
 
 
Figure 5.4: View of 96-well plate with standard calibration curve for XN (2500 ng/mL – 1,22 ng/mL 
in competition in ELISA). 
Standard curves (mean ± SD) for XN, IX and 8-PN from 15 assays, measured on three 
different days under optimized conditions, are shown in Figure 5.5 (A, B and C). The IC50 
values were 62.91 ng/mL for anti-XN, 37.15 ng/mL for anti-IX and for anti-8-PN and their 
respective limits of detection (10% inhibition) were 14.45 ng/mL, 5.62 ng/mL and 4.37 
ng/mL. Values for the LOQ (limit of quantification) were calculated as 10 x SD of the blank 
and were 41.01 ng/mL, 13.90 ng/mL and 17.10 ng/mL for XN, IX and 8-PN, respectively. 
 
 
 
 
Negative 
control   
Blanks  
Decreasing amount of XN in competition  
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Figure 5.5: Standard curves for xanthohumol (A), isoxanthohumol (B) and 8-prenylnaringenin (C) 
obtained with the optimized ELISA, means based on 15 replicate calibration curves (n=15) on three 
different days (± standard deviation). 
3.3 Specificity of the monoclonal antibodies 
The cross-reactivities of the three monoclonal antibodies against a panel of other 
phytoestrogens, chemically related compounds and 17β-estradiol (E2) are shown in Table 
5.2. Generally, all three antibodies revealed excellent specificity for their antigens. For anti-
8-PN the negligible cross-reactivity (<0.03%) presented by DMX and 6-PN is probably due to 
the impurity of the respective standards or in situ isomerization (for DMX). On the other 
hand, anti-XN showed some, negligible cross-reactivity (<0.05%) with IX and 8-PN.  
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Table 5.2: Cross-reactivity of three monoclonal antibodies against structurally related compounds. 
                          Cross-reactivity (%) 
 competitor anti-XN anti-IX anti-8-PN 
GEN 
DAID 
END 
ENL 
EQ 
COUM 
DMX 
6-PN 
E2 
XN 
IX 
8-PN 
< 0.01 
< 0.01 
< 0.01 
< 0.01 
< 0.01 
< 0.01 
< 0.01 
< 0.01 
< 0.01 
 100 
 <  0.05 
 <  0.05 
< 0.01 
< 0.01 
< 0.01 
< 0.01 
< 0.01 
< 0.01 
< 0.01 
< 0.01 
< 0.01 
< 0.01 
  100 
 < 0.01 
< 0.01 
< 0.01 
< 0.01 
< 0.01 
< 0.01 
< 0.01 
< 0.03 
< 0.03 
< 0.01 
< 0.01 
< 0.01 
  100 
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3.4 Analytical recovery 
The recovery after solvent extraction with diethyl ether was assessed by spiking a 
known amount of XN, IX or 8-PN in blank urine and serum before extraction and after 
extraction. By comparing the measured concentrations (from triplicate analyses) at low (= 
QC1; 50 ng/mL), medium (= QC2; 250 ng/mL) and high (= QC3; 750 ng/mL) QC level from the 
competitive ELISA, the extraction recovery and the possible influence of matrix components 
are assessed. In Table 5.3 the mean recoveries (with coefficients of variation) are presented 
for XN, IX and 8-PN, for three concentration levels in urine and serum. In urine the 
recoveries for XN ranged from 96.3 % to 110.4%, for IX from 89.7% to 96.9% and for 8-PN 
from 89.1% to 97.1% and in serum the recoveries ranged from 85.0% to 95.3% for XN, 97.0% 
to 100.6% for IX and 85.7% to 95.3% for 8-PN. It can be concluded, from these recovery 
experiments, that the suggested extraction method offers a simple sample preparation with 
satisfying recoveries of all three analytes at physiological relevant levels. 
    
Table 5.3: Recovery of XN, IX and 8-PN in spiked urine and serum samples after solvent extraction 
at three QC levels.  
 Recovery (CV) 
(%) 
XN IX 8-PN 
U
R
IN
E
 
low 
medium 
high 
110.38 (0.76) 
103.87 (0.22) 
96.26 (3.67) 
89.68 (1.59) 
96.44 (3.28) 
96.88 (0.25) 
89.05 (3.65) 
95.61 (0.95) 
97.13 (3.52) 
S
E
R
U
M
 
low 
medium 
high 
95.34 (8.43) 
84.98 (4.44) 
88.05 (2.33) 
97.65 (2.45) 
96.99 (4.00) 
100.58 (3.76) 
85.71 (7.07) 
90.92 (1.07) 
  95.28 (1.24) 
 
  
106 
 
3.5 Matrix effects 
The influence of certain matrix components in urine and serum was assessed, because 
they may interfere with the affinity of the antibody for its antigen. Our main goal was to 
develop a short and easy ELISA and therefore the possibility of measurement of unprocessed 
urine or serum samples was investigated. Blank urine and serum were serially diluted in PBS 
and a constant amount of antibody was added. Then, the changes in maximal absorbance 
were monitored (Table 5.4). For anti-XN, in urine a minimum dilution factor of 10 was 
required to obtain at least 80% of the maximum signal and in serum at least a 100-fold 
dilution is required. For IX and 8-PN in serum, the effect of matrix components on the 
maximum absorbance was so large that at least 50-fold dilutions are recommended. In urine, 
the influence of the matrix on the binding capacity of anti-IX and anti-8-PN was smaller. As a 
result, we concluded that the influence of matrix components on the performance of the 
ELISA was substantial and variable. 
Table 5.4: Influence of urine and serum on the maximum binding of the antibodies (without 
preliminary extraction).  
% matrix (in PBS) 
Amax (%) 
U
R
IN
E
 
 
100 
50 
20 
10 
4 
2 
1 
anti-XN 
35.71 
48.20 
63.49 
81.02 
82.79 
94.32 
91.43 
 anti-IX 
60.24 
76.48 
85.20 
99.60 
90.24 
89.76 
97.52 
  anti-8-PN 
40.86 
52.41 
70.28 
88.35 
90.26 
96.29 
96.49 
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% matrix (in PBS) Amax (%) 
S
E
R
U
M
 
 
100 
50 
20 
10 
4 
2 
1 
anti-XN 
41.63 
46.39 
46.75 
54.99 
62.21 
70.81 
78.13 
anti-IX 
56.32 
57.33 
65.94 
74.55 
77.27 
84.33 
89.60 
anti-8-PN 
60.69 
62.96 
70.25 
71.43 
77.34 
81.97 
               94.68 
 
 Therefore, for the rest of the validation an extraction of urine and serum samples prior 
to the ELISA was recommended. The matrix effect was then also assessed at three QC levels, 
by comparison of spiked samples after extraction (100% recovery) and the spikes in assay 
buffer. As shown in Table 5.5, the extraction step with diethyl ether substantially improved 
the assay performance. In urine, matrix effects gave an average underestimation of the final 
concentrations of 9.6% to 13.2% for XN, whereas for IX and for 8-PN matrix effects resulted 
in an underestimation of 0.8% to an overestimation of 9.6%. As expected, in serum, the 
underestimation of the final concentrations was slightly higher than in urine, and ranged for 
XN from 6.1% to 18.2%, for IX from 16.0% to 21.9% and for 8-PN from 13.4% to 19.8%.  
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Table 5.5: Matrix effects of extracted urine and serum samples on assay performance at three QC 
levels.     
 ME (%)  XN  IX    8-PN 
U
R
IN
E
 
low 
medium 
high 
86.91 
86.82 
90.45 
86.91 
86.82 
90.45 
99.23 
104.73 
109.61 
S
E
R
U
M
 
low 
medium 
high 
93.92 
84.49 
81.84 
78.10 
84.05 
82.95 
86.58 
81.43 
80.24 
3.6 Precision and accuracy 
Three quality control samples of XN, IX and 8-PN in urine and serum were analyzed 
twice in three replicates in the same competitive assay on the same day, as well as in 
identical assays that were performed on three consecutive days and the inter- and intra-
assay variations were calculated as %CV (Table 5.6). For urine and serum, the inter-assay 
variation was overall lower than 10%, except at the QC1 level of XN and 8-PN in serum, 
where the variation was 14.7% and 12.3%, respectively. The relative standard deviations 
were below 5% for the intra-assay variation, both in urine and serum and for all three QC 
levels. Certain factors, like evaporation of the solvents at the edge of the wells, non-
homogeneity of the temperature or slight changes in the preparation of buffers and 
solutions, can cause these variations. Therefore, the use of daily calibration curves is highly 
recommended. Furthermore, accuracy was assessed as the percentage relative error and 
never exceeded 15%, both in urine and in serum (Table 5.7). In conclusion, the obtained 
results for the accuracy and precision assessment met the acceptance criteria in analytical 
 C
h
a
p
te
r 
5
: 
M
o
n
o
cl
o
n
a
l a
n
ti
b
o
d
ie
s 
a
g
a
in
st
 p
h
yt
o
es
tr
o
g
en
s 
109 
 
validation guidelines [189], with emphasis on important issues described by Findlay and co-
workers [190].  
Table 5.6: Inter- and intra-assay variation (%CV) in urine and serum at three QC levels (n=3). 
                                     URINE                                     SERUM 
   QC level XN IX  8-PN  XN  IX  8-PN 
IN
T
E
R
-A
S
S
A
Y
 
low 
medium 
high 
1.8 
3.0 
2.2 
5.2 
8.8 
4.7 
9.5 
7.0 
5.0 
 
14.7 
7.6 
4.4 
4.7 
7.0 
6.7 
12.3 
2.7 
3.4 
IN
T
R
A
-A
S
S
A
Y
 
low 
medium 
high 
1.7 
2.1 
1.9 
3.0 
1.3 
2.9 
0.7 
0.4 
1.1 
 
1.9 
0.5 
1.7 
1.9 
1.3 
1.5 
2.9 
1.9 
2.5 
 
Table 5.7: Accuracy (%RE) in urine and serum at three QC levels (n=3).  
                                    URINE                                      SERUM 
  QC level XN IX  8-PN  XN  IX  8-PN 
low 
medium 
high 
9.2 
7.8 
1.7 
14.1 
0.1 
1.7 
11.9 
0.1 
3.2 
 
4.9 
11.6 
7.5 
2.3 
2.9 
6.3 
10.8 
2.8 
3.2 
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3.7 Correlation with LC-MS method 
We determined the correlation between the competitive ELISA and an established and 
validated LC-MS method described in Chapter 3 [150] by applying both methods on urine 
samples from a dietary intervention trial described in detail by Bolca et al. [130] (Chapter 4) 
and with Ethical Approval from the Ethics Committee of the Ghent University Hospital (EC 
UZG 2007/199; Belgian registration number: B67020072203; initial recruitment date: 
October 15, 2007). We selected 18 urine samples of subjects (both male and female, 
generally healthy individuals) who ingested with meals a hop-based supplement (MenoHop, 
Metagenics Europe): 1.20 ± 0.04 mg IX, 0.10 ± 0.01 mg 8-PN, 0.09 ± 0.01 mg 6-
prenylnaringenin, and 2.04 ± 0.06 mg XN per capsule) three times a day during 5 days, after 
a run-in phase of at least 4 days. On the last day of the intervention spot urine samples were 
collected. The urine samples were extracted and hydrolyzed as described in section 2.11 and 
IX and 8-PN concentrations were measured with the competitive ELISA and compared with 
the results from LC-MS analyses. For the ELISA, values were based on four measurements 
with the final immunoassay and for LC-MS duplicate determinations were used. The 
correlations for both IX and 8-PN urinary concentrations were found to be highly significant: 
correlation coefficients were r = 0.945 (P<0.01; n=18) and r = 0.860 (P<0.01; n=18) for IX and 
8-PN, respectively (Figure 5.4A and 5.4B). The correlation of urinary xanthohumol 
concentrations was not included in this study, because, first of all the levels in the patient 
samples were too low to get detected with the developed ELISA. Secondly, it has been 
reported before that xanthohumol has a very poor bioavailability [30, 65] and therefore this 
ELISA will not be directly applicable in the clinical field. Furthermore, serum correlations 
were also not investigated, because the amount of serum from the study was limited and 
the spiking of pooled blank serum would not have given an added value to our study.   
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A) 
 
B) 
 
Figure 5.4: Correlation graphs of significant correlation (Pearson’s correlation coefficient) between 
urinary IX (A) and 8-PN (B) concentrations measured with the validated LC-MS method and ELISA. 
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4. CONCLUSION 
 
In conclusion, three monoclonal antibodies were successfully developed against the 
hop-derived prenylflavonoids XN, IX and 8-PN. They were integrated in an indirect 
competitive ELISA, which was validated for the measurement of the respective compounds 
in urine and serum samples. This ELISA technique requires a short sample preparation that 
consists of enzymatic hydrolysis and subsequent solvent extraction with diethyl ether, to 
reduce matrix effects and avoid potential over- or underestimation. The sensitivity of this 
assay, although acceptable, is not so high as with our established LC-MS method, as shown 
in a comparative table (Table 5.8), but can be further improved by changing the type of 
immunoassay. In addition, all three antibodies showed no substantial cross-reactivity with 
related compounds and both accuracy and precision of the measurements were within the 
criteria of acceptance. Therefore, this ELISA may serve as a reliable, simple and cost effective 
tool and as a promising alternative for chromatographic methods in intervention trials that 
require the assessment of the exposure to hop-derived prenylflavonoids. Additionally, these 
monoclonal antibodies may be valuable for other applications such as time-resolved 
fluoroimmunoassay, immunocyto- and histochemistry to reveal molecular mechanisms of 
XN, IX and 8-PN and the subcellular localization and tissue distribution of these compounds.  
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Table 5.8: Comparative table of indirect competitive ELISA and LC/APCI-MS method. 
Parameter Indirect competitive ELISA LC/APCI-MS method 
Sample prep  
(after hydrolysis of 
conjugates) 
urine and serum: LLE (diethyl ether)  urine: LLE (diethyl ether) 
serum: SPE (C18) 
LOD 
 
 
XN: 14.5 ng/mL 
IX: 5.6 ng/mL  
8-PN: 4.4 ng/mL 
 urine/serum:  
XN: 0.6/1.4 ng/mL  
IX: 0.2/1.5 ng/mL  
8-PN: 0.4/1.5 ng/mL 
LOQ 
 
 
XN: 41.0 ng/mL  
IX: 13.9 ng/mL  
8-PN: 17.1 ng/mL 
 urine/serum:  
XN: 1.9/4.8 ng/mL  
IX: 0.8/5.0 ng/mL 
8-PN: 1.2/4.8 ng/mL 
Accuracy (%RE)  
(mean of three  
QC levels) 
 
urine/serum: 
XN: 6.2/8.0  
IX: 5.3/3.2 
8-PN: 5.1/5.6 
 urine/serum: 
XN: 10.4/5.1 
IX: 3.3/10.6 
8-PN: 10.1/7.4 
Precision (%CV) 
(mean of three  
QC levels) 
 
 
 
Inter-assay (urine/serum): 
XN: 2.3/8.9 
IX: 6.2/6.1 
8-PN: 7.2/6.1 
Intra-assay (urine/serum): 
XN: 1.9/1.4 
IX: 2.4/1.6 
8-PN: 0.7/2.4 
 Inter-assay (urine/serum): 
XN: 16.3/10.1 
IX: 10.7/12.4 
8-PN: 14.4/9.7 
Intra-assay (urine/serum): 
XN: 7.1/5.2 
IX: 5.2/5.6 
8-PN: 6.0/3.9 
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CHAPTER 6 
 
 
Application of a monoclonal antibody 
against xanthohumol   
IMMUNOCYTOCHEMISTRY AND -PRECIPITATION 
    
 
This chapter was published as:  
 
The prenylated chalcone xanthohumol associates with histones in breast cancer cells –             
a novel target identified by a monoclonal antibody. 
Wyns, C., Van Steendam, K., Vanhoecke, B., Deforce, D., Bracke, M. and Heyerick, A. 
Molecular Nutrition and Food Research, 2012. 56(11): p 1688-1696. 
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1. INTRODUCTION  
 
Xanthohumol (XN) (3’-[3,3-dimethyl allyl]-2’,4’,4-trihydroxy-6’-methoxychalcone), a 
yellowish prenylated chalcone, was first isolated in 1913 by Power et al. [191] from the resin 
of hops (the female inflorescences of the hop plant (Humulus lupulus L.)) and later identified 
as a new natural chalcone by Verzele and co-workers [192]. It is the most important 
prenylflavonoid in hop (from 0.1 up to 1% (w/w)) and is, therefore, present in beer and hop-
derived dietary supplements targeting the relief of menopausal symptoms [65]. 
Nevertheless, in beer, the concentration of xanthohumol is low (e.g. 28 µg/L in European 
style pilsner), due to low solubility and thermal isomerisation to the more soluble 
prenylflavanone isoxanthohumol during the brewing process [18]. Isoxanthohumol is a pro-
estrogen as it can be further converted into the potent phytoestrogen 8-prenylnaringenin  
by demethylation effected by liver enzymes or intestinal gut bacteria as described by Nikolic 
et  al. [19] and Possemiers et al. [52]. Hops are mainly used as a flavoring agent in beer, but 
over the last decade the health beneficial properties of hop derived terpenophenolics have 
gained increased attention, including the possible use of the prenylflavonoid XN as a 
chemopreventive agent. The news that the drinking of beer could have positive effects on 
mutagenesis and DNA adduct formation triggered the start of the search for possible 
constituents in beer with chemopreventive actions [193]. Miranda et al. [194] initiated the 
research into the anti-cancer bioactivity of XN, by screening it in a number of human cancer 
cell lines. XN was further described to inhibit metabolic activation of procarcinogens through 
cytochrome P450 enzymes (Phase I) [66, 67] and also to induce Phase II enzymes which can 
help in the detoxification of carcinogens [68, 69]. Gerhauser et al. [56] confirmed the broad-
spectrum chemopreventive activity of XN, acting by multiple mechanisms at the stages of 
initiation, promotion and progression of cancer. In particular, besides the Phase I and II 
modulation of carcinogen metabolism, they established that the anti-inflammatory 
properties of XN by inhibition of cyclooxygenase (COX) enzymes also contribute to the 
potential antitumor-promoting mechanisms of the molecule. Vanhoecke et al. [195] 
described the anti-invasive properties of XN in vitro with breast cancer cell lines, mediated 
by the upregulation of the E-cadherin/catenin complex. Additionally, the prevention of 
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oxidative damage by scavenging reactive oxygen species (ROS) [196] and nitrogen oxide (NO) 
production [56, 71], but on the other hand also potential prooxidative properties of XN may 
trigger the antiproliferative mechanism and the induction of apoptosis [197, 198]. Obviously, 
in the area of cancer prevention, this chalcone has already been extensively studied and 
proved to be a particularly interesting molecule, at least in vitro. Furthermore, XN can serve 
as an anti-microbial and -viral agent [199-201], promote the osteogenic differentiation [203], 
ameliorate metabolic disorders [95, 204, 205] and has anti-inflammatory capacity. The latter 
can be mediated through nuclear transcription factor 2-antioxidant responsive element 
(NrF2-ARE) signaling [206], or by the inhibition of the activation of transcription factor 
nuclear factor-kB (NF-kB) [207] and inhibition of the expression of NF-kB dependent 
proinflammatory genes [208, 209]. Any possible therapeutic application is highly dependent 
on the overall bioavailability of XN. Caco-2 cell experiments showed that, although the 
intestinal absorption of XN is extremely low, it accumulates in the cytosol of intestinal cells 
due to high protein binding [30]. Its low intestinal absorption is also reflected in the urinary 
excretion after oral administration, which tends to be very low and seems to be dose 
dependent [31, 208]. Furthermore, XN is susceptible to microbial degradation and 
transformation in the intestine, in vitro experiments also showed glucuronidation and 
sulfatation in the liver as well as in the intestine and cytochrome P450 enzymes are 
responsible for its degradation [39, 211-213]. Although several molecular working 
mechanisms have been suggested and most of the publications have described downstream 
effectors, especially the characterization of the primary molecular target of XN is an 
underexplored field of research. The aim of the present study was to investigate the cellular 
localization of XN and to identify possible intracellular binding partners in a human breast 
cancer cell line (MCF-7/6). For this purpose a recently developed specific monoclonal 
antibody against xanthohumol was used in combination with immunocytochemical and -
precipitation techniques. 
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2. EXPERIMENTAL  
2.1 Chemicals  
Xanthohumol (XN) was available in our laboratory [52] and the mouse anti-xanthohumol 
IgG1 antibody was an antibody manufactured in-house as described previously in Wyns et al. 
[214] and the previous Chapter 5. BSA, N-cyclohexyl-3-aminopropanesulfonic acid (CAPS), 
4′,6-diamidino-2-phenylindole (DAPI), Tween-20 and Nonidet P-40 were purchased from 
Sigma-Aldrich (St. Louis, MO, USA). PBS, Tris-buffered saline (TBS), trypsin/EDTA, foetal calf 
serum (FCS), DMEM, HAM’s F12, NuPage lithium dodecyl sulphate (LDS) sample buffer, 
penicillin, streptomycin, goat anti-mouse IgG Alexa 594 and Sypro Ruby Protein gel staining 
were supplied by Invitrogen (Carlsbad, CA, USA) and amphotericin B by Bristol-Meyers 
Squibb (Brussels, Belgium). NaCl, Tris and 4-hydroxybenzophenone (4-HBPH) were 
purchased from Acros Organics (Morris Plains, NJ, USA) as well as all chemicals and solvents 
(all of analytical reagent grade) for the analytical work. A 2D Quant Kit for protein 
concentration quantification was purchased from GE Healthcare (Uppsala, Sweden) and 
Protein G agarose for immunoprecipitation was obtained from Pierce (Rockford, IL, USA). 
Modified sequence grade trypsin (porcine) was purchased from Promega (Madison, WI, 
USA). Other materials and equipment for gel electrophoresis were obtained from Bio-Rad 
(Hercules, CA, USA). The solvents for the liquid chromatography were all of LC-MS quality 
(Biosolve, Valkenswaard, The Netherlands).  
2.2 Cell culture  
The human mammary adenocarcinoma (MCF-7/6) cell line (from a pleural effusion of 
mammary adenocarcinoma), was kindly provided by Dr. H. Rochefort (Unité d’ 
Endocrinologie Cellulaire et Moleculaire, Montpellier, France). This subline differs from the 
parental MCF-7 cell line because it has a nonfunctional E-cadherin complex and can express 
non-muscle myosin IIA [215]. These cells were grown and cultured in a 50/50 (v/v) mixture 
of DMEM/HAM’s F12 with 10% heat-inactivated FCS, 100 IU/mL penicillin, 100 µg/mL 
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streptomycin and 2.5 µg/mL amphotericin B. The cells were incubated in a 100% water-
saturated atmosphere with 10% CO2 at 37 °C.   
2.3 Quantification and stability of XN in cell culture medium via HPLC-
UV  
The overall solubility of XN after supplementation to the cell culture medium was 
investigated, as well as the stability of XN in the medium at the culturing temperature of 37 
°C. Growth medium (at 37 °C) was spiked with a solution of XN in 100% ethanol, so that final 
concentration of 10 µM was reached. Reference samples, spiked with a known amount of XN 
in ethanol and also blank samples (medium without XN) were included. The culture media, 
spiked with XN were kept at 37 °C for different time periods (30 min, 1 h, 2 h, 4 h, 6 h and 24 
h). Each time point was tested in triplicate. Afterwards, all the samples were spiked with 100 
µL of internal standard (4-HBPH; 1 mg 4-HBPH in 10 mL MeOH) and extracted three times 
with ethyl acetate. The organic solvent layers were evaporated under a gentle nitrogen 
stream. The resulting residue was dissolved in 500 µL MeOH/H2O (50/50) + 0.025% formic 
acid and 20 µL was injected in the HPLC for analysis. For the chromatography a Waters 
Alliance 2695 Separation Module (Waters, Milford, MA, USA) equipped with a Waters 996 
DAD as reported by Possemiers et al. [52]. Detection was done simultaneously at 370 nm for 
the quantification of XN and at 295 nm for the internal standard. Data processing was 
performed with the Waters Millenium 3.2 software.    
2.4 Cellular uptake of XN in MCF-7/6 cells  
MCF-7/6 cells were seeded in 6-well plates (Nunc, Roskilde, Denmark) at a density of 5 x 
104 cells/mL on day one. On day three, half of the medium was aspirated and fresh medium 
spiked with XN (dissolved in 100% EtOH) was added, so that the final concentration in the 
well was 10 µM. The cells were incubated for different time periods (30 min, 1 h, 2 h, 4 h, 6 h 
and 24 h). A blank control (100% EtOH without XN) was included in each experiment and 
each time point was set up in six replicates. After the end of the treatment period, the 
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medium was aspirated and transferred to a tube. Then, each well was washed twice with 1 
mL of medium and each wash was collected in the respective tube. After three further 
washing steps with 1 mL PBS, 100 µL lysis buffer (150 mM NaCl - 1% Nonidet P-40 - 50 mM 
Tris-HCL; pH 7.4) was added to each well and the plates were placed on ice for 30 minutes. 
After lysis, the cells were scraped of the plate and washed with 900 µL PBS and the resulting 
lysates were frozen at -20 °C until analysis. Before analysis, the collected medium from the 
wells and the lysates were all spiked with 100 µL internal standard and subjected to a 
solvent-solvent extraction with ethyl acetate that was repeated three times. The pooled 
organic solvent from the triple extraction step was dried under a gentle nitrogen stream and 
the residue was dissolved in 200 µL methanol. 20 µL of each sample was analyzed with HPLC-
UV as described in section 2.3.  
2.5 Immunocytochemistry  
Round glass coverslips were placed in a 24-well plate and MCF-7/6 cells were seeded as 
a suspension with a density of 3.5 x 104 cells per mL on day one. On day three, half of the 
medium was replaced by growth medium supplemented with XN (dissolved in 100% EtOH) 
or an identical volume of 100% EtOH (blank), so that a final concentration in the well of 10 
µM XN was reached. The ethanol concentration in the wells was 0.35 % (v/v) for every 
condition. Treated cells were incubated for different time periods at 37 °C (30 min, 1 h, 2 h, 4 
h, 6 h and 24 h). During the treatment the cells were also visualized microscopically to 
monitor overall cell health. After aspiration of the culture medium the cells were washed 
twice with PBS (37 °C) and fixed for 20 min in 3% paraformaldehyde in PBS at room 
temperature. After fixation, the coverslips were washed in PBS and cells were permeabilised 
with 0.2% Triton-X after 10 min incubation with NH4Cl. Then, after three washing steps with 
TBS, the fixed cells were blocked with 5% BSA in TBS for 30 min at room temperature. After 
the blocking step, blanks and positive controls were incubated with primary antibody, i.e. 
anti-xanthohumol antibody, overnight at 4 °C. The negative control (cells treated with 10 µM 
XN for 6 h) was incubated with an isotype-matched irrelevant mouse IgG1 antibody. The next 
day, after three washing steps, the coverslips were incubated with goat anti-mouse Alexa 
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594 antibody for 90 min at room temperature, and 5 min before the end samples were 
counterstained with DAPI (400 ng/mL). After washing, the coverslips were mounted in 
glycergel (Dako, Glostrup, Denmark) on a microscopic slide and kept in the dark at 4 °C until 
evaluation. The immunocytochemical localization was optically verified with a Leitz Dialux 20 
microscope (Leica, Wetzlar, Germany) using the NPL Fluotar 23 50/1.00 oil immersion 
objective. Afterwards, confocal images were captured with a Leica Sp5 AOBS confocal 
microscope (Leica, Mannheim, Germany). Images were taken using a 63x HCX PL Apo 1.4 oil 
objective. DAPI was excited with a UV diode laser at 405 nm and Alexa 594 with a HeNe 
Laser at 543 nm. Z-sections were made with stepsize 0.5.   
2.6 Sample preparation for immunoprecipitation  
MCF-7/6 cells were seeded in culture flasks (25 cm²) and when the cells reached 
approximately 70-80 % confluency, they were treated with XN for 2 h at a final 
concentration of 10 µM. Blanks treated with ethanol (0.35% (v/v)) served as a negative 
control. After the treatment, the medium was aspirated and the cells were washed twice 
with ice-cold PBS, then the cells were lysed on ice for 30 min with a non-denaturing lysis 
buffer (see section 2.4 for composition) with a complete protease inhibitor cocktail (Roche, 
Penzberg, Germany). The cells were scraped from the flasks and the supernatant of the 
centrifuged lysates was stored at –20°C. The protein concentration of the lysates was 
determined using a 2D Quant Kit (Invitrogen, Carlsbad, CA, USA). 
2.7 Immunoprecipitation with an anti-XN antibody  
The isolation and concentration of possible target proteins of XN was performed by 
immunoprecipitation (IP) with Protein G and a specific in-house monoclonal anti-XN 
antibody. In particular, 40 µL settled resin (with Protein G cross linked to agarose) was 
washed twice with 500 µL lysis buffer. Lysates (500 µL) were pre-incubated under slow 
agitation with 100 µL antibody (1 mg/mL) for 1 hour at 37 °C, and then added to the beads. 
The samples with the beads were placed on a rocker overnight at 4 °C. The next day, after 5 
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washing steps with 500 µL cold lysis buffer and collection of all the supernatants, the pellet 
of beads with bound proteins was recovered and saved for one-dimensional gel 
electrophoresis.   
2.8 One-dimensional gel electrophoresis (1D-PAGE) 
The samples from the IP, the supernatants from the washing steps in the IP and the 
original cell lysates were denatured with 40 µL NuPage LDS sample buffer supplemented 
with 4 µL of freshly made 1 M DTT and incubated at 90 °C for 5 minutes. After centrifugation, 
the denatured and reduced protein samples were loaded on a 15 or 18% Tris-HCl 
polyacrylamidegel (Biorad, Hercules, CA, USA) and electrophoresis was performed by 
applying 150 V for 30 minutes, followed by 200 V for one hour. The gel was fixed for 30 
minutes in a 10% MeOH, 7% acetic acid solution and afterwards the proteins in the gel were 
stained overnight using Sypro Ruby Protein Gel staining (Invitrogen). Protein patterns were 
scanned and digitized using the VersaDoc Imaging System (Biorad). 
2.9 Western Blotting 
The 18% gel and nitrocellulose membranes (Bio-Rad) were incubated for 15 minutes in 
CAPS buffer (pH 11) with 20% MeOH and electrophoretic transfer of proteins was performed 
by tank blotting in a Trans Blot Cell (Biorad) with CAPS buffer at 120 V for 110 minutes. 
Successful protein transfer was checked using Ponceau S solution staining (Sigma). 
2.10 Protein identification by LC-MS/MS (Q-TOF) 
The in-gel porcine trypsin digestion of the proteins of interest from the IP was 
performed as described earlier [216]. Briefly, gel pieces were excised from the gel and 
washed twice in 50% ACN in 50 mM ammonium carbonate for 10 min. After reduction with 
10 mM DTT at 56 °C for 10 min and alkylation with 100 mM iodoacetamide for 45 min at 
room temperature (both in 50 mM ammoniumcarbonate), and succeeding washing steps, 
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the pieces were dehydrated with MeCN using a Speed-Vac concentrator (Eppendorf, Le 
Pecq, France). Then, they were rehydrated with 10 ng/µL sequence grade modified trypsin 
for 30 min on ice. After digestion overnight at 37 °C the liquid was collected and the resulting 
peptides were extracted with 50% ACN followed by an extraction with 100% ACN. The 
pooled extract was finally completely dried using the Speed-Vac concentrator. Prior to 
analysis, peptides were resuspended in H2O + 0.1 % formic acid and were then analyzed and 
identified by LC-MS/MS, using a Q-TOF Ultima Mass spectrometer (Waters). The data were 
processed using Mascot Distiller and searched against the Swissprot human database, using 
the in-house Mascot daemon searching algorithm. Identification was considered positive 
with a P-value < 0.05. 
2.11  Histone H2A immunodetection 
The blot was blocked with 1% BSA in 0.3% Tween-20 in PBS for one hour and incubated 
with histone H2A rabbit anti-human polyclonal antibody (LifeSpan Biosciences, Seattle, WA, 
USA) at a concentration of 1/1000 in blocking buffer. Overnight incubation with the primary 
antibody was followed by three washing steps (5 minutes) and incubation with HRP labeled 
goat anti-rabbit IgG (1/20 000; Pierce) (1 hour). The ECL detection was carried out using 
Supersignal West Dura Extended Duration Substrate (Pierce) and protein patterns were 
scanned and digitized using the VersaDoc Imaging System (Biorad).  
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3. RESULTS 
3.1 Solubility and stability of XN in in vitro conditions 
First, we investigated the solubility of XN in the culture medium under the conditions of 
cell culture. Xanthohumol is a rather apolar molecule, with very poor solubility in aqueous 
media, but dissolves well in ethanol and DMSO [65]. Since the organic solvent concentration 
in cell culture should be kept as low as possible, it was necessary to check for possible 
solubilisation problems that could arise for XN during the experiments. Although the 
concentration of XN is quite low during our experiments (10 µM) we performed this 
investigation since good dissolution had to be assured. An extraction procedure for XN from 
cell culture medium was optimized and the final method existed of three solvent-solvent 
extraction steps of spiked medium (three concentrations) with ethyl acetate by intensive 
vortex mixing. The recovery of XN from the medium was for the 10 µM concentration 
respectively 91.8% (± 7.9 %). This extraction method was also used in the stability 
experiment with XN (10 µM incubated for 30 min, 1 h, 2 h, 4 h, 6 h and 24 h). The recovery 
of XN from the growth medium for all time periods was good with an average of 83.3 (± 
10.0%) recovery for 10 µM was obtained, respectively. No detectable degradation products 
were observed using HPLC-UV. 
3.2 Measurement of the uptake of XN in MCF-7/6 cells 
XN was added to the medium of the MCF-7/6 cells at a concentration of 10 µM and the 
cellular uptake was estimated by measuring the remaining concentration of XN in the 
medium at the end of each incubation period (Figure 6.1). The quantification of XN in the 
collected media from this experiment revealed that already after 30 minutes about 17.8% (± 
1.49 %) of the original level XN has associated with the cellular fraction. This situation 
remains more or less stable until after 4 h, when 26.7% (± 1.5 %) uptake is reached. After 6 
h, about half of the original amount of XN can be retrieved in the medium of the cells and 
this does not change until the 24 h time point and end of the experiment. Figure 6.1 also 
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shows the concentration of XN measured in the cell lysates from the uptake experiment. A 
slight increase in XN concentration over time is noticeable, but even the sum of these and 
the medium fractions, does not lead to the total dose of the administered XN. Hence, there 
must be another reason, e.g. loss during sample preparation, association with non-
extractable cellular material or rapid biotransformation, for the discrepancy between XN 
concentrations in the medium and those in the cell fractions.     
 
 
Figure 6.1: Recovery of XN (10 µM) in medium of MCF-7/6 cells and amount of XN retrieved in 
cells, after different incubation periods (n= 6; mean ± SD). 
3.3  Immunocytochemical localization of XN in MCF-7/6 cells 
Through indirect immunofluorescence we investigated the subcellular distribution of XN 
inside MCF-7/6 cells. First of all, an optimal staining procedure had to be obtained for this 
experiment and several factors, including fixation method of the cells, concentrations of 
primary and secondary antibodies, temperatures and incubation periods, were optimized. 
Finally, an optimized and reproducible procedure, described in section 2.5, was obtained. 
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Preliminary experiments revealed that after a treatment period of 6 h with 10 µM XN, staining 
of XN in the cells could be obtained. A particularly granular pattern was observed with a high 
nuclear density, while a slight staining could be observed in the cytoplasm, with no specific 
organelle or cellular structure highlighted. The blank (vehicle control, stained with anti-XN 
antibody and secondary antibody) and the negative control (treatment with XN 10 µM 6 h, 
stained with unlabeled irrelevant mouse IgG1 and secondary antibody) gave no staining at all 
(Figure 6.2a+b). Furthermore, the same optimized staining procedure was repeated at least 
five times on cells that were treated for 30 min, 1 h, 2 h, 4 h, 6 h and 24 h with 10 µM XN. As 
can be observed in Figure 6.2a, already after 30 min the same pattern as with the 6 h 
treatment can be observed, although with a weaker staining. Treatment with a concentration 
of 50 µM XN for the same time periods gave similar results (pictures not shown here). 
Confocal imaging showed that with increasing treatment period, the nuclear staining pattern 
only intensified and also emphasized that there was no staining of the nucleoli. These findings 
provided us with the information that XN was widely distributed in the nucleus. Nevertheless, 
several localizations like cytoplasmic and nuclear membranes, cytoskeletal structures, and 
certain organelles (e.g. ER, mitochondria…) could be excluded based on the typical granular 
and mainly nuclear pattern.   
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Figure 6.2a: Immunostaining of XN with anti-XN antibody in MCF-7/6 cells. Nucleus stained with 
4,6-diamidino-2-phenylindole (DAPI) and anti-XN antibody with Alexa 594 anti-mouse IgG (blank: 
no XN; negative control: XN and mouse IgG1 as primary antibody). 
 
  
128 
 
 
Figure 6.2b: zoomed in on Alexa-staining of XN (positive control; 10 µM 6 h treatment). 
3.4 Identification of target binding proteins of XN in MCF-7/6 cells 
Immunoprecipitation with an anti-XN antibody was used to isolate possible target 
proteins of XN in MCF-7/6 cells. The proteins from the lysates after treatment (10 µM  XN for 
2 h) that were retained by immunoprecipitation were subjected to 1D-PAGE. As depicted in 
Figure 6.3, this resulted, for the treatment group, for the 10 µM treatment 2 h time point in 
clear positive staining of a series of proteins in the low-molecular weight area below 20 kDa. 
Immunoprecipitation of untreated cells (6 h, vehicle control) did not produce the same 
pattern of protein bands in that area. Subsequently the relevant proteins were further 
identified after in gel digestion. Mass spectrometric analysis revealed that the bands of 
interest from the treatment group were belonging to the histone protein families. More 
specifically, histones H2A, H2B and H4 with molecular weights of 14 kDa (H2A and H2B) and 
11 kDa, respectively (which corresponds to their location on the gels) were identified (all 
with p-value < 0.05). In order to confirm the identity of one member of these protein family, 
immunoblotting with anti-histone H2A antibody was performed. 
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Figure 6.3: 1D-PAGE of: lysates from untreated (UT) MCF-7/6 cells after isolation with IP; detection 
of histones H2A, H2B and H4 in cell lysates after incubation with XN (10 µM 2 h) after isolation 
with IP. The proteins (below 20 kDa and between brackets) were identified by mass spectrometry. 
Next to each lane with the isolated proteins from IP, the supernatants (SN) from that IP was 
spotted, a molecular marker (MM) was used for indication of the molecular weights. 
3.5 Immunodetection of histones in MCF-7/6 cell lysates 
One of the cell lysates (10 µM XN, 2 h treatment) in which, after immunoprecipitation, 
histones were identified as the binding proteins of XN in vitro (section 3.3), was subjected to 
immunodetection with an anti-histone H2A antibody. The results of this control experiment 
are summarized in Figure 6.4. In the lane of the untreated cell lysate that also underwent 
immunoprecipitation, no histone H2A could be detected. On the other hand, in the treated 
cell lysate one of the bands below 20 kDa was identified as histone H2A. Histone H2A was 
also identified in cell lysate before immunoprecipitation, although with a lower intensity. 
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Thus, immunoprecipitation with the anti-XN antibody resulted in an enrichment of histone 
H2A in our sample.  
 
 
Figure 6.4: Western blot with immunodetection with anti-histone H2A antibody. Lane 1: untreated 
cell lysate after IP, lane 2: treated cell lysate after IP (10 µM 2 h) and lane 3: treated cell lysate (10 
µM 2 h) without IP. In lane 2 and 3 visualisation of histone H2A at 14 kDa.                                                                                                     
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4. DISCUSSION  
 
This study aimed to gain insight into the in vitro uptake and the subcellular fate of XN in 
a breast cancer cell line (MCF-7/6) and to identify possible intracellular binding partners to 
provide more information about the underlying mode-of-action of bioactivities reported for 
XN. Initially, we studied the solubility and stability of XN in cell culture medium at 
experimental conditions, an aspect often forgotten in molecular studies that can greatly 
influence the results. It was shown previously that XN does not readily dissolve in aqueous 
solutions and presumably is neither so stable in it [18, 217]. Our experiments showed that at 
37 °C XN dissolves as good as completely in the culture medium and the stability is also 
satisfactory. Only after 6 h of incubation about 25% of the original amount of XN could not 
be retrieved, but after 24 h this was still the case. We concluded that the solubility and 
stability of XN in our cell culture medium were appropriate for further experiments. The 
differences in solubility and stability of XN with previous reports may be due to the nature of 
the growth medium, which differs from water and may cause cosolvation or contain certain 
lipophilic components that enhance dissolution and stability. Motyl et al. [218] recently 
investigated the solubility of xanthohumol in cell culture work and concluded that a 
minimum of 10% serum in the medium increases the solubility and prevents the absorption 
to various plastic materials. They also assumed possible interactions with serum proteins in 
in vitro experiments, which may impact upon the uptake of xanthohumol in the cells.  
 
Additionally, we investigated the cellular uptake of XN in MCF-7/6 cells in vitro. Already 
after 30 minutes a significant portion of XN was associated with the cellular fraction and 
after 6 h about 45% of the total amount of XN added could not be retrieved from the 
medium fraction. We also observed that, although the added amount of XN tends to 
decrease rapidly, this trend slows down afterwards (1 h and 2 h). This observation may be 
due to association with the cell wall, rather than an effective uptake, but could not be 
clarified from this type of experiment. After 24 h, approximately the same amount is 
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recovered from the medium as with 6 h, which may indicate that after a rapid and strong 
accumulation in the cells a saturation plateau is reached. Pang et al. [30], who studied the 
uptake of XN in intestinal cells, observed a strong intracellular accumulation of XN. Through 
ultrafiltration and LC-MS techniques they provided evidence that XN bound to cytosolic 
proteins in Caco-2 cells treated for 1 h with 10 µM XN. Furthermore, covalent binding of XN 
with cystein residues of proteins like Keap 1 by a Michael-Type addition has been reported 
as a possible first step in the mechanism of inducing chemopreventive activity [219].  
 
Our immunocytochemistry experiments showed that XN can rapidly locate 
intracellularly, both cyto- and nucleoplasmic, but tends to accumulate more in the nucleus 
over time in comparison to the cytoplasm. After 6 h exposure to a 10 µM concentration of 
XN, resulted in a clear nuclear staining, with a granular pattern. On the other hand, the faint, 
typically aspecific, staining in the cytoplasm that already appeared after 30 min did not 
further increase in intensity to the same extent as the nuclear staining. These observations, 
which were highly reproducible, instructed us to isolate/purify the binding partner of XN in 
conditioned cell lysates of MCF-7/6 cells by means of immunoprecipitation. Using Q-TOF 
mass spectrometry we were able to identify histones (i.e. histone H2A, H2B and H4) as the 
proteins that were differentially detected on the 1D-PAGE of immunoprecipitated XN-
positive cell lysates. The identity of one of the bands of interest in the low-molecular region 
(below 20 kDa) was confirmed by means of Western Blotting and immunodetection. The 
application of our specific monoclonal antibody against the prenylated flavonoid XN, opens 
up a whole field of research opportunities related to the unraveling of the exact mode-of-
action of XN. To the best of our knowledge, histones have not been reported previously as 
possible protein targets of XN in breast cancer cells.  
 
Histones are very basic proteins that form an octameric core, consisting of a H3-H4 
tetramer and two H2A-H2B dimers, around which the DNA strand is coiled. The modification 
of histone proteins is an epigenetic mechanism that effects the chromatin structure and 
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gene expression. Acetylation for instance, one of the posttranslational modifications, which 
is regulated by opposing activities of histone acetyltransferases (HATs) and histone 
deacetylases (HDACs), affects the function of transcription factors and the subsequent 
oncogenic transformation. Epigenetic regulators, influencing chromatin modifications at the 
histone core, have been under investigation in recent times, as promising therapeutics in 
cancer therapy. Dietary polyphenols, which have been suggested as potential 
chemopreventive agents, are also thought to modulate epigenetic alterations in cancer cells, 
but the precise mechanism how they regulate and effect modifications is hardly unraveled. 
Link et al. recently [220] reviewed the role of polyphenols like curcumin (curry), (-)-
epigallocatechin-3-gallate (EGCG; green tea) and several others which can indirectly induce 
histone modifications acting as HAT and HDAC inhibitors. It would be interesting to 
investigate if the introduction of those inhibitors into the type of experiment we performed, 
would impact upon xanthohumol binding on histones. Methylation and demethylation of 
proteins, on the other hand, plays also an important role in nuclear hormone receptor 
regulated transcription. Xanthohumol, to the best of our knowledge, is not known for its 
direct action on steroid receptors. In estrogen receptor dependent cell lines like MCF-7/6, 
xanthohumol may influence nuclear hormone signaling indirectly by interference in histone 
modification processes. Additionally, it would also be recommended to repeat experiments 
in steroid free conditions to clarify the possible role of xanthohumol in NR-mediated 
transcription.  
 
Clearly, these are all assumptions based on preliminary findings and basic knowledge of 
nuclear signaling pathways. Hypothetically, in our case we could assume that the association 
of XN with histones, may interfere with the posttranslational modifications of histones and 
therefore explain its versatile spectrum of effects on cancer cells. Nevertheless, this 
interaction needs to be worked out in detail, e.g. what amino acids or specific sites are 
targeted, what kind of interaction is there between XN and histones, is it directly, and 
furthermore, is there a modulation of the gene expression accomplished. To check the 
universal character of this finding, other cell lines would have to be applied in this type of 
experiment. Additionally, medicinal chemistry approaches could be applied for the 
  
134 
 
optimization of derived molecules targeting the same application. Obviously, future studies 
are necessary to reveal the biological relevance of the binding of XN to histones and its 
consequences and the availability of a specific monoclonal antibody and the established, 
optimized techniques from this study has already opened new perspectives and may spur 
further research in this field.   
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Summary and general conclusions  
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This thesis describes the development and validation of two major methods for the 
analytical determination of phytoestrogens in biological matrices, i.e. a chromatographic 
method coupled with (APCI-)MS for the determination of 13 phytoestrogens (including gut 
metabolites) in urine and serum; and a non-chromatographic method using monoclonal 
antibodies in an enzyme-linked immunosorbent assay (ELISA) for the hop-derived 
xanthohumol (XN), isoxanthohumol (IX) and 8-prenylnaringenin (8-PN). Furthermore, the 
focus also lies on the exploration of applications of both methods and tools in the analysis of 
real samples. 
 
In Chapter 1, on the basis of a literature survey, the targeted compounds, i.e. 
phytoestrogens were discussed on different levels like food sources, activities, bioavailability 
and metabolism. Phytoestrogens are defined as plant-derived non-steroidal secondary 
metabolites, which can mimic or modulate the actions of endogenous estrogens usually by 
binding to estrogen receptors. The majority of phytoestrogens are flavonoids, substituted 
phenolic compounds, belonging to three groups, i.e. isoflavones (from soy (Glycine max (L.) 
Merr.), prenylated flavonoids (from hops (Humulus lupulus L.) and coumestans (from red 
clover, alfalfa). The non-flavonoid lignans (from flax seed (Linum usitatissimum L.) are 
another large group of phytoestrogens which can also be daily consumed through plant-
based food stuff or through the intake of dietary supplements. Concomitantly, 
phytoestrogens have been in the spotlight as very interesting research subjects, because of 
their broad spectrum of activities in the prevention and protection against certain diseases 
like cancer, cardiovascular disease and osteoporosis. Their health properties are largely 
depending on their bioavailability and consequently the physiological levels that are reached 
after consumption. The intestinal metabolism has also shown to play an important role in 
the explanation of many inter-individual differences in exposure levels of hormonally active 
compounds. Nevertheless, to control the intake and uptake of phytoestrogens and their 
effects at cellular level, either in clinical environments or controlled laboratory conditions, 
analytical tools for their determination and quantification are required and useful tools.  
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In Chapter 2 of this thesis the aims and most important objectives are outlined. The 
latter were part of a contracted research on phytoestrogens from supplements and their 
biological availability, physiological and toxicological impact with respect to human health in 
food supplements (acron: FYTOES) supported by the Federal Public Service (Health, Safety of 
the food chain and environment.  
 
Chapter 3 describes the successful development and optimization of a new analytical 
HPLC-APCI(MS) method for the determination and quantification of 13 phytoestrogens 
including their precursors and gut microbial metabolites (genistein (GEN), daidzein (DAID), 
equol (EQ), dihydrodaidzein (DHD), O-desmethylangolensin (O-DMA), coumestrol (COUM), 
secoisolariciresinol (SECO), matairesinol (MAT), enterolactone (ENL), enterodiol (END), 
xanthohumol (XN), isoxanthohumol (IX) and 8-prenylnaringenin (8-PN)) in urine and serum. 
The simple sample preparation procedure consists of enzymatic deconjugation followed by 
liquid-liquid extraction (LLE) or solid-phase extraction (SPE) for urine or serum, respectively. 
  
During the method development, first of all, the chromatographic separation of the 
analytes of interest and internal standard was optimized, using reversed phase 
chromatography. Several factors like the stationary phase, mobile phase composition, pH, 
column temperature and mobile phase additives were optimized to ensure an adequate 
separation within a short run time. The final method uses an XBridge C18 column at a 
temperature of 55 °C with a mobile phase gradient consisting of water and a 
methanol/acetonitrile mixture (80:20, w/w), both acidified with 0.025% (v/v) formic acid. In 
20 minutes the target compounds are separated with baseline resolution (except for EQ, 
GEN and ENL; R < 1.5) and the column is equilibrated for the next run. Subsequently, by 
coupling the LC to an Agilent 1200 series Multimode Source detector, complete resolution 
was accomplished. Next, for each component individually, the interface and MS parameters 
were optimized and the optimal ionization method was chosen. Atmospheric Pressure 
Chemical ionization (APCI), operating in the positive mode generated pseudomolecular ions 
[M + H]+ for most compounds, except for SECO which gave [M+H-2H2O]
+  as the base peak.   
Only END and ENL were ionized through APCI in the negative mode ([M - H]-), because higher 
  
138 
 
sensitivity was obtained. The fragmentor voltage, which differs per molecule, was set using 
the chosen ionization method. Also four MSD signals were set, in view of sensitivity and 
resolution and finally, gain values and MSD cycle times were set per programmed signal. 
Furthermore, this bioanalytical method was fully validated (according to the 
recommendations of the FDA) on the basis of selectivity, linearity, sensitivity, accuracy and 
precision. As a result this method was found suitable for routine analysis of samples with 
phytoestrogen levels in the lower ppb range (LOD: urine: 0.2-7.7 ng/mL; serum: 1.4-20.4 ng/ 
mL), with the exception of SECO (urine: 65.1 ng/mL; serum: 132.6 ng/mL), with linearity (r² > 
0.995) for all the analytes over the dynamic ranges. It also proved to allow an accurate and 
precise quantification of the targeted phytoestrogens and their metabolites. The accuracy 
(expressed as percentage relative error %RE) was within the acceptable ranges of 20% and 
inter-assay precision for urine and serum did not exceed 20%. The intra-assay precision was 
below 10% for urine and serum for all analytes, except for END and DAID and ENL in urine 
and serum, respectively. Also an assessment of matrix effects in urine and serum was made 
following the guidance of Matuszewski et al. [110]. Overall, there was found no more than 
15% variation due to matrix effects in urine and serum.  
 
In Chapter 4  the developed and validated LC/(APCI)MS method served as a valuable 
tool in the analysis part of a randomized cross-over dietary trial with co-supplementation of 
soy-, hop-and/or flax-based food supplements by Bolca et al. [130]. This study revealed that 
the bioavailability of mixed phytoestrogens is strongly determined by the microbiome of 
each individual and personalized screenings prior the use of these combinations in 
supplements, are therefore highly recommended. 
 
Chapter 5 gives an overview of the development of monoclonal antibodies against 
phytoestrogens and their subsequent application in an enzyme-linked immunosorbent assay 
(ELISA) for biological matrices. The aim was to develop monoclonal antibodies against 
daidzein, genistein, coumestrol, xanthohumol (XN), isoxanthohumol (IX) and 8-
prenylnaringenin (8-PN). Several polyclonal antibodies have been developed in the past 
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against phytoestrogens like daidzein, genistein, equol, coumestrol, enterolactone [175-181] 
what proves their immunogenicity. Monoclonal antibodies, which have the advantages of 
their specificity, homogeneity and long term availability, are up till now only available 
against daidzein, genistein and equol. Although, it has to be kept in mind that before 
immunization the target phytoestrogens have to be conjugated to bovine serum albumin, 
because with their low molecular weight, they normally do not evoke immune responses in 
vivo.  
 
In that way, the first step in the development was the coupling of the target compounds 
to BSA, forming 4’-O-carboxymethyldaidzein, -genistein, -xanthohumol, -isoxanthohumol, -8-
prenylnaringenin and 3-O-carboxymethylcoumestrol. Secondly, after immunization of the 
BALB/c mice with the antigens (i.e. phytoestrogen-conjugates), by applying a cell fusion 
procedure with polyethylene glycol (PEG) to the mouse spleen cells and murine myeloma 
NS0 cells, the respective hybridomas were constructed. With HAT selection medium, that 
contains aminopterin which blocks the de novo pathway, the fused B cell-myeloma hybrids 
are distinguished from unfused myeloma and B-cells. Then, with a non-competitive 
screening ELISA based on antigen-coated plates, only a few hybridomas could be selected, 
moreover those which produced antibodies against XN, IX and 8-PN. The latter antibodies 
were then also tested in an indirect, yet competitive ELISA to investigate the affinity of the 
produced antibodies for the original compounds of interest. The monoclonality of the 
antibodies was then ensured via limiting dilution. The clones of interest were grown in 
CELLine bioreactors and large amounts of monoclonal antibodies could be harvested every 
month for some time. The monoclonal antibody solutions were purified from the medium 
using FPLC and HiTrap Protein G columns. In total 59 mg , 195 mg and 52 mg of pure 
(checked with gel electrophoresis and Coomassie blue staining) anti-XN, anti-IX and anti-8-
PN were obtained.  
 
Using purified monoclonal antibodies, the different steps and parameters of the 
competitive ELISA (dilutions for the coating antigen, the blocking buffer and the primary and 
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secondary antibody, and the type of secondary antibody and enzymatic substrate, as well as 
the incubation temperature and time periods) were optimized. The final ELISA procedure 
makes use of immunogen-coated microtiterplates and a peroxidase-labeled anti-mouse IgG1 
secondary antibody with ABTS as a chromogenic substrate.  For XN the IC50 value derived 
from the standard curve was 62.91 ng/mL, and for both IX and 8-PN 37.15 ng/mL. In cross-
reactivity studies, the mAbs proved to possess highly specific binding capacities in an 
optimized competitive indirect ELISA.  
 
 The assay was validated for the quantitative analysis of XN, IX and 8-PN in urine and 
serum. A simple sample pretreatment procedure using a diethyl ether extraction was 
optimized and the recoveries and matrix effects were assessed. The validity of the 
established assay was tested and mean inter- and intra-assay variations in urine were 2.32% 
and 1.91%, respectively for XN, 6.24% and 2.39%, respectively for IX and 7.18% and 0.74%, 
respectively for 8-PN. In serum, the mean inter- and intra-assay variations were 8.90% and 
1.37%, respectively for XN, 6.13% and 1.57%, respectively for IX and 6.13% and 2.43%, 
respectively for 8-PN. Furthermore, the method demonstrated excellent accuracy and 
significant correlation with measurements by the established and validated HPLC-MS 
method from Chapter 3.  
 
Chapter 6 deals with the exploration of the immunocytochemical application of the 
developed monoclonal antibody against xanthohumol (XN). The intracellular fate of 
xanthohumol is an underexplored field in the research for the molecular mechanisms 
causing its wide range of effects in chemoprevention and gene expression involved in 
hepatic metabolism. The monoclonal antibody was used to elucidate possible targets for the  
binding of XN in a human mammary carcinoma cell line (MCF-7/6). Prior to the 
immunochemical experiments in growth medium with XN, its solubility and stability were 
investigated and found appropriate. They showed that the after 6 h of incubation at 37 °C, 
and even after 24 h, about 50% of the original amount of XN could not be retrieved in the 
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medium. The cellular uptake and distribution of XN in MCF-7/6 cells was investigated using 
an optimized immunocytochemistry technique. After incubation of MCF-7/6 cells, with 10 
µM XN for 0.5 h up to 6 h, we observed primarily a granular nuclear staining, which 
intensified with increasing exposure times. Immunoprecipitation of cell lysates (treated with 
10 µM XN for 2 h) revealed binding of xanthohumol to a fraction of proteins with a 
molecular weight below 20 kDa. All controls (blanks and negative) did not result in the same 
band pattern that was observed with the positive samples. Further analysis of the protein 
mixture via LC-MS/MS (Q-TOF) resulted in the identification of specific members of the 
histone family, i.e. histone H2A, H2B and H4. The identity of histone H2A was confirmed 
using immunodetection with a specific anti-histone H2A antibody. 
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Samenvatting   
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Deze thesis beschrijft de ontwikkeling en validatie van twee analytische methodes voor 
de bepaling van fyto-oestrogenen in biologische matrices, meer bepaald een 
vloeistofchromatografische methode in combinatie met massaspectrometrische detectie 
(MS) (Atmosferische Druk Chemische Ionisatie) voor de bepaling van 13 fyto-oestrogenen 
(met inbegrip van intestinale metabolieten) in urine en serum en een niet-
chromatografische methode gebruik makend van monoklonale antilichamen in een enzyme-
gelinkte immunosorbent assay (ELISA) voor het hop-afgeleide xanthohumol (XN), 
isoxanthohumol (IX) en 8-prenylnaringenin (8-PN). Bovendien ligt de focus vooral op de 
toepassing van de ontwikkelde methodes als tools voor de analyse van echte stalen. 
 
In Hoofdstuk 1 werden op basis van een literatuurstudie, de betreffende verbindingen, 
zijnde fyto-oestrogenen, besproken op verschillende niveaus zoals voedselbronnen, 
biologische activiteiten en beschikbaarheid en algemeen metabolisme. Fyto-oestrogenen 
worden gedefinieerd als plantaardige, niet-steroïdale secundaire metabolieten, die acties 
van endogene oestrogenen kunnen nabootsen en dit meestal door hun binding aan 
oestrogeen receptoren. De meerderheid van de fyto-oestrogenen zijn flavonoïden, 
gesubstitueerde fenolische verbindingen, die behoren tot drie groepen, i.e.  isoflavonen (van 
soja (Glycine max (L.) Merr.), geprenyleerde flavonoïden (van hop (Humulus lupulus L.) en 
coumestanen (van rode klaver, alfalfa). De niet-flavonoïde lignanen (van lijnzaad (Linum 
usitatissimum L.) zijn een andere grote groep fyto-oestrogenen die ook dagelijks kunnen 
geconsumeerd worden via plantaardige voedingsmiddelen of via de inname van 
voedingssupplementen. Gelijktijdig staan fyto-oestrogenen vaak in de schijnwerpers als zeer 
interessante onderzoeksonderwerpen vanwege hun brede spectrum van activiteiten in de 
preventie en bescherming tegen bepaalde ziekten zoals kanker, hart- en vaatziekten en 
osteoporose. Hun gezondheidseigenschappen zijn grotendeels afhankelijk van hun 
biologische beschikbaarheid en bijgevolg dus de fysiologische levels die na consumptie 
bereikt worden. Uiteraard speelt het intestinale metabolisme ook een belangrijke rol bij de 
vele inter-individuele verschillen in niveaus van blootstelling aan hormonaal actieve 
verbindingen. Wanneer men de inname en de opname van fyto-oestrogenen en hun 
effecten op cellulair niveau wil bepalen, hetzij in een klinische omgeving of gecontroleerde 
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laboratoriumomstandigheden, zijn betrouwbare analytische methoden voor hun bepaling en 
kwantificering echter een eerste vereiste. 
 
In Hoofdstuk 2 zijn de opbouw en de belangrijkste doelstellingen van deze thesis 
beschreven. Deze laatste waren onderdeel van een contractueel onderzoek naar fyto-
oestrogenen uit voedingssupplementen. Meer bepaald hun biologische beschikbaarheid, 
fysiologische impact en toxische implicaties met betrekking tot de menselijke gezondheid 
(acron: FYTOES) ondersteund door de Federale Overheidsdienst (Gezondheid, Veiligheid van 
de Voedselketen en Leefmilieu).  
 
Hoofdstuk 3 beschrijft de succesvolle ontwikkeling en optimalisatie van een nieuwe 
HPLC-APCI(MS) analysemethode voor de bepaling en de kwantificering van 13 fyto-
oestrogenen, met inbegrip van hun precursoren en microbiële darmmetabolieten 
(genisteïne (GEN), daidzeïne (DAID), equol (EQ), dihydrodaidzeïne (DHD), O-
desmethylangolensin (O-DMA), coumestrol (COUM), secoisolariciresinol (SECO), matairesinol 
(MAT), enterolacton (ENL), enterodiol (END), xanthohumol (XN), isoxanthohumol (IX) en 8-
prenylnaringenine (8-PN)) in urine en serum. De eenvoudige staalvoorbereiding bestaat uit 
enzymatische deconjugatie gevolgd door vloeistof-vloeistof extractie (LLE) of vaste-fase-
extractie (SPE) voor urine of serum, respectievelijk. 
 
Gedurende de ontwikkeling van deze methode is allereerst de chromatografische 
scheiding van de analyten en interne standaard geoptimaliseerd, met behulp van 
omgekeerde fase chromatografie. Verschillende factoren zoals de stationaire fase, de 
samenstelling van de mobiele fase, pH, kolomtemperatuur en mobiele fase additieven zijn 
op punt gesteld om voor een adequate scheiding te zorgen in een korte run. De finale 
methode maakt gebruik van een XBridge C18-kolom bij een temperatuur van 55 °C met een 
mobiele fase-gradiënt bestaande uit water en een mengsel van methanol/acetonitrile 
(80:20, m/m), beide aangezuurd met 0.025% (v/v) mierenzuur. In 20 minuten worden de 
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verbindingen gescheiden met basislijn resolutie (behalve EQ, GEN en ENL; R < 1.5) en wordt 
de kolom geëquilibreerd voor een volgende run. Volledige resolutie werd bereikt door 
koppeling van het LC-gedeelte met een Agilent 1200 serie Multimode Source Detector. 
Vervolgens werden voor elke verbinding afzonderlijk, de interface en MS parameters 
geoptimaliseerd en de optimale ionisatie methode gekozen. Atmosferische druk chemische 
ionisatie (APCI), in de positieve mode, genereerde pseudomoleculaire ionen [M + H]+ voor de 
meeste verbindingen, met uitzondering van SECO die [M + H-2H2O]
+ als de hoofdpiek.   
Alleen END en ENL werden geïoniseerd via APCI in de negatieve modus ([M - H]-), omdat dan 
hogere gevoeligheid werd verkregen. De fragmentorvoltage, die per molecule verschilt, 
werd ingesteld samen met de gekozen ionisatie methode. Alsook werden vier MSD signalen 
vastgelegd, met oog op de gevoeligheid en resolutie. Tenslotte werden de gainwaarden en 
MSD cyclustijden ingesteld per geprogrammeerd signaal. 
 
 Bovendien werd deze bio-analytische methode volledig gevalideerd (volgens de 
aanbevelingen van de FDA) op basis van selectiviteit, lineariteit, gevoeligheid, 
nauwkeurigheid en precisie. Bijgevolg bleek deze methode geschikt voor routinematige 
analyse van stalen met fyto-oestrogeen niveaus in het lagere ppb-bereik (LOD: urine: 0.2-7.7 
ng/mL; serum: 1.4-20.4 ng/mL), met uitzondering van SECO (urine: 65.1 ng/mL; serum: 132.6 
ng/mL), met lineariteit (r² > 0.995) voor alle analyten over de dynamische bereiken. Ook 
bleek een nauwkeurige en precieze kwantificering van de beoogde fyto-oestrogenen en hun 
metabolieten mogelijk met deze methode. De nauwkeurigheid (uitgedrukt als percentage 
relatieve fout; %RE) was binnen het acceptabele bereik van 20% en de inter-assay precisie 
voor urine en serum bedroeg niet meer dan 20%. De intra-assay precisie was minder dan 
10% voor urine en serum voor alle analyten, behalve voor END en DAID en ENL in urine en 
serum, respectievelijk. Er werd ook een beoordeling van de matrixeffecten in urine en serum 
gemaakt naar richtlijnen van Matuszewski et al. [110]. Globaal werd er niet meer dan 15% 
variatie gevonden die toe te schrijven zou zijn aan matrixeffecten in urine en serum. 
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In Hoofdstuk 4 diende de ontwikkelde en gevalideerde LC/(APCI-)MS methode als een 
waardevolle tool in het analytische deel van een gerandomiseerde cross-over voedingstrial 
met co-supplementatie van soja-, hop-en/of vlas-gebaseerde voedingssupplementen door 
Bolca et al. [130]. Deze studie toont aan dat de biobeschikbaarheid van fyto-oestrogenen 
sterk bepaald wordt door het microbioom van elk individu en dat gepersonaliseerd 
screenings nuttig kunnen zijn vóór het gebruik van deze voedingssupplementen.   
 
Hoofdstuk 5 geeft een overzicht van de ontwikkeling van monoklonale antistoffen tegen 
fyto-oestrogenen en hun latere toepassing in een enzyme-linked immunosorbent assay 
(ELISA) voor biologische matrices. Het doel was het ontwikkelen van monoklonale 
antistoffen tegen daidzeïne, genisteïne, coumestrol, xanthohumol (XN), isoxanthohumol (IX) 
en 8-prenylnaringenin (8-PN). Verschillende polyklonale antilichamen werden reeds 
ontwikkeld tegen fyto-oestrogenen zoals daidzeïne, genisteïne, equol, coumestrol en 
enterolacton, wat hun immunogeen vermogen bewijst. Monoklonale antilichamen, die de 
voordelen hebben van hun specificiteit, homogeniteit en de beschikbaarheid op lange 
termijn, zijn tot nu toe alleen beschikbaar tegen genisteïne, daidzeïne en equol. Niettemin, 
dient ermee rekening te worden gehouden, dat vóór de immunisatie, fyto-oestrogenen 
geconjugeerd moeten worden met bovien serum albumine (BSA), omdat met hun laag 
molecuulgewicht, ze normaal geen immuunrespons opwekken in vivo. Op die manier was de 
eerste stap in de ontwikkeling de koppeling van de verbindingen aan BSA, waarbij 4’-O-
carboxymethylgenisteïne, -daidzeïne, -xanthohumol, -isoxanthohumol, -8-prenylnaringenine 
en 3-O-carboxymethylcoumestrol. Daarna werden BALB/c muizen geïmmuniseerd met de 
antigenen (d.w.z. fyto-oestrogeen-conjugaten), en door toepassing van een celfusie- 
procedure met polyethyleenglycol (PEG) op de muis miltcellen en myeloma NS0 cellen, 
werden de respectieve hybridoma’s geconstrueerd. Met HAT selectiemedium, dat 
aminopterine bevat die de de novo pathway blokkeert, werden de gefuseerde B-cel-
myeloma hybriden onderscheiden van de myeloom- en B-cellen. Dan, met een niet-
competitieve screenings ELISA op basis van antigeen gecoate platen, konden enkel een paar  
hybridoma’s worden geselecteerd, die antilichamen tegen XN, IX en 8-PN produceerden. 
Deze laatste antistoffen werden vervolgens ook getest in een indirecte, competitieve ELISA 
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om de affiniteit van de geproduceerde antilichamen voor de oorspronkelijke verbindingen te 
onderzoeken. De monoklonaliteit van de antilichamen werd vervolgens gewaarborgd via de 
methode van beperkende verdunning. De klonen van belang werden in cultuur gebracht in 
CELLine bioreactoren en grote hoeveelheden van monoklonale antilichamen konden elke 
week geoogst worden, dit gedurende enkele maanden. De monoklonaal antilichaam 
oplossingen werden verder opgezuiverd uit het medium gebruik makende van FPLC en 
HiTrap Proteïne G kolommen. In totaal werd 59 mg, 195 mg en 52 mg (gecontroleerd met 
behulp van gelelektroforese met Coomassie blauw kleuring) zuiver anti-XN, anti-IX en anti-8-
PN verkregen. 
 
Met behulp van de opgezuiverde monoklonale antilichamen, werden de verschillende 
stappen en parameters van de competitieve ELISA (verdunningen van de antigen coating, de 
blockingbuffer en het primaire en secundaire antilichaam; en het type van secundair 
antilichaam en enzymsubstraat, evenals de incubatietemperatuur en -tijd perioden) 
geoptimaliseerd. De definitieve ELISA-procedure maakt gebruik van immunogeen gecoate 
microtiterplaten en een peroxidase gelabeld antimuis-IgG1 secundair antilichaam met ABTS 
als chromogeen substraat. Voor XN was de IC50-waarde afgeleid van de standaard curve 
62.91 ng/mL, en voor zowel IX en 8-PN 37.15 ng/mL. Via kruisreactiviteitsstudies werd 
aangetoond dat de monoklonale antilichamen zeer specifieke bindingscapaciteiten vertonen 
in een geoptimaliseerde competitive indirecte ELISA. 
 
De ELISA-test is gevalideerd voor de kwantitatieve analyse van XN, IX en 8-PN in urine en 
serum. Een eenvoudige voorbehandelingsprocedure met behulp van een diëthylether 
extractie werd geoptimaliseerd, alsook werden de recovery’s en matrixeffecten beoordeeld. 
De validiteit van de gevestigde assay werd getest en voor inter- en intra-assay variaties in 
urine werden waarden berekend van 2.32% en 1.91%, respectievelijk voor XN, 6.24% en 
2.39%, respectievelijk voor IX en 7.18% en 0.74%, respectievelijk voor 8-PN. In serum 
bedroegen de gemiddelde inter- en intra-assay variaties 8.90% en 1.37%, respectievelijk voor 
XN, 6.13% en 1.57%, respectievelijk voor IX en 6.13% en 2.43%, respectievelijk voor 8-PN. 
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Bovendien, de methode vertoonde uitstekende nauwkeurigheid en significante correlatie 
met metingen door de gevestigde en gevalideerde HPLC-MS methode uit Hoofdstuk 3. 
  
Hoofdstuk 6 handelt over de aanwending van een andere immunochemische toepassing 
van het monoklonale antilichaam tegen xanthohumol (XN). Het intracellulaire lot van 
xanthohumol is een nog weinig besproken deel in het onderzoek naar de moleculaire 
mechanismen van de brede waaier aan effecten in chemopreventie en genexpressie die 
betrokken zijn bij levermetabolisme. Het monoklonale antilichaam werd gebruikt voor het 
ophelderen van mogelijke doelwitten voor de binding van XN in een menselijke borstklier 
kanker cellijn (MCF-7/6). Voorafgaand aan de immunochemische experimenten in 
groeimedium met XN, zijn de oplosbaarheid en stabiliteit van XN onderzocht en 
aanvaardbaar bevonden. Deze experimenten toonden aan dat XN na 6 uur incubatie bij     
37 °C, en zelfs na 24 u, ongeveer 50% van de oorspronkelijke hoeveelheid XN niet kon 
worden terug gevonden in het celmedium. De opname en distributie van XN in MCF-7/6 
cellen werd onderzocht met behulp van een geoptimaliseerde immunocytochemische 
techniek. Na incubatie van MCF-7/6 cellen, met 10 µM XN voor 0.5 u tot 6 u, werd 
voornamelijk een granulaire nucleaire kleuring waargenomen, die versterkte met 
toenemende blootstellingstijden. Na immunoprecipitatie van cellysaten (behandeld met 10 
µM XN voor 2 u) bleek dat XN binding gaf met een fractie van eiwitten met een moleculair 
gewicht kleiner dan 20 kDa. Alle controlestalen (blanco’s en negatieve controles) leidden 
niet tot hetzelfde patroon dat werd waargenomen bij de positieve stalen. Verdere analyse 
van het eiwitmengsel via LC-MS/MS (Q-TOF) resulteerde in de identificatie van bepaalde 
leden van de histonfamilie, d.w.z. histon H2A, H2B en H4. De identiteit van histon H2A werd 
bevestigd met behulp van immunodetectie met een specifiek anti-histon H2A antilichaam. 
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General discussion and  
future perspectives   
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The biological mechanisms of phytoestrogens and their potential application as health-
beneficial component in food supplements, have been studied intensively over the last few 
decades. Unfortunately, the focus is hardly drawn on the renewal, extension and 
simplification of analytical methods for their determination, either qualitatively or 
quantitatively. Nevertheless, the basis of every complete decision-making in laboratory or 
clinical environment is based on accurate and precise detection tools and/or methods. 
Additionally, it is also a bonus if the methods are simple, do not require experienced staff or 
expensive equipment and offer a rapid solution in routine analysis of large numbers of 
samples.  
 
The new or improved detection tools discussed in this thesis, as well as their 
applications, have been developed and run in view of the simplification of the analysis of 
phytoestrogens in biological matrices. Moreover, they can be a contribution to other 
research groups investigating pharmacokinetics of phytoestrogens, molecular biology and 
therapeutic applications with dietary supplements.  
 
The developed LC/APCI-MS method for 13 phytoestrogens (including gut microbial 
metabolites) in urine and serum covers the simultaneous determination and quantification 
of the most important members of the 4 major groups of phytoestrogens, i.e. isoflavones, 
lignans, prenylated flavonoids and coumestans and includes also their most important 
biological metabolites.  This analytical method has been applied to analyze the urinary and 
serum samples generated in a dietary intervention trial. For that type of trial, the LC-MS 
method proved its efficacy, moreover the possibility to determine all the targeted 
compounds in one run, with a minimal effort put in sample preparation and technical 
simplicity. Nevertheless, further improvement of this type of method, is warranted to 
maximize its contribution and value in clinical environments. More sophisticated techniques 
such as LC-MS/MS and UHPLC-MS/MS, which were not readily available during this research 
project, could significantly improve the speed and efficacy, without any loss of specificity and 
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accuracy. At the moment of finalization of this thesis and the generation of this chapter,  
literature search showed that some research groups successfully improved the sample 
preparation, method sensitivity and overall efficiency of the detection of some groups of 
phytoestrogens. The first [221] was conducted by applying an extraction-free method for the 
measurement of isoflavones and lignans with APPI, rather than using ESI or APCI. The latter 
[222] was realized by optimizing the speed through the use of UHPLC and improving 
sensitivity by using tandem MS technique. These improvements were applied for the 
detection of some but unfortunately not all of the compounds integrated in the method of 
this research project. 
 
The establishment of the second and also very challenging part of this research project, 
was the development of a series of monoclonal antibodies against the most important 
members of the main groups in the class of phytoestrogens: genistein, daidzein, equol, 
enterodiol, enterolactone, xanthohumol, isoxanthohumol, 8-prenylnaringenin and 
coumestrol. Given their non-immunogenic nature, the synthesis of haptens of all these 
molecules and linking those to a protein was absolutely necessary, and successfully 
conducted for genistein, daidzein, coumestrol, isoxanthohumol, xanthohumol and 8-
prenylnaringenin. Immunogens for the other compounds were not synthesized because of 
the limited time and lack of experienced staff.  At the time the research project was 
conducted, only the generation of monoclonal antibodies against daidzein, genistein and 
equol were described by other research groups in literature. Therefore, the most innovative 
antibodies, were used for generation of a monoclonal based ELISA, immunocytochemistry 
and –precipitation. A number of aspects in the development, optimization and validation of 
an ELISA with monoclonal antibodies were explored during this project. Nevertheless, 
further investigation and exploration of the possibilities with the developed monoclonal 
antibodies would be useful to improve the sensitivity for measurement in biological samples. 
These antibodies, and especially the anti-xanthohumol antibody could serve as a very 
interesting tool for further exploration of the cellular target of this hop-derived compound. 
Xanthohumol has been suggested as an interesting natural compound with many health 
beneficial properties. The metabolism of xanthomol has already been thoroughly studied 
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through in vitro studies with human and rat liver microsomes, microorganisms and phase II 
enzymes. Also a few in vivo studies (in rats) [65, 210, 223] are available so far and very 
recently, Legette et al. [224] performed the first study to elucidate the pharmacokinetic 
parameters in humans. In the latter study experiments with a single oral dose of pure 
xanthohumol (20, 60 or 180 mg) revealed pharmacokinetic parameters showing a distinct 
biphasic absorption pattern with a first peak around 1 h and a second peak between 4-5 h 
after ingestion. Steady-state plasma concentrations were calculated to be 1.5, 18 and 40 
µg/L for the 20, 60 and 180 mg doses, respectively. A half-life time of 20 h was observed for 
the lowest dose and 18 h for the highest dose. The biphasic pattern could be due to 
enterohepatic circulation, or absorption of redissolved xanthohumol that may have 
precipitated in intestinal fluids. Another important finding of that study is the parallel 
between human and animal pharmacokinetics. Because of the similarity of xanthohumol 
metabolism between animals and humans, findings can easily be translated to future clinical 
work. In conclusion this important in vivo human study revealed that the issue of poor 
bioavailability of xanthohumol, or plasma and tissue levels of xanthohumol, can be 
eliminated by using of a self-emulsifying isotropic mixture of xanthohumol, oleic acid, Tween 
80 and propylene glycol for oral administration. This in turn opens up new perspectives for 
future cancer research on the efficacy of xanthohumol against a number of systemic tumors 
and enhances the importance of biological effects observed in cell culture studies. The tend 
to modify the transcription through demethylation and acetylation of histones in breast 
cancer cell lines has recently also been observed and described for the isoflavones genistein, 
daidzein and equol [225]. Therefore, especially the association of xanthohumol with histones 
and the possible influence on posttranslational modifications seems to be a highly 
interesting perspective in cancer research. The value of the developed anti-xanthohumol 
antibody in that field has already been expressed in literature [226].   
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APPENDIX  
 
Table A.1: Summary of LC/MS and LC/MS-MS methods for the simultaneous detection of 
phytoestrogens (isoflavones and lignans) in biological samples. 
Chromatographic methods 
Method Analytes Matrix Sensitivity Ref.  
HPLC/(APCI)MS 
HPLC/(ESI)MS 
HPLC/(APCI)MS-MS 
HPLC/(ES)MS-MS 
HPLC/(ES)MS-MS 
HPLC/(APCI)MS-MS 
DAID, DHD, GEN, DHG,    
O-DMA, EQ  
DAID, DHD, GEN, DHG, 
GLYC, O-DMA, END, ENL & 
3 others 
DAID, GEN, EQ, O-DMA, 
MAT, END, ENL, COUM 
DAID, GEN, GLYC, EQ,    
O-DMA,  END, ENL 
DAID, GEN, EQ, O-DMA, 
END, ENL 
DAID, GEN, EQ, O-DMA, 
END, ENL  
urine 
urine/plasma 
urine/serum                   
 
urine                             
urine 
urine 
5 ng/mL                 
(EQ: 200 ng/mL) 
LOQ urine: 1–39 nM       
LOQ plasma: 1–29 nM 
urine: 0.2–9.3 ng/mL       
serum: 0.1–2.4 ng/mL 
10 pg/mL                
(EQ: 100 pg/mL) 
0.05–0.4 ng/mL 
0.05–2.7 ng/mL 
[119] 
[120] 
[121] 
[123] 
[101] 
[101] 
Abbreviations: APCI: atmospheric pressure chemical ionization, ESI: electrospray ionization, MS(-MS): 
(tandem) mass spectrometry, Mw: molecular weight, DAID: daidzein (Mw: 254 g/mol), DHD: 
dihydrodaidzein (Mw: 256 g/mol), GEN: genistein (Mw: 270 g/mol), DHG: dihydrogenistein (Mw: 272 
g/mol), GLYC: glycitein (Mw: 284 g/mol), EQ: equol (Mw: 242 g/mol), O-DMA: O-
desmethylangolensin (Mw: 258 g/mol), MAT: matairesinol (Mw: 358 g/mol), END: enterodiol (Mw: 
302 g/mol), ENL: enterolactone (Mw: 298 g/mol), COUM: coumestrol (Mw: 268 g/mol). 
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Table A.2: Summary of immunoassays for the detection of phytoestrogens (isoflavones and 
lignans) in biological samples. 
Immunoassays 
Method Compounds  Type Ab Sensitivity Ref.  
RIA 
RIA 
TR-FIA 
ELISA 
 
RIA 
TR-FIA 
RIA 
ELISA 
TR-FIA 
ELISA 
TR-FIA 
8-PN 
COUM 
ENL 
C7 serie: DAID, GEN, 
BIOCHANIN A, EQ      
C8 serie: DAID, FORM 
DAID 
GEN  
BIOCHANIN A 
BIOCHANIN A 
DAID 
GEN 
DAID, GEN, EQ   
polyclonal 
polyclonal 
polyclonal 
polyclonal 
 
polyclonal 
polyclonal 
polyclonal 
polyclonal 
  monoclonal 
  monoclonal 
  monoclonal 
0.3 ng/mL 
12 pg/tube 
1.5–540 nmol/L 
IC50 : 10 ng/mL             
(DAID: 0.8 ng/mL)          
IC50: 15.6, 7.8 ng/mL 
0.4 pg/tube 
1.2 – 2.8 pg/tube 
3.1 pg/tube  
5.3 pg/well                         
0.5 ng/mL 
0.5 ng/well 
DAID: 3.9 nmol/L           
GEN: 8.7–88.8 nmol/L 
(serum – urine)                
EQ: 2.2 nmol/L 
[40] 
[172] 
[173] 
[174] 
 
[175] 
[176] 
[177] 
[177] 
[178] 
[179] 
[180] 
Abbreviations: ELISA: enzyme-linked immunosorbent assay, RIA: radioimmunoassay, TR-FIA: time-
resolved fluoroimmunoassay, IC50: concentration of competitor that gives 50% inhibition, Mw: 
molecular weight, DAID: daidzein (Mw: 254 g/mol), GEN: genistein (Mw: 270 g/mol), ENL: 
enterolactone (Mw: 298 g/mol), COUM: coumestrol (Mw: 268 g/mol), FORM: formononetin (Mw: 
268 g/mol), EQ: equol (Mw: 242 g/mol), BIOCHANIN A (Mw: 284 g/mol). 
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